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Abstract 
 
Background and aims: ‘Fat in the wrong place’, i.e. accumulation of lipid in insulin sensitive 
tissues such as skeletal muscle and the liver has been shown to be associated with insulin 
resistance independent of subcutaneous fat. The mechanisms underlying these associations 
are poorly understood. Hypothetically, insulin resistance could be mediated via direct effects 
of intracellular lipid on insulin signalling or indirectly via release of adipocytokines such as 
adiponectin. Studies I and II were undertaken to determine, whether fasting insulin 
concentration and accumulation of intramyocellular lipid (IMCL) is associated with 
alterations in insulin signalling and whether such an association is independent of obesity and 
physical fitness. Study III was undertaken to characterize gene expression in adipose tissue of 
patients with lipodystrophy and insulin resistance due to treatment of HIV-infection by highly 
active antiretroviral therapy (HAART). In study IV, we wanted to determine whether 
adiponectin expression and circulating concentrations are abnormal in patients with HAART-
associated lipodystrophy (HAL) and if so, whether such alterations are related to 
intrahepatocellular lipid. 
 
Experimental material, subjects and methods: In study I, for method development, we 
compared insulin signalling assays in rat gastrocnemius muscle [insulin receptor (IR), insulin 
receptor substrate-1 (IRS-1), p85 subunit of phosphatidylinositol-3 kinase (PI 3-kinase), and 
kinase activity assay (PI 3-kinase)] using freeze-dried and purified, or frozen specimens. In 
study II, insulin signalling in human muscle was compared between 10 subjects with IMCL 
higher and 10 subjects lower than the median. Insulin sensitivity (euglycaemic 
hyperinsulinaemic clamp), body composition and maximal aerobic capacity were also 
measured. IMCL content was measured by proton nuclear magnetic resonance spectroscopy 
(1H-MRS). In studies III and IV, liver fat was measured by 1H-MRS and gene expression in 
subcutaneous adipose tissue biopsies by real-time polymerase-chain reaction in 30 patients 
with HAL and 13 HIV patients without lipodystrophy matched for age, gender and body 
mass. Total abdominal, subcutaneous and intra-abdominal were measured by magnetic 
resonance imaging.  
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Results: Insulin signalling in rat freeze-dried muscle was comparable but less variable than in 
conventionally proceeded biopsies. Human muscle biopsies had on the average 11 % non-
muscle contaminants (I). Subjects with lower than median IMCL had higher rates of glucose 
uptake, lower serum fatty acid concentrations during hyperinsulinaemia and higher insulin-
stimulated tyrosine phosphorylation of IR and IRS-1-associated PI 3-kinase activity than 
subjects with IMCL above median (II). The patients with HAL had several features of insulin 
resistance, including fasting hyperinsulinaemia and hypertriglyceridaemia compared to the 
HIV patients without lipodystrophy. In patients with HAL expression of the transcription 
factors (peroxisome proliferator activated receptor γ and δ, sterol regulatory binding protein
1c, peroxisome proliferator activated receptor γ co-activator (PGC-1), lipoprotein lipase, acyl 
CoA synthase and glucose transport protein 4 (GLUT4) were lower, whereas markers of 
inflammation (interleukin-6, cluster of differentiation 45) higher in patients with than without 
lipodystrophy (III). mRNA concentrations of fatty acid transport proteins 1 and 4 and of 
adipocyte and keratinocyte lipid binding proteins were similar in both groups (III). In study 
IV in the same patients, adiponectin gene expression in subcutaneous adipose tissue was 
lower in patients with than without lipodystrophy. Both serum adiponectin and mRNA 
concentrations correlated closely with features of insulin resistance, including liver fat 
content. 
 
Conclusions: Freeze-drying and purification of human skeletal muscle biopsies allows more 
accurate measurement of insulin signalling than use of non-purified muscle. High IMCL in 
insulin-resistant non-obese non-diabetic men is associated with defects in early insulin 
signalling independent of body weight and physical fitness. Lipodystrophy accompanying 
HAART is characterized by insulin resistance and decrease of mRNA concentrations of 
several adipogenic transcription factors, PGC-1 and GLUT-4, an increase in inflammatory 
markers and a decrease in adiponectin. The relationship between adiponectin and liver fat 
raises the possibility that humoral factors released by adipose tissue regulate liver fat content.  
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1. INTRODUCTION 
Insulin resistance, a state where one or several of insulin’s biological actions are impaired, 
characterizes both patients with excessive amounts of subcutaneous fat (obesity) and those 
who lack subcutaneous or visceral fat altogether (lipoatrophy). Both obese subjects and 
patients with lipoatrophy are at increased risk of developing type 2 diabetes and 
cardiovascular disease (104,254). Therefore, it is important to understand the molecular 
mechanisms underlying insulin resistance. 
 
In recent years, studies of humans (275,283,284) and genetically engineered animals (48) 
have suggested that accumulation of triglycerides (TG) in insulin-sensitive tissues such as 
skeletal muscle and the liver may be the most proximal correlate of insulin resistance. 
However, as TGs themselves are unlikely to act as signalling molecules, it is likely that 
interactions with insulin action stem more from the metabolically active forms of lipid in 
muscle, such as long-chain fatty acid-CoA (LCACoA). They could accumulate either from a 
dietary source or could be derived from adipose tissue depots. The LCACoAs can, based on 
animal studies, regulate insulin signalling in muscle via multiple mechanisms including direct 
effects on enzyme activities (47,270), and effects mediated via diacylglycerol (DAG)-induced 
activation of protein kinase C (PKC), which in turn downregulate insulin signalling 
(32,52,53,99,126,126,137). There are, however, no data in humans which would link any 
defects in insulin signalling in skeletal muscle to intramyocellular lipid (IMCL). 
 
The use of highly active antiretroviral theraphy (HAART) has dramatically improved survival 
of patients with HIV but is, in approximately 50 % of the patients, associated with serious 
metabolic side effects characterized by lipodystrophy (LD) and insulin resistance (42). The 
pathogenesis of this side effect is poorly understood. It is thought that HAART primarily 
affects metabolism in adipose tissue but how this results in whole-body insulin resistance in 
addition to LD is unclear. One possibility is that lipodystrophic adipose tissue either over- or 
undersecretes mediators, which affect insulin sensitivity of other tissues such as the liver. 
 
The first aim of this thesis was to investigate the molecular mechanisms of insulin action in 
skeletal muscle in apparently healthy men with IMCL higher and lower than the median. The 
second aim was to characterize alterations in gene expression in patients with HAL and to 
determine whether the observed alterations in adipose tissue are related to fat accumulation in 
the liver. 
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2. REVIEW OF THE LITERATURE 
 
2.1. Insulin signal transduction in skeletal muscle 
2.1.1. Insulin signalling cascade 
The first event in the insulin signalling cascade is binding of insulin to its receptor. The 
insulin receptor (IR) is a transmembrane glycoprotein that belongs to a receptor tyrosine 
kinase family of receptors. IR is composed of two extracellular α-subunits and two 
transmemrane β-subunits joined by disulfide cross-bridges. The IR is expressed in two 
isoforms (A and B) differing by 12 amino acids due to alternative splicing of exon 11. The 
type B receptor displays greater insulin-stimulated tyrosine kinase activity and ability to 
phosphorylate insulin receptor substrate (IRS) proteins (146) and predominates in classical 
insulin-sensitive tissues such as the liver, muscle and adipose tissues, whereas the type A 
isoform is found mostly in fetal tissues, the adult central nervous system and haematopoetic 
cells (93,195,198,256). After insulin binds to the α-subunit of the IR, insulin receptor tyrosine 
kinase activity (IRTK) is activated, and the IR undergoes autophosphorylation on several 
tyrosine residues located in the cytoplasmic portion of the β-subunit (306). In the absence of 
its ligand, the IR resides in the plasma membrane. Upon insulin binding, the ligand-receptor 
complex is internalized into endosomes within minutes (38). The acidic pH of endosomes 
induces dissociation of insulin from its receptor and allows the degradation of insulin by 
endosomal acidic insulinase (18). The IR is then recycled back to the cell surface.  
 
Activated IR phosphorylates a number of intracellular substrates on tyrosine residues, 
including Gab-1, Shc, Cbl and members of the IRS family (Fig. 1). These substrates interact 
with IR by specific domains including PH, PTB and SH2 proteins. Pleckstrin homology (PH) 
domain, found in most of the proteins, interacts with the IR and is involved in targeting of the 
IRS proteins to the membrane and the IR (324). The phosphotyrosine binding protein (PTB) 
domain, also present in most of the IRS proteins, recognizes an asparagine-proline-any amino 
acid-phosphotyrosine (NPXpY) motif in the IR (75,318). Grb2-associated binder-1 (Gab-1) 
has no PTB domain and is phosphorylated by the epidermal growth factor receptor rather than 
the IR (118). Shc has no PH domain and is mainly bound by Grb2 which leads mainly to 
activation of a Ras/mitogen activated protein kinase (MAPK) pathway (245) (see below, 
MAPK pathway). The tyrosine phosphorylation of protooncogene Cbl seems to be required 
for insulin-stimulated glucose uptake in addition to the classic IRS-pathway (21).  
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Fig 1. An overview of insulin signalling pathways. Upon binding insulin induces 
autophosphorylation of the IR on tyrosine residues. Activation of the IRTK leads to 
phosphorylation of a number of cellular substrates, including Cbl, IRS, Gab1, and Shc. After 
phosphorylation, the signal is conducted downstream via interaction of the substrates with 
SH2-containing proteins. The IR phosphorylates Cbl via the adaptor protein CAP. After 
phosphorylation, Cbl translocates to the lipid raft subdomain of the plasma membrane, where 
it interacts with the adaptor protein Crk. This pathway is also necessary for the stimulation of 
glucose transport by insulin. The IRS family of substrates interacts with PI 3-kinase (PI3K), 
which produces PIP2 and PIP3 which activate downstream cascades, including PKB/p70rsk 
which stimulates protein synthesis, and atypical PKCs or PKB/GSK3 which activate glucose 
uptake and glycogen synthesis. Gab1 interacts with phopshotyrosine phosphatase SHP2 
which activates the MAPK pathway. Phosphorylation of Shc results in its binding to the 
adaptor protein Grb2, activation of the protooncogene Ras, and the MAPK pathway. 
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There are at least four distinct IRS proteins in mammals, with IRS-1 and IRS-2 found in most 
tissues and apparently having major roles in co-ordinating actions of insulin in peripheral 
carbohydrate and lipid metabolism, and β-cell function (157). The IRS-3 isoform is not found 
in humans (26). Table 1 lists mice knockout models that clarify the role of different IRSs in 
metabolism and mitogenesis. Mice lacking the IRS-1 protein exhibit generalized pre- and 
post-natal growth retardation, as well as insulin resistance but do not develop overt diabetes 
(12,278). On the contrary, IRS-2 deficient mice have defective growth in only some tissues 
(138,245,313) and develop type 2 diabetes (313). IRS-3- and IRS-4-knockout mice have 
normal or nearly normal growth and metabolism (78).  
 
Table 1. Murine phenotypes characterized by deficiency of specific isoforms of IRS. Adapted 
from reference 39. 
Genotype Body 
weight 
Fasting 
glucose 
Insulin 
levels 
Glucose 
tolerance 
Insulin 
resistance 
β-cell mass 
IRS1-/- -50% Normal Increased Normal Muscle Two-fold 
IRS2-/- -10% - Decreased  Impaired Liver, 
muscle 
-50% 
IRS3-/- Normal Normal Normal Normal No - 
IRS4-/- -10% Decreased Normal Normal No - 
 
Many proteins have SH2 domains and associate with IRS-1. These include the PI 3-kinase 
and Grb2. The docking sites of PI 3-kinase and Grb2 in IRS-1 are, however, different. Grb2 
can also associate with Shc and activate the Sos/Ras complex, which is the first step of the 
MAPK pathway and mitogenesis (247).  
 
PI 3-kinase pathway  
The phosphatidyl inositol 3-kinase (PI 3-kinase) pathway is mainly involved in mediating the 
metabolic effects of insulin, such as glucose transport, glycogen and protein synthesis, ion and 
amino acid transport, and lipid metabolism (245). The PI 3-kinase is a heterodimer composed 
of a p110 catalytic subunit and a p85 regulatory subunit. After the SH2 domain of the p85 
regulatory subunit of PI 3-kinase attaches to IRS-1, p110 catalytic subunit, which is 
responsible for the lipid kinase activity of PI 3-kinase, catalyzes the phosphorylation of 
membrane-bound PIP2 to PIP3. This step has been shown to be a critical step which 
ultimately leads to insulin-dependent glucose transporter 4 (GLUT4) translocation to plasma 
 17 
membrane. Increased PIP3 activates a protein kinase cascade, stimulating the piruvate 
dehydrogenase kinase (PDK) (6), which phosphorylates and activates two classes of 
serine/threonine kinases: protein kinase B (PKB, also known as Akt) and the atypical protein 
kinase C (PKC) (isoforms ζ and λ) (162,244). Members of the PKC family of 
serine/threonine kinases have been implicated in several of insulin’s actions (162). Different 
isoforms of PKC have been shown to undergo translocation from the cytosol to the membrane 
in response to insulin stimulation in different tissues. Atypical PKCs (ζ and λ) have been 
proposed to play a role in insulin-dependent glucose transport (148,266) and protein synthesis 
(187). It is also known that PKCs can activate the MAPK pathway and the transcription factor 
nuclear factor-kB, leading to increased gene expression and protein synthesis (139). PKB 
phosphorylates and regulates the function of many cellular proteins involved in processes that 
include metabolism, apoptosis and proliferation (206). Among the targets of PKB are 
glycogen synthase kinase 3 (GSK3) and glycogen-associated protein phosphatase 1 (PP1). 
GSK3 is phosphorylated and inactivated in response to PKB stimulation. Decreased activity 
of GSK3 leads to the dephosphorylation and activation of glycogen synthase (GS). Insulin 
activates GS by promoting its dephosphorylation, through the inhibition of kinases such as 
protein kinase A or GSK3, and activation of PP1 (34). Upon its activation downstream of PI 
3-kinase, PKB is transmitting the insulin signal by phosphorylation of GSK3, the forkhead 
transcription factors and cAMP response element-binding protein (49). 
 
MAPK pathway 
The MAPKs are evolutionary conserved enzymes that play an important role in regulating 
cell proliferation, differentiation and apoptosis. Four groups of MAPKs have been identified 
in mammalian cells. These are extracellular signal-regulated protein kinase (ERK), c-Jun N-
terminal kinase (JNK), the p38 kinases and ERK5/Big MAPK 1. While ERK is mainly 
activated by mitogens and growth factors including insulin, p38 and JNK are activated by 
many environmental stress stimuli (e.g. ultraviolet and ionizing radiation), resulting in 
apoptosis (50,213). ERK pathway involves the tyrosine phosphorylation of IRS proteins 
and/or Shc, which interact with the adapter protein Grb2 and recruit son-of-sevenless 
exchange protein to the plasma membrane for activation of Ras. Activated Ras binds to and 
activates the MAPK kinase kinase (Raf-1). Activated Raf-1 phosphorylates and activates the 
MEK, which in turn phosphorylates and activates ERK (271) (Fig.1). Activated ERK can 
translocate into the nucleus, where it catalyzes the phosphorylation of transcription factors 
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and initiates a transcriptional programme that leads to cellular proliferation or differentiation 
(33).  
 
Other pathways 
In addition to PI 3-kinase activity, other signals seem to be required for insulin-stimulated 
glucose uptake. This alternative pathway appears to involve tyrosine phosphorylation of the 
protooncogene Cbl, the substrate of the IRTK. Cbl-associated protein (CAP), which is not 
phosphorylated in response to insulin, targets Cbl to the IR. After phosphorylation, Cbl 
translocates to caveolae, a specialized subdomain of the plasma membrane. Inhibition of the 
CAP-Cbl interaction by dominant negative CAP correlates with inhibition of insulin-
stimulated glucose transport and GLUT4 translocation in a wortmannin-independent fashion, 
suggesting that Cbl participates in a PI 3-kinase-independent pathway where insulin 
stimulates GLUT4 translocation in adipocytes (21). 
 
The insulin signalling cascade is regulated by protein tyrosine phosphotyrosine phosphatase 
(PTP) activity. In rat skeletal muscle, inmmunodepletion studies have demonstrated that 
leucocyte common antigen (LAR), phosphotyrosine phosphatase SHP2 and PTP-1B are the 
three major enzymes responsible for PTP activity (5). The expression levels and/or activity of 
these specific PTPs are increased in insulin resistant obese patients (4). LAR negatively 
regulates insulin signalling through dephosphorylation of IRS-2 (or other IRS proteins), 
although IR and IRS-1 may be affected in other tissues or physiological states. PTP-1B 
knockout mice have enhanced insulin sensitivity, increased phosphorylation of the IR in liver 
and muscle tissue after insulin injection in comparison to PTP-1B +/+ mice (76).  
 
The adenosine monophosphate-activated protein kinase (AMPK) has been implicated in the 
stimulation of glucose uptake into skeletal muscle and inhibition of liver gluconeogenesis. 
AMPK is a heterotrimeric protein, composed of one catalytic (α) and two noncatalytic (β and
γ) subunits (311) which is activated by cellular stress associated with ATP depletion (114). 
AMPK mediates several critical exercise-induced mitogenic and metabolic events in skeletal 
muscle. An increase in AMPK activity in response to muscle contraction or exercise 
correlated with GLUT4 translocation and glucose transport in skeletal muscle 
(23,24,115,160). In rats, metformin activates AMPK in hepatocytes resulting in a decrease in 
the activity of acetyl-CoA carboxylase, an increase in fatty acid oxidation and suppression of 
lipogenic enzymes and sterol regulatory binding protein 1c (SREBP-1c) expression (335). 
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2.1.2. Acquired defects in insulin signalling 
Obesity 
Insulin sensitivity related to lowering of whole-body glucose levels decreases with increasing 
body weight (35). Molecular mechanisms for this association are poorly understood (245) but 
obese subjects show muscle insulin resistance and appear to have insulin signalling defects in 
skeletal muscle. Morbidly obese subjects have reduced IRS-1 content, insulin-stimulated IRS-
1 phosphorylation and PI 3-kinase activation which is paralleled by a decrease in insulin-
stimulated glucose uptake in skeletal muscle strips (95). Pregnant obese women with or 
without gestational diabetes have been reported to have impaired insulin-stimulated IRS-1 
phosphorylation, which was primarily due to a decrease in IRS-1 protein, while IRS-2 
expression appeared to be increased (84). In another study, obese subjects with impaired 
glucose tolerance (IGT) had lower IRS-1 tyrosine phosphorylation than normal subjects, 
significantly impaired IRS-2 tyrosine phosphorylation, defective IRS-2-associated PI 3-kinase 
activation, and impaired PKC activation in myotubes (295). PTPase could more rapidly 
dephosphorylate IRS-2 in myotubes from patients with IGT than in normal subjects. PTPase 
activity is increased in skeletal muscle in obese subjects (4,185). PTPase activity was also 
found to be 2-fold increased in omental fat compared to subcutaneous fat (319). In morbidly 
obese individuals, the reduced insulin-stimulated glucose transport may be explained partly 
by reduced GLUT4 expression in skeletal muscle (67). 
 
An increase of certain intracellular lipid molecules can activate signalling pathways that 
downregulate insulin action. Increased diacylglycerol (DAG) levels in muscle are associated 
with activation of one or more isoforms of the PKC family, which is known to attenuate 
insulin signalling, especially at the level of IRS-1 (250). De novo synthesis of ceramide can 
inhibit more distal sites by activating PTP 2A and thereby promoting dephosphorylation and 
inactivation of PKB (250). The JNK activity which is abnormally elevated in obesity (116), 
can interfere with insulin action in cultured cells (116). These mechanisms may account at 
least in part for the reduced insulin sensitivity occurring in obesity and type 2 diabetes. 
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Physical inactivity 
The ability of physical exercise to improve glucose metabolism has been known for more than 
100 years, but the exact mechanisms of this effect have only recently started to become clear. 
Contraction causes no stimulation of autophosphorylation of isolated IRs (287) or IRTK 
activity in human muscle (316), and has no effect on IRS-1-associated PI 3-kinase activity in 
human skeletal muscle (316). Short-term endurance training did not alter IR or IRS-1 mRNA 
expression (297). Chronic exercise is associated with increased insulin sensitivity, enhanced 
insulin-stimulated phosphotyrosine-associated PI 3-kinase activity and decreased levels of 
IRS-2 in skeletal muscle (122,143).  
 
MAPK signalling pathways are activated in human skeletal muscle in response to acute, 
short-term exercise (17,152,307,308) and endurance running (31,333). MAPK signalling 
pathways appear to play a critical role in the transcriptional regulation of muscle genes in 
response to exercise (308). For example, activation of ERK1/2 and JNK by exercise and 
contraction is associated with the rapid induction of immediate early genes such as c-fos (261) 
and c-jun (15,16).  
 
Despite contradictory data on effects of physical training on insulin signalling in humans, it is 
well established in rats that exercise stimulates glucose uptake by enhancing the translocation 
of GLUT4 (70,117). Such glucose transporter recruitment can occur independent of PI 3-
kinase (163,175,323). This documents that exercise and insulin trigger GLUT4 translocation 
in muscle by effects on different signalling mechanisms.  
 
AMPK is an important mediator of muscle contraction-induced glucose transport (311). An 
increase in AMPK activity in response to muscle contraction or exercise correlates with 
GLUT4 translocation and glucose transport in skeletal muscle (336). The greater the force 
production generated by contraction (125), or the greater the intensity of treadmill running 
exercise (226), the greater the activation of AMPK. In humans, moderate-intensity cycle 
exercise (86,312,317), as well as high-intensity ’sprint’ exercise (51) increases skeletal 
muscle AMPK activity. Transgenic overexpression of a dominant inhibitory mutant of AMPK 
in skeletal muscle completely blocks the ability of hypoxia to activate glucose uptake, 
whereas only partially reducing contraction-stimulated glucose uptake (202). Thus, AMPK-
dependent and AMPK-independent pathways contribute to the regulation of glucose uptake in 
skeletal muscle in response to exercise.  
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Hyperglycaemia  
Type 1 diabetes. Patients with type 1 diabetes are insulin resistant compared to age, gender 
and weight-matched normal subjects, if glycaemic control is poor (330). Improvement of 
glycaemic control by continuous subcutaneous insulin infusion therapy enhances insulin 
action despite reduced insulin requirements (329). Insulin sensitivity is also normal in clinical 
remission of type 1 diabetes (330). These observations suggest that hyperglycaemia itself 
induces insulin resistance and this indeed has been shown to be the case (328).  
 
Type 2 diabetes. Although the pathogenesis of insulin resistance in type 2 diabetes almost 
certainly is multifactorial, the degree of insulin resistance in type 2 diabetes is proportional to 
glycaemic control (326)  as is the case in type 1 diabetes. Indeed, the insulin resistance which 
characterizes patients with type 2 diabetes, but not equally obese non-diabetic patients with a 
family history of diabetes, can largely be attributed to chronic hyperglycaemia (167).  
 
Possible mediators of hyperglycaemia-induced insulin resistance. 
Except the hyperglycaemia-induced activation of PKC, which leads to the inhibition of the 
IRTK activity (32) and thus, insulin resistance, the molecular mechanism of hyperglycaemia 
remained, however, a mystery until 1991 when the hexosamine pathway was discovered. The 
rate-limiting enzyme of the hexosamine pathway, glutamine fructose-6-phosphate 
amidotransferase (GFA) converts glutamine and fructose-6-phosphate to glucosamine-6-
phosphate (285). The end-product of the hexosamine pathway, uridine diphosphate-N-acetyl-
glucosamine (UDP-GlcNAc) is attached to the OH group of threonine and serine residues of 
proteins, which results in O-glycosylation of proteins (110). Glucosamine bypasses the rate-
limiting reaction in the hexosamine pathway. In rats, infusion of glucosamine increases 
muscle UDP-GlcNAc concentration, and decreases insulin-stimulated glucose transport and 
glycogen storage. It has multiple effects on insulin signalling molecules: reduction in insulin-
stimulated IRS-1 tyrosine phosphorylation, IRS-1 association with the p85 regulatory subunit 
of PI 3-kinase and IRS-1-associated PI 3-kinase activity, as well as decrease in insulin-
stimulated GS activity (215). Glucosamine also increases O-linked UDP-GlcNAc 
modification of IRS-1 and IRS-2 (215). In humans, GFA activity is increased in proportion to 
the degree of hyperglycaemia in skeletal muscle of patients with type 2 diabetes (327). 
Transgenic mice overexpressing GFA in muscle and adipose tissue exhibit whole-body 
insulin resistance (59). 
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Insulin signalling defects in diabetic subjects. 
Data are conflicting regarding insulin signalling in skeletal muscle of non-obese or 
moderately obese type 2 diabetic subjects. IR tyrosine phosphorylation has been found to be 
normal in the quadriceps femoris muscle of type 2 diabetic subjects incubated in vitro for 40 
min in the absense or presence of insulin (2.4-60 nmol/l), with the peak phosphorylation at 8 
min (151). Other studies have found impaired phosphorylation of IR or decreased IRTK 
activity (14,177,207). In other studies IRTK activity was similar in subjects with and without 
type 2 diabetes (144). Insulin-stimulated GLUT4 translocation and PI 3-kinase activity have 
been reported to be decreased (27,61,151) or normal (106,216).  
 
Excess of counterregulatory hormones 
Catecholamines, growth hormone and cortisol all decrease muscle glucose uptake and induce 
insulin resistance in vivo in skeletal muscle and in the liver (165,232,233).  
 
Chronic growth hormone excess in rodent models decreases IR, IRS-1, and IRS-2 tyrosine 
phosphorylation in response to insulin in skeletal muscle (69). Growth hormone also acts 
directly in fat cells by increasing lipolysis, which may exacerbate insulin resistance in the 
liver and skeletal muscle. Growth hormone therefore induces insulin resistance and causes 
hyperglycaemia, and is recognized as the main cause of the clinical Dawn phenomenon in 
type 1 diabetic subjects (40).  
 
β-adrenergic agents such as isoprenaline (isoproterenol), when incubated in vitro with 
adipocytes decreases apparent insulin-binding affinity, with no change in receptor number 
(219). This effect is mimicked by cAMP analogues and agents such as the phosphodiesterase 
inhibitor methylxanthine, which increases intracellular cAMP levels (219). Interestingly, 
epinephrin also causes translocation of GLUT-4 to the plasma membrane in muscle, but 
glucose transport in inhibited at high physiological concentrations because it also breaks 
down muscle glycogen, thus increasing intracellular glucose-6-phosphate (G6P) levels (164). 
α-Adrenergic agonists do not elicit these effects.  
 
Hypercortisolaemia is associated with increased glucose production by the liver (9), 
decreased peripheral glucose uptake and utilization (63,209), decreased protein synthesis, and 
increased protein degradation in muscle (224). There are no data on effects of glucocorticoid 
treatment or endogenous hypercortosolaemia on insulin signalling in human skeletal muscle. 
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Cortisol is also produced outside the adrenal gland in tissues such as subcutaneous and 
visceral adipose tissue and the liver (255) in humans in a reaction catalyzed by 11β-HSD-1. 
Transgenic mice overexpressing 11β-HSD-1 in subcutaneous adipose tissue develop a full-
blown metabolic syndrome characterized by visceral obesity and insulin resistance (183). 
11β-HSD-1 activity is increased in adipose tissue of obese as compared to non-obese subjects 
(225). The role, of any of excess of 11β-HSD-1 in causing insulin resistance in humans is 
unclear but under intense investigation. 
  
Elevated circulating FFAs 
Plasma FFAs modulate insulin sensitivity and metabolic actions of insulin in skeletal muscle, 
heart and the liver (25,29,155,208). In the liver, FFAs stimulate glucose production and 
induce hepatic insulin resistance (80). FFAs also impair insulin-stimulated glucose uptake in 
human skeletal muscle and the heart (208).  
 
Dresner et al. reported the reduction of glucose transport activity, IRS-1 tyrosine 
phopshorylation and IRS-1-associated PI 3-kinase activity after acute elevations in FFAs  in 
healthy non-obese individuals (72). Similar finding were found by Griffin et al. in rats after a 
5 h infusion of lipids to raise plasma FFA levels (99).  
 
The mechanism underlying insulin resistance in human skeletal muscle induced by FFAs is 
controversial. First, Randle proposed that FFAs compete with glucose as the major energy 
substrate in cardiac muscle, leading to decreased glucose oxidation when FFAs are elevated 
(223). He showed that in the heart FFAs increased citrate and G6P concentration and the latter 
inhibited glucose phosphorylation by hexokinase (223). Since visceral fat is observed to be 
less sensitive to insulin than subcutaneous fat, the resulting direct flux of FFAs from visceral 
adipocytes through the portal vein to the liver can stimulate glucose production in the liver 
(244) - a single signal for insulin action and insulin resistance to the liver. These findings led 
Bergman and coworkers to propose the ’single gateway hypothesis’ (25). However, G6P 
levels and intracellular glucose decrease rather than increase in response to increased lipid 
availability in human skeletal muscle (72,150). In type 2 diabetic subjects the intracellular 
glucose concentration was 2-fold reduced, a value that was 1/25 of it what be if hexokinase 
were the rate-controlling enzyme in glucose metabolism (56). The latter suggests a rate-
limiting step at the level of glucose transport rather than phosphorylation.  
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Finally, infusion of intralipid to rats seems to activate the hexosamine pathway (239) and 
induce insulin resistance, which is why the hexosamine pathway has been called a nitrient-
sensing’ pathway. In humans, Gumbiner et al. examined IR tyrosine phosphorylation in 
muscle biopsies taken before and after lipid/heparin infusion and found no reduction in IR 
autophosphorylation (103).  
 
Taken together, the molecular mechanisms underlying FFA-induced insulin resistance in 
human skeletal muscle are still unresolved, although glucose uptake seems rate-limited at the 
level of transport rather than phosphorylation.  
 
IMCL 
Recently, several studies have shown an association between lipid accumulation in skeletal 
muscle and insulin resistance (83,94,128,153,181,214,221). In four of these studies, this 
relation was shown to be caused by intramyocellular rather than extramyocellular lipids, as 
measured by 1H-MRS (83,128,153,218). In humans, it is unclear whether IMCL is associated 
with insulin resistance independent of obesity. In 20 Europeans, Forouhi et al. (83) found the 
relationship  between IMCL and insulin resistance to disappear after adjusting for obesity. In 
another study, no relation was found between IMCL and whole-body insulin sensitivity 
measured using the insulin tolerance test (221). In two other studies performed in offspring  of 
type 2 diabetic patients, insulin resistance could not be attributed to obesity (128,218). Krssak 
et al. (153) found that IMCL did not correlate with insulin sensitivity, but in that study, both 
men and women were included and analyzed as one group. Women appear to have more 
IMCL than men for the same BMI (218) but similar insulin sensitivity; women also have 
greater adiposity than men with similar BMI (325). That's why, there is a lack of a correlation 
between IMCL and insulin sensitivity as it may have been confounded by the mixing of sexes.  
 
At the cellular level, IMCL can interfere with insulin signalling via several mechanisms. They 
include inhibition via PKC activation and ceramide formation. In addition, LCACoAs can 
directly inhibit enzyme activity such as hexokinase (270) and GS (47). Increased glucose 
metabolism in muscle will exacerbate these effects, as this will enhance production of 
malonyl CoA, which inhibits oxidation of fatty acids. DAG inhibits insulin-stimulated IRS-1-
associated PI 3-kinase activity (137,169,199). Treating various cell lines with phorbol esters, 
which mimic the effects of DAG, inhibits insulin signalling to IRS-1 (137) and PKB (199). 
Moreover, several PKC isoforms including PKC α (52,53), β1 and β2 (32,126), δ (126,137), γ 
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(52), and τ (99,137) are downstream effectors of DAG that antagonize insulin signalling by 
phosphorylating IRS-1 on inhibitory serine residues. Rodent models of insulin resistance 
showed elevated levels of DAG (250). DAG derived from polyunsaturated FFAs is a stronger 
activator of PKC, than that from saturated FFAs (298). Ceramide blocks insulin signalling by 
preventing the activation of PKB (251,274) by accelerating PKB dephosphorylation via PTP 
2A (243,253,280).  
 
In humans, IMCL can be rapidly modified since infusion of FFAs can increase IMCL in 
soleus and tibialis muscle in healthy men during a 5 h hyperinsulinaemic euglycaemic clamp 
(36). The changes in plasma FFAs and IMCL-TG also induced insulin resistance in those 
subjects (36). Infusion of insulin for 67 h has also been shown to increase IMCL content in 
soleus muscle and intrahepatic lipid content in diabetic patients (11). Fasting for 72 h 
increases plasma FFA concentration and accumulation of IMCL in the vastus lateralis muscle 
(267). Chronic interventions, like weight loss following gastric bypass surgery, have been 
shown to decrease IMCL in type I and II muscle fibers and enhance insulin action (96). 
Biliopancreatic diversion which was accompanied by weight loss normalized insulin 
sensitivity, GLUT4 expression in skeletal muscle, leptin concentrations and markedly 
decreased IMCL (97). 
 
Infections 
Acute and chronic infections impair glucose tolerance (246) and may complicate maintenance 
of good glycaemic control in diabetic patients (228). This deterioration is due to insulin 
resistance in both skeletal muscle and the liver (293). The exact mediators of insulin 
resistance are unclear but could involve increased secretion of counterregulatory hormones, 
TNFα, and interleukins (189-191,258). TNFα-induced insulin resistance is due to reduced 
tyrosine phosphorylation of IRS-1 (120) because of increased serine phosphorylation of IRS-1 
(134,276). The mechanisms via which counterregulatory hormones induce insulin resistance 
have been discussed above. 
 
IL-6 inhibits insulin signalling in hepatocytes (257). Members of the suppressor of cytokine 
signalling (SOCS) family are associated with the IR, and their ectopic expression inhibits IR 
signalling (258). Several SOCS proteins are induced by IL-6. Ectopically expressed SOCS-3 
leads to a decrease in insulin-dependent IR phosphorylation, IRS-1 tyrosine phosphorylation, 
association of IRS-1 with the p85 subunit of PI 3-kinase, and activation of PKB in 
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hepatocytes. These data suggest that induction of SOCS-3 in liver may be an important 
mechanism of IL-6 mediated insulin resistance (258).  
 
2.1.3. Genetic defects in regulators of insulin action in humans 
Genes encoding key elements of the insulin signal transduction pathway may be responsible 
for both the defects of insulin action and insulin secretion. Several of these genes are also 
expressed in pancreatic β-cells, and recent results from knockout animals have demonstrated 
that insulin signalling itself may play an important role in the mechanisms of insulin secretion 
(156,313). 
 
More than 100 different mutations have been found in the coding regions of the IR gene on 
chromosome 19p (279,294). These patients have severe insulin resistance associated with 
leprechaunism, or with acanthosis nigricans, hirsutism and marked hyperinsulinaemia (82). 
Mutations of the α-subunit of the IR lead to complete loss of its function and development of 
leprechaunism (147) or partial loss of IR function and development of Rabson-Medenhall 
syndrome (91). Mutations in the tyrosine kinase domain of the IR lead to type A insulin 
resistance (hyperandrogenism, polycystic ovary syndrome, oligo- or amenorrhoea, 
anovulation, acne, baldness, short stature, muscle cramps) (133). 
 
Arg972 polymorphism of IRS-1 in its heterozygous form is associated in obese non-diabetic 
subjects with a 50 % reduction in insulin sensitivity compared to obese subjects without 
polymorphism, indicating that the polymorphism potentiates obesity-associated insulin 
resistance (54). Expression of the Arg972 IRS-1 variant in L6 myocytes results in a 
significant decrease in GSK3 phosphorylation and inactivation by PKB (124). Overall, these 
results suggest that the Arg972 IRS-1 polymorphism might contribute to the development of 
insulin resistance by impairing the ability of insulin to activate IRS-1/PI 3-kinase/PKB/GSK3 
signalling pathway, thus leading to defects in glucose transport, glucose transporter 
translocation and glycogen synthesis. Several additional polymorphisms and amino acid 
substitutions have been described, but their frequency is lower than that of the Arg972 variant 
(259). 
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In contrast to the insulin-resistant phenotype of IRS-2 -/- mice, polymorphisms of the human 
IRS-2 gene do not appear to contribute to the pathogenesis of either the common form of type 
2 diabetes or early-onset autosomal dominant type 2 diabetes (259). IRS-3 is not expressed in 
human tissues (26). Polymorphisms of the IRS-4 gene are common in Caucasians but do not 
seem to be associated with type 2 diabetes or insulin resistance (8). Similarly, an association 
between polymorphisms of the muscle GS gene on chromosome 19q and type 2 diabetes has 
been observed in Finnish (101) and Japanese (159) but not in French subjects (337). Taken 
together, these results suggest that the IRS-1 and muscle GS genes may act in some 
populations as minor susceptibility genes for insulin resistance. Recently, a rare P387L 
variant in PTB-1B has been described and associated with a 3.7-fold genotype-relative risk of 
type 2 diabetes in a Danish Caucasian population. This variant impairs in vitro serine 
phosphorylation of the PTP-1B protein (74). 
 
The regulatory G-subunit of the glycogen-associated form of PP1 plays a crucial role in 
muscle tissue glycogen turnover. Gene encoding for this protein is polymorphic at codon 905 
and has been associated with insulin resistance and insulin hypersecretion in Danish patients 
with type 2 diabetes (108). 
 
The β3-adrenergic receptor, located mostly in visceral fat, is involved in the regulation of 
lipolysis and thermogenesis (172). A point mutation in the gene encoding this receptor is 
associated with increased susceptibility to gain weight in a population of morbidly obese 
subjects (55), with a reduced metabolic rate and early onset of type 2 diabetes (300), and with 
the development of upper body obesity and insulin resistance (309) in patients with type 2 
diabetes. 
 
Peroxisome proliferator activated receptor (PPAR) γ2 gene has a Pro12Ala polymorphism
that may cause a reduction in the transcriptional activity of PPARγ, and, hence, is associated
with decreased insulin resistance and decreased risk of type 2 diabetes (272). In an obese 
group, subjects with Ala12 were more insulin sensitive than those without. The frequency of 
Ala12 was significantly lower in the diabetic group, suggesting that this polymorphism 
protects against type 2 diabetes (131). 
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2.2. Insulin signal transduction in adipose tissue 
2.2.1. Overview of insulin action in adipose tissue 
Adipocytes possess receptors for growth factors (IGF-I and –II, epidermal, platelet-derived, 
and fibroblast growth factors), hormones (insulin, glucagon, growth hormone, 
glucocorticoids, androgen, estrogen, progesterone, triiodothyronine, thyroid-stimulating 
hormone), cytokines (leptin, TNF-α, IL-6), vitamin D, very low density, low-density, and 
high-density lipoproteins, nuclear factors (PPARγ, RAR/RXR), catecholamines (β-1,2,3, α-
1,2) and peptides (gastrin, gastric inhibitory peptide, glucagon-like peptide-1, neuropeptide Y-
Y1, atrial natriuretic peptide, neuropeptide) (85). 
 
Insulin is a key regulator of adipocyte metabolism. Insulin promotes lipogenesis by several 
mechanisms, including fostering of differentiation of preadipocytes to adipocytes and, in 
mature adipocytes, by stimulating glucose transport and TG synthesis and by inhibiting 
lipolysis (231). Insulin stimulates adipocyte lipogenesis by stimulating the activities of 
pyruvate dehydrogenase (PDH), acetyl CoA carboxylase and fatty-acid synthetase. Insulin 
increases glucose uptake and hence the availability of pyruvate for de-novo fatty-acid 
synthesis, glycerol-phosphate for FFA esterification by inhibiting adipocyte lipolysis via 
hormone-sensitive lipase and by promoting FFA re-esterification. In vivo, a small increment 
of 10-15 mU/l in plasma insulin above fasting is sufficient to suppress circulating FFA 
concentrations (30). 
 
The antilipolytic effect of insulin requires much lower insulin concentrations than stimulation 
of glucose transport. Hence, even in insulin resistant states in which glucose transport is 
impaired, sensitivity to insulin’s antilipolytic effect is relatively preserved, resulting in 
maintenance or expansion of adipose stores (132). The sensitivity of adipocytes to lipolytic 
triggers depends on their localizations. Lipolytic activity is the highest in visceral, lower in 
abdominal subcutaneous, and the lowest in peripheral subcutaneous adipocytes. Human 
subcutaneous adipocytes express β1- and β2-adrenoreceptors (154). Visceral adipocytes also 
express β3-adrenoreceptors, which contribute to lipolysis. Unlike in humans, peripheral white 
adipocytes of rats and mice contain high levels of the β3-adrenoreceptors, while the 
expression of β3-adrenoreceptors in visceral adipocytes of the obese Zucker rat and the obese 
ob/ob mouse is decreased (154). Several studies suggest that subjects with larger 
subcutaneous adipocytes are more prone to the development of insulin resistance and type 2 
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diabetes, independently of total body fat mass or distribution. This observation has recently 
been confirmed in a prospective study of Pima Indians (304,305). 
 
Insulin action in adipocytes involves changes in gene transcription that involves regulation of 
a variety of transcription factors. These proteins are expressed in a cascade in which CCAAT 
enhancer binding protein (C/EBP) β and δ are among the earliest seen. These two proteins
induce expression of PPARγ, which in turn activates C/EBPα. C/EBPα feeds back on PPARγ 
to maintain the differentiated state. C/EBP β and δ double knockout mice express normal 
levels of PPARγ and C/EBPα, suggesting the existence of a C/EBP-independent mechanism 
for inducing PPARγ. This may involve a transcription factor known as adipocyte 
differentiation and determination factor 1 (ADD1)/SREBP. It can activate PPARγ by inducing 
its expression as well as by promoting the production of an endogenous PPARγ ligand. These 
factors contribute to the expression of genes which characterize the terminally differentiated 
adipocyte phenotype (237). Transcription factors of the forkhead family may also play a 
major role in transducing insulin signals to the nucleus (145). Moreover, the differentiation of 
human preadipocytes to mature adipocytes was characterized by a marked (>10-fold) increase 
in IRS-1 protein expression whereas IRS-2 expression was only modestly increased (>2-fold) 
(217). These changes were associated with full development of the human adipocyte 
phenotype, including increased insulin-stimulated glucose transport capacity and increased 
expression of GLUT4 (217). 
 
Insulin resistance in obesity and type 2 diabetes is manifested by decreased insulin-stimulated 
glucose transport and metabolism in adipocytes and skeletal muscle and by impaired ability of 
insulin to suppress hepatic glucose output (46). These functional defects may result from 
impaired insulin signalling in all three target tissues and, in adipocytes, also from 
downregulation of the major insulin-responsive glucose transporter GLUT4. In both muscle 
and adipocytes, insulin binding to its receptor, receptor phosphorylation and tyrosine kinase 
activity, and phosphorylation of IRSs are reduced (46). In adipocytes from obese humans with 
type 2 diabetes, IRS-1 expression is reduced, resulting in decreased IRS-1-associated PI 3-
kinase activity, and IRS-2 becomes the the main docking protein for PI 3-kinase (235). In 
contrast, in skeletal muscle of obese, type 2 diabetic subjects, IRS-1 and IRS-2 protein levels 
are normal but PI 3-kinase activity associated with both IRSs is impaired (142).  
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Mice with fat-specific disruption of the insulin receptor gene (FIRKO mice) have low fat 
mass and are protected against age-related and hypothalamic lesion-induced obesity, and 
obesity-related glucose intolerance (28). Primary adipocytes from knockout mice lacking 
IRS-1 showed a decrease in glucose transport and GLUT4 translocation to the plasma 
membrane in response to insulin (278). In agreement with these results, it has been shown in 
human adipocytes that IRS-1 is the main docking protein for the binding and activation of PI 
3-kinase in response to insulin (235). Recent studies show reduced IRS-1 expression in 
adipocytes of not only in morbidly obese and type 2 diabetic, but also of healthy first-degree 
relatives of type 2 diabetic subjects (44,45) as well as insulin-stimulated PI 3-kinase activity 
and insulin-stimulated glucose transport and GLUT4 expression (45). 
 
2.2.2. Adipocytokines 
Adipocytes secrete a wide range of products (85), which may impair insulin action through 
endocrine effects on distant target tissues and/or have paracrine actions on neighbouring cells. 
Cytokines are soluble proteins synthesized by immune or non-immune cells, which mediate 
intercellular communication by transmitting information to target cells through receptor-
ligand interactions. 
 
TNFα expression is increased in obesity, and interferes with insulin signalling by inducing 
phosphorylation of IRS-1 at serine residues and thus, inhibiting IR activity (119,135). TNFα 
rapidly inhibits insulin signalling at the level of PI 3-kinase and insulin-stimulated glucose 
transport in isolated human adipocytes (170). The effect of TNFα correlated with inhibition of
tyrosine phosphorylation of IRS-1 while autophosphorylation of the IR β-subunit was 
unaffected (170).  
 
IL-6 production is positively correlated with BMI (291). Human omental fat produces more 
IL-6 than subcutaneous adipose tissue. TNFα increases IL-6 production in differentiated 3T3-
L1 adipocytes (102). 
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Adiponectin (also known as Acrp30 and AdipoQ) is a cytokine-like protein with some 
structural homology to TNFα. Adiponectin expression and/or secretion is increased by insulin 
like growth factor-1 and PPARγ agonists, and decreased by TNFα, glucocorticoids, β-
adrenergic agonists and cAMP (268). In rodents, adiponectin expression and secretion fall 
with increasing fat mass, and its replenishment improves insulin resistance in various models 
of genetic and dietary-induced obesity (22). In lipodystrophic mice models, adiponectin and 
leptin ameliorated insulin resistance (263,321). In both lipoatrophic and obese mice, infusion 
of adiponectin increased β-oxidation of FFA in muscle and decreased TG content in skeletal 
muscle and the liver (321). Treatment with insulin-sensitizing PPARγ agonists such as
rosiglitazone increases adiponectin expression (58). 
 
In humans, circulating adiponectin levels are low in obesity (13) and type 2 diabetes (121), 
and increase with weight loss (22,322). However, an increase in subcutaneous fat mass in 
obesity may not explain such a reduction since serum adiponectin concentrations are also 
reduced in generalized forms of non-HIV lipodystrophy (109). It is possible that insulin 
resistance in both obese subjects and patients with LD is determined by the amount of fat in 
the liver and skeletal muscle (227). 
 
Adiponectin inhibits the inflammatory process and possibly atherogenesis by suppressing the 
migration of monocytes/macrophages and their transformation into foam cells (212). 
Hypoadiponectinaemia was found as an independent risk factor for coronary artery disease in 
age-matched Japanese subjects (158). 
 
Adiponectin enhances insulin sensitivity in both muscle and the liver by activating AMPK 
(320). This is accompanied by an inhibition of acetyl-CoA carboxylase and increased FFA 
oxidation in myocytes and a reduction of molecules involved in gluconeogenesis in the liver 
(320). The adiponectin gene is localized on human chromosome 3q27, a locus that has been 
associated with susceptibility to type 2 diabetes and the metabolic syndrome in genetic studies 
(273). Furthermore, adiponectin is a sticky molecule which accumulates in vessel walls and 
inhibits TNF-α-induced cell adhesion, and may therefore protect against endothelial 
dysfunction (211).  
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Leptin, a protein product of the ob gene, is secreted by fat cells in proportion to body fat 
stores (286). Leptin decreases food intake and increases energy expenditure. Leptin mRNA 
expression is higher in subcutaneous than omental adipocytes (196). Large fat cells contain 
more leptin than small adipocytes of the same individual (3,60). Insulin in vivo increases 
leptin secretion. This action of insulin does not seem to be affected by insulin resistance in 
type 2 diabetes (180,289). PPARγ agonists inhibit leptin expression (64). 
 
PAI-1 is a member of the family of serine protease inhibitors and is the main regulator of the 
endogenous fibrinolytic system (310). Elevated plasma concentrations of PAI-1 have been 
found in obese (129) as well as lipodystrophic subjects (332). Increased PAI-1 concentrations 
may contribute to the prothrombotic state in obesity and type 2 diabetes (262).  
 
Resistin is the product of an adipocyte-specific gene whose expression is regulated by PPARγ 
agonists and insulin (111,112,197,301) and was shown to cause insulin resistance in mice 
(269). The human homologue of resistin is expressed in circulating monocytes and at very 
low levels in adipose tissue (204). Thus, data regarding the role of resistin in the development 
of obesity and insulin resistance are contradictory (269,301). 
 
2.2.3. Lipodystrophy and insulin resistance 
Human lipodystrophies 
The LDs are a heterogeneous group of disorders characterized by local LD and loss of body 
fat (lipoatrophy) (88). Atrophy can be localized (’partial’ lipodystrophy) or complete 
(’generalized’ lipodystrophy) (230). LDs can be genetic, autoimmune, inflammatory or 
acquired. The most common lipodystrophic condition in humans is that caused by HAART in 
patients with HIV (Table 2). The phenotype associated with LD is variable and characterized 
by hypertriglyceridaemia, insulin resistance, and increased risk of type 2 diabetes and 
cardiovascular disease. Insulin resistance is present in patients with genetic LDs, specifically 
autosomal dominant partial lipodystrophy of the Dunnigan type and autosomal recessive 
complete LD of the Berardinelli-Seip type.  
 
Recently, a new form of genetic LD was identified when three lipodystrophic patients were 
found to have dominant negative mutations in the PPARγ gene (19). The affected subjects 
had severe insulin resistance, hypertension, dyslipidaemia, and hyperuricaemia. The LD is 
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similar to that seen in familial partial Dunnigan LD and HIV-associated, with a paucity of 
limb and gluteal fat, but normal facial and abdominal fat (91). 
 
Table 2. Characterization of human lipodystrophies. Adapted from reference 88. 
Type of lipodystrophy  Insulin 
resistance 
Age of 
onset 
Localization of 
fat loss 
Localization of 
fat excess 
1. Familial/genetic types 
 
    
1.1.Congenital generalized 
LD (Berardinelli-Seip 
syndrome)  
+ + + Birth Face, neck, trunk, 
limbs, intra-
thoracic and intra-
abdominal, bone 
marrow 
 
1.2.Familial partial LD     
1.2.1.Dunnigan variety + + Puberty Trunk, limbs None 
1.2.2.Köberling variety +  Not 
known 
Limbs Trunk 
1.2.3.Mandibuloacral 
dysplasia 
- (+) Not 
known 
Limbs  
2. Acquired types      
2.1.Acquired generalized 
LD (Lawrence syndrome) 
+ + +  Childhood Face, neck, trunk, 
limbs, palms, 
soles 
None 
2.2.Acquired generalized 
LD (Barraquer-Simons 
syndrome) 
− (+) Childhood Face, neck, upper 
trunk, upper 
limbs 
Lower 
abdomen, hips, 
lower limbs 
2.3.LD in HIV infected 
patients 
+ + All ages Face, trunk, limbs Neck, upper 
body, intra-
abdominal 
2.4.Localized LD: induced 
by drugs  
- All ages Depends on the 
cause 
 
2.5.Idiopathic - (+) All ages   
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A striking syndrome of peripheral LD, hyperlipidaemia and insulin resistance characterizes 
patients receiving HAART. Up to 53 % of patients using HAART may experience some 
degree of LD within the first year of treatment, making this the most common form of human 
LD (42,43). Typical features include fat wasting over the face, limbs and buttocks, with fat 
accumulation in the abdomen and/or dorsocervical spine (’buffalo hump’). This is associated 
with insulin resistance, which in some cases progresses to diabetes and dyslipidaemia. 
Although the LD has been most commonly associated with the use of protease inhibitors, 
nucleoside analogues may also cause the syndrome (43,100). The mechanism of developing 
LD is not understood.  
 
Lessons from genetically engineered animals 
Studies in lipoatrophic mice have provided insight into the pathogenesis of insulin resistance 
characterizing not only obese but also lipoatrophic subjects. There are three mouse models of 
complete lipoatrophy. The first model was created by Ross et al. and used targeted expression 
of an attenuated diphtheria toxin to adipose tissue (238). All mice died within a day of birth 
with chylous ascites. The second model was created by Moitra et al. by expression of an 
artificial transcription factor in adipose tissue, which prevented DNA binding of β-ZIP 
transcription factors such as C/EBP and Jun which are critical for adipocyte growth and 
differentiation (194,292). The resulting A-ZIP/F-1 transgenic mice lacked visible white 
adipose tissue during development. The third transgenic mice model of LD was created by 
overexpression of SREBP1c in adipose tissue (264). It is unclear why overexpression of an 
active SREBP1c would result in white adipose tissue deficiency. The second and the third 
models are similar in that both feature absent white adipose tissue, insulin resistance, 
hyperglycaemia, hyperlipidaemia, organomegaly and a fatty liver. The models differ in that 
the A-ZIP/F1 mice lack both white and brown adipose tissue, while SREBP1c mice have 
increased amounts of immature brown adipose tissue and Pref-1, the biochemical marker of 
immature white adipose tissue. 
 
Insulin signalling abnormalities in transgenic models. A-ZIP/F1 mice had a defect in insulin 
activation of IRS-1 in muscle and IRS-1-associated PI 3-kinase activity in liver  (141). In 
SREBP1c overexpressing mice, baseline levels of IRS-1 and IRS-2 were low in adipocytes, as 
was IRS-2 in hepatocytes (264,265).  
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Leptin and adiponectin. In A-ZIP/F1 mouse model of lipoatrophic diabetes leptin 
overexpression partially improved insulin action (73). Leptin replacement has also recently 
been shown to reverse insulin resistance in human subjects with lipoatrophic diabetes and low 
circulating leptin levels (210). All murine models of LD showed both insulin resistance and 
decreased leptin levels. In mice with adipocyte specific SREBP1c overexpression, leptin 
administration improved insulin sensitivity, decreased plasma glucose levels, decreased 
excess hepatic fat, but did not correct the lipodystrophy (263). In contrast, leptin 
administration only minimally improved insulin resistance in A-ZIP/F1 mice (90), while 
offspring from crosses with leptin overexpressing mice showed decreased insulin and 
improved hepatic steatosis (73). Thus, leptin may not be the sole factor contributing to 
improved insulin resistance in LD. Treatment of lipoatrophic diabetes with adiponectin 
improved insulin resistance, and the effects were additive to those of leptin (321). 
 
Fat transplantation. Implantation of white adipose tissue into A-ZIP/F-1 mice completely 
corrected hyperglycaemia and hyperinsulinaemia, and glucose uptake (89). Euglycaemic and 
hyperinsulinaemic clamp studies of white adipose tissue transplanted A-ZIP/F-1 mice showed 
normalization of insulin activation of IRS-1 and IRS-2-associated PI 3-kinase activity in 
muscle and liver respectively, along with decreased TG levels in liver and muscle (89). This 
demonstrates that subcutaneous fat contributes to maintenance of normal insulin sensitivity, 
and also that intrahepatocellular and intramyocellular lipid cause insulin resistance.  
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3. AIMS OF THE STUDY 
 
The present study was undertaken to identify: 
 
1. Early defects of insulin signalling in skeletal muscle of healthy lean subjects, 
specifically their association with potential signs of subclinical insulin resistance such as 
elevated fasting insulin concentrations (study I) and increased intramyocellular lipid content 
(study II). 
 
2. Potential defects in markers of adipogenesis, inflammation and secretion of 
adipocytokines in adipose tissue of insulin resistant patients with HAL, specifically 
alterations in the expression of adipogenic transcription factors, PGC-1 and inflammatory 
markers (study III), and circulating concentration of adiponectin and its expression in the 
adipose tissue (study IV). 
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4. STUDY DESIGNS 
 
4.1. Measurement of key insulin signalling molecules in freeze-dried and purified muscle 
in animals and healthy subjects (study I) 
Animals. Male Wistar rats (95-115 g) were purchased from the Helsinki University Animal 
Laboratory. The animals were kept in a 12-h light-dark cycle for 1 week before the 
experiments. After an overnight fast the rats were anaesthetized by an intraperitoneal injection 
of sodium pentobarbital (5 mg/100 g body weight) and then given an intraportal injection of 
either insulin (15 IU) or saline (control group) to obtain tissue samples representing insulin-
stimulated and non-stimulated states.  
 
Human subjects. Thirteen healthy men (42 ± 2 yrs) with a BMI ranging from 21 to 32 kg/m2 
(25.7 ± 0.7 kg/m2, mean ± SEM) with no family history of type 2 diabetes were studied on 
two occasions. On the first occasion, insulin sensitivity was measured using the euglycaemic 
hyperinsulinaemic clamp technique. Before and after 30 min of the insulin infusion, muscle 
biopsies were taken from the left and right vastus lateralis muscles, for determination of early 
insulin signalling steps. On the second study occasion, maximal oxygen consumption 
(VO2max) was measured directly using an incremental bicycle ergometer test. The subjects 
were divided by their median fasting insulin concentration in two groups (Table 3). 
 
Table 3. Characteristics of the groups in study I 
 Fasting insulin < median 
 
Fasting insulin > median 
Number of subjects 6 7 
Fasting serum insulin (mU/l) 4 ± 1 8 ± 1** 
Age (years) 45 ± 3 44 ± 3 
Body mass index (kg/m2) 24 ± 1 25 ± 1 
VO2max (ml/kg· min) 37 ± 4 34 ± 2 
M-value (mg/kg⋅min) 5.5 ± 0.4 3.4 ± 0.4** 
Fasting plasma glucose (mmol/l) 5.2 ± 0.1 5.9±0.3* 
Serum triglycerides (mmol/l) 0.9 ± 0.1 1.4 ± 0.2* 
HDL cholesterol (mmol/l) 1.7 ± 0.1 1.3 ± 0.1* 
Data are means ± SEM, *p < 0.05, **p < 0.005 
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4.2. IMCL and insulin signalling defects in human skeletal muscle (study II) 
A total of 20 healthy men (42 ± 2 years), with a BMI ranging from 21 to 32 kg/m2 (25.7 ± 0.7 
kg/m2, mean ± SEM) and no family history of type 2 diabetes, were studied on three 
occasions. On the first visit, IMCL content was measured using proton spectroscopy of the 
vastus lateralis muscle. On this visit, visceral and subcutaneous fat were also quantified using 
MRI. The subjects were divided into two groups: low IMCL (LoIMCL; 3.0 ± 0.5 resonance of 
intramyocellular CH2 protons in lipids/resonance of CH3 protons of total creatine (CrT) 
[IMCL/CrT]) and high IMCL (HiIMCL; 9.5 ± 0.9 IMCL/CrT) based on their median IMCL 
content (6.1 IMCL/CrT) (Table 4). The LoIMCL and HiIMCL groups were comparable with 
respect to several parameters thought to cause insulin resistance. On the second study 
occasion, maximal oxygen consumption (VO2max) was measured directly using an 
incremental bicycle ergometer test. On the third occasion, insulin sensitivity was measured 
using the euglycaemic hyperinsulinaemic clamp technique. Before and after 30 min of insulin 
infusion, biopsies of the left and right vastus lateralis muscles were taken, respectively, for 
determination of early insulin signalling steps.  
 
Table 4. Characteristics of the groups in study II 
 IMCL > median 
 
IMCL < median 
 
Number of subjects 10 10 
Fasting serum insulin (pmol/l) 55 ± 10 38 ± 4* 
Age (years) 43 ± 3 40 ± 3 
Body mass index (kg/m2) 26 ± 1 26±1 
VO2max (ml/kg· min) 33 ± 2 36 ± 3 
Lean body mass (kg) 67 ± 3 64 ± 3 
Fasting plasma glucose (mmol/l) 5.8 ± 0.2 5.4 ± 0.1 
Serum triglycerides (mmol/l) 1.6 ± 0.3 1.1 ± 0.2 
HDL cholesterol (mmol/l) 1.3 ± 0.1 1.5 ± 0.1 
Data are means ± SEM, *p < 0.05 
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4.3. Expression of adipogenic transcription factors, PGC-1 and inflammatory markers 
in subcutaneous adipose tissue in patients with HAL (study III) 
The patients were recruited from the HIV outpatient clinic of the Helsinki University Central 
Hospital. Patients' characteristics are given in Table 5. The subjects had had to be treated with 
HAART for at least 18 months prior to enrollment. Those belonging to the lipodystrophy 
group (HAART+LD+) had self-reported symptoms of loss of subcutaneous fat with or 
without increased girth, breast size or development of a buffalo hump. A single investigator 
(Jussi Sutinen) confirmed these findings before inclusion in the study. Patients without 
lipodystrophy (HAART+LD-) had received HAART without developing changes in body 
composition.  
 
All patients were studied after an overnight fast at 8 a.m. A blood sample was taken for 
measurement of serum concentrations of glucose, insulin, cholesterol, triglycerides, and HDL 
cholesterol. Thereafter a needle aspiration biopsy of subcutaneous fat was taken under local 
anaesthesia as previously described (331). The fat sample was immediately frozen and stored 
in liquid nitrogen until analysis. In order to quantify any blood contamination of the samples, 
the concentration of haemoglobin was measured based on the absorbance of the homogenized 
sample at 560 nm, which was corrected for circulating haemoglobin concentration and 
homogenized sample size. The groups did not differ in this respect. In addition, in each 
patient the volumes of intra-abdominal and subcutaneous fat depots were determined using 
MRI, and waist-to-hip ratio was measured as detailed below.  
 
4.4. Adiponectin expression in subcutaneous adipose tissue and adiponectin circulating 
concentration in patients with HAL (study IV) 
The same subjects as in study III participated in study IV (Table 5). Hepatic fat was measured 
using 1H-MRS. Adiponectin expression in adipose tissue and its circulating concentrations in 
serum were measured. 
 
The purpose, nature, and potential risks of studies I-IV were explained to the patients before 
their written informed consent was obtained. The studies protocols were approved by the 
ethical committee of the Helsinki University Central Hospital. 
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Table 5. Characteristics of the groups in studies III and IV  
Variable HAART+LD+ 
 
HAART+LD- 
Number of subjects (males/females) 25 / 5  9 / 4 
Age (years) 43 ± 2  39 ± 2 
Weight (kg) 73 ± 2  69 ± 4 
Body mass index (kg/m2) 23.6 ± 0.5  22.4 ± 1.1 
Total abdominal fat/MRI (cm3) 3100 ± 300 2700 ± 500 
Subcutaneous fat / MRI (cm3) 1100 ± 200 1800 ± 300* 
Intra-abdominal fat/MRI (cm3) 1900 ± 200 900 ± 300** 
Waist-to-hip ratio 0.99 ± 0.01 0.89 ± 0.03*** 
Skinfold thickness (mm) 38 ± 3  54 ± 5***  
Plasma glucose (mmol/l) 5.5 ± 0.3 5.0 ± 0.1 
Serum insulin (mU/l) 11 ± 1 6 ± 1** 
C-peptide (nmol/l) 0.81 ± 0.06 0.51 ± 0.09** 
Serum triglycerides (mmol/l) 3.4 ± 0.4 1.2 ± 0.1*** 
Serum HDL cholesterol (mmol/l) 1.1 ± 0.1  1.6 ± 0.1*** 
Liver fat (%) 7.6 ± 1.7 2.1 ± 1.1*** 
Time from diagnosis of HIV (yrs) 8.4 ± 0.6 8.7 ± 1.3 
Duration of HAART (yrs) 4.3 ± 0.2 3.8 ± 0.4 
Currently receiving a protease 
Inhibitor 
73 % 69 % 
Most recent viral load (log10 
copies/ml) 
1.9 ± 0.1 1.6 ± 0.2 
Most recent CD4 count (cells/mm3) 572 ± 54 516 ± 70 
HAART+LD+: HIV-positive patients with HAART-associated lipodystrophy; HAART+LD-: 
HIV-positive patients using HAART but without lipodystrophy; MRI: magnetic resonance 
imaging. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 
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5. METHODS 
 
5.1. Insulin signaling assays (studies I, II) 
5.1.1. Processing of muscle specimens 
Animal experiments (study I). Three minutes after the insulin injection (15 U Actrapid 
intraportally) and pentobarbital anaesthesia rat gastrocnemius muscle was dissected out and 
snap frozen in liquid nitrogen after which the rats were sacrificed with CO2. Gastrocnemius 
muscle was divided into two pieces and snap-frozen in liquid nitrogen. The first piece (’wet’) 
was thawed and homogenized as such (100 mg muscle/1 ml buffer A containing (in mM) 25 
Tris-HCL (pH 7.4), 10 Na3VO4, 100 NaF, 10 Na4P2O7, 10 EGTA, 10 EDTA, 1 
phenylmethylsulfonyl fluoride (PMSF), and 5 µg/ml leupeptin, 5 µg/ml aprotinin, and 1 % 
NP40. The other piece (’dry’) was lyophilized (200-400 Pa, Edward freeze-dryer, Crawley 
Sussex, England) for 14 h, macroscopically dissected free of fat, blood and connective tissue 
at room temperature. The tissue taken for the analysis was a macroscopically pure muscle 
fiber preparate. Both wet and dry samples were homogenized (HETO, Birkerod, Denmark) 
for 2 min (Fig. 2).  
 
Human skeletal muscle (studies I, II). Biopsies of human vastus lateralis muscle were taken 
under local lidocaine anaesthesia with a Bergström needle before and after 30 min of the 
insulin infusion. The two biopsies were taken from opposite sites. The specimen was removed 
from muscle with suction applied through a syringe attached to the needle and then shot by 
rapidly emptying the syringe into liquid nitrogen (296). This procedure allowed the samples 
to be frozen within 3 seconds. The specimens were stored in liquid nitrogen until freeze-
drying. To minimize the variability due to non-muscle contaminants, the muscle biopsy (∼50 
mg) was lyophilized, macroscopically dissected, and pure muscle fibers were homogenized in 
buffer A described earlier. After centrifugation (55 000 rpm, 1 h, +4 o C, 70.1 TI rotor, 
Beckman Instruments, Palo Alto, CA), the supernatant was transferred to another tube and its 
protein content was determined (Pierce, Rockford, IL). The supernatant was thereafter 
aliquoted for direct immunoblotting and immunoprecipitation experiments. 
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Fig. 2. Processing rat and human muscle biopsies. Insulin was administered after overnight 
fast. In rats, a gastrocnemius muscle was dissected out and snap-frozen in liquid nitrogen. 
Each piece was divided in two parts: one was homogenized as such, and the other was freeze-
dried and purified of non-muscle contaminants. After homogenization, ultracentrifugation 
and measurement of the protein concentration, the supernatant was aliquoted for 
immunoprecipitation and SDS-PAGE electrophoresis. Immunoblotting was done using 
specific antibodies and molecules of interest were detected by ECL or autoradiography. The 
PI 3-kinase assay was done using IRS-1 immunoprecipitates. In humans, normolycaemic 
hyperinsulinaemia was maintained for 120 min. Biopsies of vastus lateralis muscle were 
taken before and after 30 min of hyperinsulinaemia. Biopsies were snap-frozen in liquid 
nitrogen, freeze-dried and processed as in the animal experiments. 
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5.1.2. Immunoprecipitation 
To define posttranslational modification (tyrosine phosphorylation of IR) and IRS-1 
associated PI 3-kinase enzymatic activity the muscle homogenates were immunoprecipitated 
with an appropriate antibody (anti-IR or anti-IRS-1) and 40 µl of 50 % protein A-Sepharose 
slurry (6 MB) for 2 h at 4 o C. The beads were washed 3 times with lysis buffer and dried 
before proceeding. For determination of tyrosine phosphorylation (pY) 25 µl of 2x Laemmli 
sample buffer was added on the dried immunoprecipitates, heated (+96 o C) for 3 min and 
stored in –80 o C. For IRS-1-associated PI 3-kinase in vitro assay, the washed and dried 
immunoprecipitates were stored at –80 o C without denaturing the sample (Fig. 2).  
 
5.1.3. SDS-PAGE and immunoblotting 
Supernatants and immunoprecipitates stored at –80 o C in Laemmli sample buffer were heated 
for 3 min before protein separation by sodium dodecyl sulfate/polyacrylamide gel 
electrophoresis (SDS-PAGE). SDS-PAGE gel acrylamide strength was chosen based on the 
size of the protein of interest. After electrophoresis the proteins were transferred to 
polyvinylidene difluoride membranes (Immobilon-P) by transfer using buffer, which 
contained 10 % SDS, 99 % methanol, 1.9 M glycine and 0.25 M Trizma-base. After 
Immobilon-P membranes were blocked in PBS containing 0.1 % Tween-20 and 5 % non-fat 
milk for at least 30 min at room temperature and washed 3 times in PBS-Tween, they were 
subjected to immunoblotting: incubated with primary antibody (against phosphorylated 
tyrosine (pY20) or IR, 1:2 000 or 1:500 dilution) for 1 h, washed 3 times for 10 min, and then 
incubated with secondary HRP-linked rabbit anti-mouse antibodies (1:1 000 dilution), washed 
3 times and detected by ECL.  The films were scanned with tabletop scanner and analyzed by 
Image Gauge software (version 3.12, Fuji Photo Film, Tokyo, Japan). 
 
5.1.4. PI 3-kinase assay 
The dried protein-A Sepharose beads were washed twice with PI 3-kinase reaction buffer 
containing 20 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 0.5 mM EGTA, dried quickly and 
then resuspended in the same buffer supplemented with the PI 3-kinase substrate PI, which 
was freshly suspended in 50 µl of PI 3-kinase reaction buffer by sonication for 10 min at 4 o 
C. PI 3-kinase reaction was initiated by addition of 5 µl of MgCl2-ATP mixture (200 mM 
MgCl2, 200 µM ATP) containing 5 µCi of [γ-32P]-ATP to the immunoprecipitates and 
incubated for 25 min at room temperature. The reaction was terminated by adding 150 µl of 
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chloroform-methanol-11.6 N HCl (100:200:2). After adding 120 µl of chloroform and 120 µl 
of methanol-1 N HCl (1:1) twice the organic phase was separated by centrifugation at 14 000 
rpm for 1 min, the resulting organic phase was dried in SpeedVac (UVS400A, Savant 
Instruments, NY) dissolved in 15 µl of chloroform, spotted on thin layer chromatography 
plates and developed in chloroform-methanol-28 % ammonium hydroxide-water (43:38:5:7) 
for 1 h. The phosphorylated products were visualized by autoradiography after an overnight 
exposure and quantified by Bio-Imaging analyzer (BAS-5000; Fuji, Tokyo). 
 
5.1.5. Materials for insulin signalling assays 
Regular insulin was from Novo Nordisk (Actrapid, Bagsvaerd, Denmark). Polyclonal 
antibodies against the insulin receptor (IR, JD 15, JD 433) and insulin receptor substrate-1 
(IRS-1, JD 288) were generous gifts from Professor C. Ronald Kahn (Joslin Diabetes Center). 
The antibody against the p85 subunit of PI 3-kinase was from Upstate Biotechnology (Lake 
Placid, NY). HRP-linked rabbit anti-mouse and donkey anti-rabbit antibodies, the ECL kit 
and [125I] protein A were from Amersham Pharmacia Biotech (Amersham Place Little 
Chalfont Buckinghamshire, England). [γ-32P] ATP was from NEN Life Science Products, 
Zaventem, Belgium; PI-from Avanti Polar Lipids (Alabaster, Alabama); silica gel thin layer 
chromatography plates-from Merck (Darmstadt, Germany); Immobilon-P transfer membranes 
-from Millipore Corporation (Bedford, MA); protein A Sepharose 6 MB - from Amersham 
Pharmacia Biotech AB (Uppsala, Sweden); reagents for SDS-PAGE-from Bio-Rad 
Laboratories (Richmond, CA). All other reagents were purchased from Sigma Chemical Co. 
(St. Louis, MO). 
 
5.2. Human studies (studies I, II) 
5.2.1. Whole-body glucose uptake 
Whole-body glucose uptake was measured by the euglycaemic hyperinsulinaemic clamp 
technique (66). After an overnight fast, two indwelling catheters were inserted, one in an 
antecubital vein for infusion of insulin and glucose, and another in a hand vein, which was 
kept in a heated chamber (65 o C) to arterialize venous blood (184). The rate of the continuous 
insulin infusion was 40 mU/m2 ⋅ min, or 1 mU/kg ·  4min. The rate of the glucose infusion was 
adjusted to maintain euglycaemia based on plasma glucose measurements that were 
performed every 5 minutes from arterialized venous blood. Whole-body insulin sensitivity 
(M-value) was calculated from the glucose infusion rate needed to maintain euglycaemia after 
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correction for changes in the glucose pool size (66). Blood samples were taken at 30 min 
intervals for measurement of serum free insulin concentrations. The muscle biopsy from 
vastus lateralis muscle from one leg was taken at the beginning of the clamp and from the 
other leg after 30 min of insulin infusion. The biopsies were freeze-dried, purified and 
processed as described in section 5.1.1 (Fig. 2). 
 
5.2.2. Maximal aerobic power 
Maximum aerobic power (VO2max) was measured directly, using an incremental work-
conducted upright exercise test with an electrically braked cycle ergometer (Ergometer 
Ergoline 900ERG, Germany) combined with continuous analysis of expiratory gases and 
minute ventilation (Vmas 229 series, SensorMedics). Exercise was started at a workload of 50 
watts. The workload was then increased by 50 watts every 3 min until perceived exhaustion or 
a respiratory quotient of 1.10 was reached. The highest maximal aerobic power observed 
during a 30 sec period was defined as VO2max. 
 
5.2.3. Body composition 
IMCL (1H-MRS) 
Magnetic resonance (MR) images for localization and 1H-MR spectroscopy were acquired 
using a 1.5 T MR system (Magnetom Vision; Siemens, Erlangen, Germany). A loop surface 
coil was used for detection. The subjects lay supine, with the left leg immobilized by firm 
padding. One-third of the distance from the trochanter major of the femur to the middle of the 
patella was measured, and the center of the coil was placed in contact with that spot. The 1H-
spectra were obtained from quadriceps femoris (vastus lateralis) muscle (Fig. 3). The volume 
of interest, voxel (13 x 13 x  20 mm3), was placed inside the lateral part of the vastus lateralis 
muscle to ensure parallel fiber orientation. The position of the voxel was chosen on the T1-
weighted MR images so that it did not contain any visible fat or fasciae known to contain 
significant amounts of adipocytes which would affect the resonance-frequency shift data (Fig. 
3). Spatial localization was achieved by using a stimulated echo acquisition mode applied 
with a repetition time of 3 000 ms, with an echo time of 20 ms, and a mixing time of 30 ms. 
We used 128 excitations with water presaturation. The resonance at 1.5 ppm originates from 
the extramyocellular CH2-protons of lipids (TGs and FFAs) and the resonance at 1.3 ppm 
from intramyocellular CH2-protons of lipids (249,277). An example of the proton spectra is 
shown in Fig. 3. Resonance intensities were expressed relative to the resonance at 3.0 ppm, 
which is derived from the CH3-protons of total creatine (CrT; creatine and phosphocreatine). 
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The spectral data were fitted in time domain with the program MRUI, based on the solving of 
nonlinear least squares problems (62). The IMCL data were quantified by using CrT signal 
intensity as a reference. The total water-to-CrT ratios were constant between subjects (signal 
intensity ratio 829 ± 46, correlation coefficient for signal intensity of water vs. CrT 0.96) and 
the CrT-to-water ratio (x104) averaged 12.9 ± 0.9 and 12.3 ± 1.2 in the LoIMCL and HiIMCL 
groups, respectively (ns). We chose IMCL/CrT for grouping criterion because both signals are 
of intramyocellular origin and of comparable magnitude of intensity. 
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Fig. 3. Proton magnetic resonance spectroscopy of human vastus lateralis muscle. The 
volume of interest, voxel, was placed inside the lateral part of the vastus lateralis muscle. The 
resonance at 1.5 ppm (EMCL) originates from the extramyocellular CH2-protons of lipids 
(triglycerides and fatty acids) and the resonance at 1.3 ppm (IMCL) from intramyocellular 
CH2-protons of lipids. Resonance intensities are expressed relative to the resonance at 3.0 
ppm (Creatot), derived from the CH3-protons of total creatine (CrT; creatine and 
phosphocreatine).  
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Intra-abdominal, subcutaneous and liver fat  
A series of T1-weighted transaxial scans for the determination of visceral and subcutaneous 
fat were acquired from a region extending from 8 cm above to 8 cm below the 4th and 5th 
lumbar interspace (16 slices, field of view 375 x 500 mm2, slice thickness 10 mm, and breath-
hold repetition time divided by the echo time 138.9 ms/4.1 ms), as previously described (242). 
Visceral and subcutaneous fat areas were calculated using an image analysis program (Alice 
3.0, Parexel, Walthham, MA). A histogram of pixel intensity in the intra-abdominal region 
was displayed, and the intensity corresponding to the nadir between the lean and fat peaks was 
used as a cut point. Visceral adipose tissue was defined as the area of pixels in the intra-
abdominal region above this cut point. For calculation of subcutaneous adipose tissue area, a 
region of interest was first manually drawn at the demarcation of subcutaneous adipose tissue 
and visceral tissue (242). To measure liver fat content by 1H-MRS, localized single voxel (2 x 
2 x 2 cm3) proton spectra were acquired using a 1.5 T whole body system (Siemens 
Magnetom Vision, Erlangen, Germany), which consisted of a combination of whole-body and 
loop surface coils for radio frequency transmitting and signal receiving (Fig. 4). 
 
Fig. 4. Proton magnetic resonance spectra from 2 patients with different percent of liver fat 
(LFAT). The CH2 signal is derived from intrahepatocellular protons of lipids. The percent 
LFAT was calculated by dividing the area under the CH2 signal by the sum of the areas under 
the water and CH2 signals. 
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T1-weighted spin echo MR images were used for localization of the voxel of interest within 
the right lobe of the liver. Vascular structures and subcutaneous fat tissue were avoided in 
localization of the voxel. Subjects were lying on their stomach on the surface coil, which was 
embedded in a mattress in order to minimize abdominal movement due to breathing. The 
single voxel spectra were recorded by using the stimulated echo-acquisition mode sequence 
with an echo-time of 20 ms, a repetition time of 3 000 ms and a mixing time of 30 ms. A total 
of 1024 data-points over 1000 kHZ spectral width with 32 acquisitions were collected. Water-
suppressed spectra with 128 acquisitions were also recorded to detect weak lipid signals. The 
short echo-time and the long repetition time were chosen to ensure a fully relaxed water 
signal, which was used as an internal standard. Chemical shifts were measured relative to 
water at 4.80 ppm. The methylene signal, which represents intracellular triglyceride, was 
measured at 1.4 ppm. The spectra were fitted in the time domain using the variable projection 
method (VARPRO) (62). Spectroscopic intracellular triglyceride content was expressed as a 
ratio of the area under the methylene peak to that under the methylene and water peaks x 100 
(= % liver fat, LFAT). This measurement of percent hepatic fat by proton spectroscopy has 
been validated against histologically determined lipid content of liver biopsies in humans 
(282), animals (277) and against estimates of fatty degeneration or infiltration by X-ray 
computed assisted tomography (171). Examples of two spectra of subjects with low and high 
liver fat are shown in Fig. 4.  
 
Body fat content and other measurements  
Body composition (fat mass, fat free mass and percentage of body fat) was determined by 
bioelectrical impedance plethysmography (BioElectrical Impedance Analyzer System model 
#BIA-101A; RJL Systems, Detroit, Michigan) (174). Waist circumference was measured 
midway between the lower rib margin and the iliac crest, and hip circumference over the 
greater trochanters (205). Skinfold thicknesses (sum of mean values of triplicate 
measurements) were determined at 6 sites (triceps, biceps, subscapular, iliac crest, thigh and 
cheek). 
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5.2.4. Analytical methods 
Plasma glucose concentrations were measured in duplicate using the glucose oxidation 
method (Beckman Glucose Analyzer II, Beckman Instruments, Fullerton, CA) (130). Serum 
free insulin concentrations were determined by double antibody radioimmunoassay 
(Pharmacia Insulin RIA Kit, Pharmacia, Uppsala, Sweden) after precipitation with 
polyethylene glycol. Serum FFA concentrations were determined by the fluorometric method 
(192). Serum high density lipoprotein cholesterol and TG concentrations were determined 
with respective enzymatic kits from Roche Diagnostics using an autoanalyzer (Roche 
Diagnostics Hitachi 917, Hitachi Ltd, Tokyo, Japan). HIV viral load was measured using the 
HIV-1 Monitor Test (Roche Diagnostics, Branchburg, NJ) with a detection limit of 50 
copies/ml. Serum IL-6 concentration was measured using an enzyme-linked immunoassay 
(Quantikine, R&D Systems, Minneapolis, MN). Serum adiponectin concentration was 
measured using a commercial enzyme-linked immunosorbent assay (Human Adiponectin 
ELISA kit, B-Bridge International, San Jose, CA).  
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5.3. RNA isolation and measurement of gene expression adipose tissue (studies III, IV) 
5.3.1. Processing of fat biopsy and total RNA isolation  
Approximately 100 mg (41-137 mg) of frozen fat tissue was homogenized in 2 ml of RNA 
STAT-60 (Tel-Test, Friendswood, TX) and total RNA was prepared according to 
manufacturer’s instructions. After DNase treatment  (RNase-free DNase set, Qiagen, Hilden, 
Germany) RNA was subjected to cleanup (RNeasy mini kit, Qiagen, Hilden, Germany). Fig. 
5 depicts how RNA was used.  
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Fig. 5. Design of the experiments using total RNA from human fat. Fat obtained by an 
aspiration biopsy (around 100 mg) was snap-frozen in liquid nitrogen and stored in liquid 
nitrogen until analysis. Total RNA was isolated, cleaned, and used for: RNA concentration 
measurements using RiboGreen assay, assessment of RNA quality using agarose gel or 
bioanalyzer and the reverse-transcriptase (RT) reaction for cDNA synthesis and PCR. The 
remaining total RNA was stored in liquid nitrogen.  
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5.3.2. Quantification of RNA concentration and synthesis of cDNA 
RNA concentrations were measured using the RiboGreen fluorescent nucleic acid stain (RNA 
quantification kit, Molecular Probes, Eugene, OR). Average yields of total RNA were 3.3 ± 
0.4 µg per 100 mg of adipose tissue wet weight, and were not significantly different between 
HIV positive patients with or without lipodystrophy, and healthy controls. Total RNA was 
suspended in water and stored at –80 o C until the reverse-transcriptase reaction. 0.1 µg total 
RNA was transcribed into cDNA using M-MLV reverse transcriptase (Life Technologies, 
Paisley, UK) and oligo (dT)12-18 (0.5 µg/µl) primers.  
 
5.3.3. Real-time PCR 
Relative quantification of the mRNAs was performed by real-time PCR using LightCycler 
technology (Roche Diagnostics GmbH, Mannheim, Germany) for quantification of β-actin, 
PPARγ, LPL, SREBP1c and adiponectin (at the Minerva Institute for Medical Research), and 
TaqMan technology using ABI PRISM 7000 Sequence Detection System (PE Applied 
Biosystem, Foster City, CA) for quantification all the other genes (at the King Gustaf V 
Research Institute, Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden). 
PCR allows amplification of DNA from a selected region of the genome a billionfold. 2 µl of 
diluted cDNA was brought to a volume of 20 µl with reaction mix (Roche Diagnostics), 
containing a final concentration of 3 mM MgCl2, 2 µl of LightCycler-FastStart DNA Master 
SYBR Green I and 0.5 µM of primers. SYBR Green is a fluorofor, a double-stranded DNA 
binding dye, which fluoresces when only bound to DNA and thus makes the signal much 
more specific than in conventional PCR.  
 
5.3.4. Quantification of mRNA using real-time PCR 
β-actin, PPARγ, LPL, SREBP-1c and adiponectin   
Quantification of the mRNAs was performed by real-time PCR using LightCycler technology 
(Roche Diagnostics GmbH, Mannheim, Germany). 2 µl of 1:10 diluted cDNA was brought to 
a final volume of 20 µl, which contained 3 mM MgCl2, 2 µl of LightCycler-FastStart DNA 
SYBR Green I Mix (Roche Diagnostics), and 0.5 µM of primers. After initial activation of the 
DNA polymerase at 95 o C for 10 min, the amplification conditions were as follows: 40 cycles 
consisting of denaturation at 95 o C for 15 sec, annealing for 5 sec at 57 o C (β-actin), 56 o C 
(PPARγ), 58 o C  (LPL), for 10 sec at 60 o C (SREBP-1c), or for 5 sec at 58 o C (adiponectin) 
and extension at 72 o C. The extension times (sec) were calculated from the amplicon size 
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(base pairs/25). Fluorescent data were acquired at the end of each extension phase. After 
amplification, a melting curve analysis from 65 o C to 95 o C with a heating rate of 0.1 o C/sec 
with a continuous fluorescence acquisition was made.  
 
The primers for PPARγ, LPL, SREBP-1c and β-actin are listed in Table 6. A standard curve 
for PPARγ was created using purified cloned plasmid cDNA (QIAquick PCR purification kit, 
Qiagen, Hilden, Germany). For human β-actin, LPL and SREBP-1c expression, standard 
curves were created from a specific PCR product. To account for differences in RNA loading, 
PPARγ, SREBP-1c and LPL were expressed relative to β-actin. The mRNA concentration of 
human β-actin was not different between the groups (217 ± 44 in the HAART+LD+ and 180 
± 40 in the HAART+LD- group, ns).  
 
Human β2-microglobulin, GLUT1, GLUT4, PGC-1, PPARδ, ALBP, KLBP, FATP-1 and –4, 
ACS, CD45 and IL-6 gene expression  
TaqMan real-time semiquantitative PCR was performed according to the manufacturer’s 
protocol using ABI PRISM 7000 Sequence Detection System instrument and software (PE 
Applied Biosystem, Foster City, CA). Primer and probe sets were designed using the 
manufacturer’s software and sequences available in GeneBank I (Table 6). IL-6 was 
measured using Pre-Developed TaqMan Assay Reagents (PE Applied Biosystem, Foster City, 
CA). The GLUT4 primer set has been published (229). Differences in loading of RNA were 
adjusted for by expressing results relative to β2-microglobulin. mRNA concentrations of β2-
microglobulin were not different between the groups (606 ± 71 in the HAART+LD+ and 645 
± 73 in the HAART+LD- group, ns). Expression levels were quantified (AU) by generating a 
six-point serial standard curve (302). The mRNA concentrations of GLUT1, GLUT4, PGC-1, 
PPARδ, ALBP, KLBP, FATP-1 and FATP–4, ACS, CD45 and IL-6 are given relative to β2-
microglobulin mRNA concentration. 
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Table 6. Primers and probes used for mRNA analyses 
mRNA  
Gene Bank 
Number 
Sense primers Antisense primers Probe 
PPARγ 
U79012 
5’-CTCATATCCGAGGGCCAA 5’-TGCCAAGTCGCTGTCATC * 
β-actin 
M10277 
5’-CACACTGTGCCCATCTACGA 5’-CCATCTCTGCTCGAAGTCC * 
SREBP-1c 
NM004176 
5’-GCGGAGCCATGGATTGCAC 5’- CTCTTCCTTGATACCAGGCCC * 
LPL 
NM000237 
5’-GGTCGAAGCATTGGAATCCAG 5’-TAGGGCATCTGAGAACGAGTC * 
Adiponectin 
XM 003191 
5’-CAGAGATGGCACCCCTGGTG 5’-TTCACCGATGTCTCCCTTAG * 
β2microglobulin 
AH002619 
5’-GCCTGCCGTGTGAACCAT 5’- TTACATGTCTCGATCCCACTTAACTAT 5’-TGACTTTGTCACAGCCCA 
GLUT1 
NM006516 
5’-CCTGTGGGAGCCTGCAAA 5’-TCTATACACAACAGGGCAGGAGTCT 5’-CACTGCTCAAGAAGAC 
GLUT4 
14758189 
5’-GCTACCTCTACATCATCCAGAATCTC 5’-CCAGAAACATCGGCCCA 5’-CTGCCAGAAAGAGTCTGAAGCGCCT 
PGC-1 
AH008808 
5’-AGAGACAAATGCACCTCCAAAAA 5’-AAAGTTGTTGGTTTGGCTTGTAAGT 5’-AAGTCCCACACACAGTCGCAGTCACAA 
PPARδ 
NM006238 
5’-CACACGGCGCCCTTTG 5’-CCTTCTCTGCCTGCCACAA 5’-ATCCACGACATCGAGAC 
CD45 
NT004612 
5’-TCTTGGCATTTGGCTTTGC 5’-GGAGACTGACTGCGTGTGTGA 5’-CTGGACACAGAAGTATTT 
ALBP 
NM001442 
5’-TGATAAACTGGTGGTGGAATGC 5’-CCCTTGGCTTATGCTCTCTCA 5’-TCATGAAAGGCGTCACTTCCACGAGA 
KLBP 
NM001444 
5’-GGGAAGGAAAGCACAATAACAAGA 5’-CGAGTACAGGTGACATTGTTCATG 5’-CACACTCCACCACTAATTTCCCATCTTTCAATT 
FATP-1 
AX015323 
5’-AGATGCCCGCTCACTTCG 5’-GCTAAGGCCCTGATCTTTGGA 5’-CCACCGCCGCCACCATTTCTC 
FATP-4 
AF055899 
5’-CAAGACCATCAGGCGCG 5’-CGCACCTTTGCCTTCACCT 5’-TATCTTTGGCGGCCTGGTCCTCCT 
ACS 
L09229 
 
5’-CAAAGACGGCTGGTTACACACA 5’-TCCGGTCGATAATTTTCAAGGT 5’-CCATTTGGTAACCATTTTCCGATGTCCC 
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5.4. Statistical analyses 
Student’s t-test was used for comparison signals in wet versus dry muscle samples in study I 
and in high versus low intramyocellular lipid content groups in study II.  For comparison of 
FFA concentrations between the groups in study II, analysis of variance for repeated measures 
was used. Correlation coefficients were calculated using Pearson’s correlation coefficient in 
study II. In studies III and IV the unpaired t-test was used to compare differences between the 
groups after logarithmic transformation when necessary. Correlations were calculated using 
Spearman’s rank correlation coefficient. Categorical variables were compared using Fisher’s 
exact test. All calculations were performed using the Systat statistical package, version 10.0 
(Systat, Evanston, IL) or GraphPad Prism, version 2.01 (GraphPad Inc, San Diego, CA). In all 
the studies data are shown as mean ± standard error of mean. A p-value less than 0.05 was 
considered statistically significant.  
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6. RESULTS 
 
6.1. Insulin signalling in freeze-dried rat skeletal muscle (study I) 
The non-muscle contaminants varied between 1 and 40 % (mean 11 %) of dry muscle weight. 
To test the feasibility of insulin signalling assays in freeze-dried purified muscle, we 
measured insulin signalling molecules in rat gastrocnemius muscle and compared the results 
with those obtained using conventionally prepared muscle samples.  
 
Protein expression of signalling molecules  
Protein expression of the IR, IRS-1 and p85 subunit of PI 3-kinase in freeze-dried rat 
gastrocnemius muscle were of the same order of magnitude as in wet, conventionally 
processed muscle samples (Fig. 6). 
Si
gn
a
l i
n
te
n
sit
y 
in
 
fr
ee
ze
-
dr
ie
d 
ra
t m
us
cl
e
(A
U
, %
 o
f w
et
)
IRS-1IR
20
60
100 
140 
n=19n=6
p85
n=8
 
Fig. 6. Protein expression of the IR, IRS-1 and the p85 subunit of the PI 3-kinase in freeze-
dried rat gastrocnemius muscle relative to wet specimens (set as 100 %). Equal amounts of 
protein (0.05 mg) were separated by SDS-PAGE and immunoblotted with anti-IR, anti-IRS-1 
and anti-p85 antibodies, respectively. 
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Tyrosine phosphorylation of IR and IRS-1-associated PI 3-kinase activity in dry versus wet 
rat muscle preparates 
To determine the extent of IR tyrosine phosphorylation, the tissue lysates were 
immunoprecipitated with IR antibodies and then immunoblotted with antiphosphotyrosine 
antibodies. Insulin increased tyrosine phosphorylation of the -subunit of the IR 9.4 ± 1.0-
fold in freeze-dried and 6.4 ± 0.9–fold in wet muscle (p < 0.05, dry vs wet, Fig. 7, panel A). 
IR protein expression was slightly lower in freeze-dried (87 ± 8 AU) than in wet (113 ± 8 AU, 
p < 0.05, n = 6) muscle. As shown in Fig. 7, panel B, PI 3-kinase activity in IRS-1 
immunoprecipitates in dry and wet rat muscle samples was preserved during freeze-drying. 
The large dose of insulin (15 IU) given to rats 3 minutes prior to removal of gastrocnemius 
muscle increased IRS-1-associated PI 3-kinase activity similarly in wet (4.0 ± 0.4-fold 
relative to basal) and dry (3.8 ± 0.8-fold relative to basal, ns) samples. IRS-1 protein 
expression was slightly lower in freeze-dried (86 ± 9 AU) than in wet (114 ± 9 AU, p < 0.05, 
n = 6) muscle. 
 
Coefficient of variation of repeated measurements in freeze-dried samples 
To examine whether freeze-drying reduces variation of repeated measurements, we compared 
variation of protein expression of the p85 regulatory subunit of PI 3-kinase after 4 different 
homogenizations using freeze-dried and wet samples of the same rat gastrocnemius muscle. 
Protein expression of freeze-dried and wet muscle p85 was identical (57600 ± 2358 AU and 
57480 ± 6875 AU) but the coefficient of variation was significantly lower in freeze-dried and 
purified (8.2 %) as compared to wet (23.9 %) samples (p < 0.05). 
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Fig. 7, panel A: Insulin-stimulated tyrosine phosphorylation of IR in wet and freeze-dried 
(dry) rat skeletal muscle. Equal amounts of protein (0.4 mg) were immunoprecipitated with 
anti-IR antibodies, separated by SDS-PAGE, and immunoblotted with anti-pY antibodies. The 
band migrating at 95 kDa represents the tyrosine phosphorylated IR signal.  Data (mean ± 
SEM, n = 8) are expressed relative to basal which is shown as the broken line. Panel B: IRS-
1-associated PI 3-kinase activity in wet and freeze-dried (dry) rat gastrocnemius muscle. 
Equal amounts of protein (1.4 mg) were immunoprecipitated with anti-IRS-1 antibodies. The 
kinase activities were measured in the presence of PI and [32P] ATP, and PIP3 was separated 
by TLC. Data (mean ± SEM, n = 6) are expressed relative to basal activity. The upper panel 
shows a representative TLC. The lower panel shows PI 3-kinase activity 3 min after a 15 IU 
intraportal injection of insulin. 
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6.2. Insulin signalling in freeze-dried human skeletal muscle (study I) 
Healthy men without family history of type 2 diabetes (n = 13) were divided into two groups 
by the median fasting serum insulin concentration, as it is the most physiological 
measurement of insulin sensitivity: low insulin group (LI) and high insulin insulin (HI). The 
men with HI were more insulin-resistant than were men with LI. The HI group was 
characterized by a significantly lower rate of whole-body glucose uptake (3.4 ± 0.4 vs 5.5 ± 
0.4, HI vs LI, p < 0.005), higher serum TGs (1.4 ± 0.2 vs 0.9 ± 0.1, HI vs LI, p < 0.05), lower 
high density lipoprotein cholesterol (1.3 ± 0.1 vs 1.7 ± 0.1, HI vs LI, p < 0.05) and higher 
fasting plasma glucose (5.9 ± 0.3 vs 5.2 ± 0.1, HI vs LI, p < 0.05) concentrations than the LI 
group. The subjects were matched for age, gender and BMI and had similar VO2max (see 
characteristics of the subjects in Table 1 of original publication I and Table 3).  
 
As methodological experiments on rats demonstrated the feasibility of the freeze-drying, all 
muscle biopsies from humans were freeze-dried prior to the analysis. In freeze-dried human 
skeletal muscle, insulin-stimulated tyrosine phosphorylation of the IR was higher (200 ± 40 
%) in the below median insulin group compared to the above median insulin group (81 ± 22 
%, p < 0.05, Fig. 8, panel A). IRS-1-associated PI 3-kinase activity was also higher in the 
below median insulin group (109 ± 23 %) than in the above median insulin group (59 ± 19 %, 
p < 0.05, Fig. 8, panel B). Individual insulin-stimulated IRS-1-associated PI 3-kinase 
activities varied from 46 to 176 AU (3.8-fold) and were significantly inversely correlated with 
fasting serum insulin concentrations (Fig. 9) which varied from 3 to 9 mU/l (3-fold).  
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Fig. 8, panel A: Insulin-stimulated tyrosine phosphorylation of IR in human vastus lateralis 
muscle from healthy subjects subdivided based on their median serum insulin concentration. 
Equal amounts of protein (1.4 mg) were immunoprecipitated with anti-IR antibodies, 
separated by SDS-PAGE, and immunoblotted with anti-pY antibodies. The band migrating at 
95 kDa represents the tyrosine phosphorylated IR signal.  Data (mean ± SEM, n = 8) are 
expressed relative to basal that is shown as broken line. Panel B: IRS-1-associated PI 3-
kinase activity in human skeletal muscle. Equal amounts of protein were immunoprecipitated 
with anti-IRS-1 antibodies. The kinase activities were measured in the presence of PI and 
[32P] ATP, and PIP3 was separated by TLC. Data (mean ± SEM, n = 6) are expressed 
relative to basal activity. The upper panel shows a representative TLC. The lower panel 
shows PI 3-kinase activity 3 min after 30 min insulin infusion. 
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Fig. 9. The relationship between insulin-stimulated PI 3-kinase activity in freeze-dried and 
purified muscle of human vastus lateralis biopsies taken after 30 min of physiological 
hyperinsulinaemia (S-insulin 0.4 nmol/l), and fasting serum insulin concentrations. 
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Fig. 10. Distribution of IMCL in human vastus lateralis muscle measured by proton nuclear 
magnetic resonance spectroscopy in 20 healthy men. The median value is shown by the 
horizontal line.  
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6.3. Insulin signalling pathways and IMCL (study II) 
20 healthy subjects with no family history of type 2 diabetes were divided into groups with 
high IMCL (HiIMCL; 9.5 ± 0.9 IMCL/CrT, n = 10) and low IMCL (LoIMCL; 3.0 ± 0.5 
IMCL/CrT, n = 10), the cut point being median IMCL (6.1 IMCL/CrT, Fig. 10). The LoIMCL 
and HiIMCL groups were comparable with respect to age (43 ± 3 vs  40 ± 3 years, ns, 
HiIMCL vs LoIMCL), BMI (26 ± 1 vs 26 ± 1 kg/m2, ns, Fig. 11, panel B), and maximal 
oxygen consumption (33 ± 2 vs 36 ± 3 ml ·  kg-1 ·  min-1, ns, Fig. 11, panel D) (Table I in 
original publication II and Table 4). The groups also had similar volumes of visceral (3.4 ± 
0.5 vs 2.9 ± 0.3 l, LoIMCL vs HiIMCL, ns) and subcutaneous (2.9 ± 0.3 vs 2.5 ± 0.5 l, ns) fat. 
Plasma TG concentrations were slightly higher in the HiIMCL group than in the LoIMCL 
group, but other lipid concentrations were comparable between the groups. 
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Fig. 11. IMCL (panel A), BMI (panel B), insulin sensitivity (panel C), and VO2max (panel D) 
in subjects with low (LoIMCL) and high (HiIMCL) IMCL. NS, p < 0.001, and p < 0.05 denote 
differences between the groups. 
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Insulin action on glucose and lipid metabolism 
The fasting plasma glucose concentrations as well as the steady-state mean plasma glucose 
concentrations during the euglycaemic hyperinsulinaemic clamp study (5.2 ± 0.1 vs 5.2 ± 0.1 
mmol/l, HiIMCL vs LoIMCL, ns) were comparable between the groups. The HiIMCL group 
had a 46 % higher fasting insulin concentration (Table 1 in original publication II and Table 
4), and the insulin concentration remained slightly but significantly higher during the 
euglycaemic hyperinsulinaemic clamp in the HiIMCL group (450 ± 24 vs 382 ± 18 pmol/l, 
HiIMCL vs LoIMCL, p < 0.05), despite a similar insulin priming and infusion protocol. The 
serum insulin concentrations at the time of the muscle biopsy (30 min) were comparable 
between the groups (382 ± 26 vs 340 ± 20 pmol/l, HiIMCL vs LoIMCL, respectively, ns). 
Whole-body insulin-stimulated glucose uptake was lower in the HiIMCL group (3.0 ± 0.4 mg 
·  kg-1 ·  min-1) than the LoIMCL group (5.1 ± 0.5 mg ·  kg-1 ·  min-1, p < 0.05, Fig. 11, panel C). 
There was significant inverse correlation between whole body glucose uptake and IMCL (Fig. 
12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12. The relationship between IMCL and in vivo insulin sensitivity (Pearson’s correlation 
coefficient). 
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Basally, before the insulin infusion, serum FFA concentrations were comparable between the 
groups. During hyperinsulinaemia, the FFA concentrations decreased slower (0.47 ± 0.04 vs 
0.31 ± 0.21 mmol/l at 20 min, HiIMCL vs LoIMCL,  p < 0.01) and remained higher (0.23 ± 
0.02 vs 0.17 ± 0.02 mmol/l at 120 min) in the HiIMCL compared with the LoIMCL group 
(Fig. 13). IMCL was significantly correlated with serum FFA at all time points during the 
insulin infusion and with the mean FFA concentration during hyperinsulinaemia (r = 0.53, p < 
0.02) but not with the fasting FFA concentration (r = 0.22, ns). 
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Fig. 13. Serum FFA concentrations in LoIMCL (open circles) and HiIMCL (black circles) 
groups during the euglycaemic hyperinsulinaemic clamp study. *p < 0.05, **p < 0.01 for 
difference between the groups at a given time point. 
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IR tyrosine phosphorylation and PI 3-kinase activity 
Insulin-induced IR tyrosine phosphorylation was determined using immunoblotting from anti-
IR immunoprecipitates after SDS-PAGE by determining the increase above basal 
phosphorylation in each subject. There were no detectable differences in the IR expression 
level by direct immunoblotting from the tissue homogenates. Normalized for respective 
protein expression level in each subject, the HiIMCL group had a blunted insulin–stimulated 
IR tyrosine phosphorylation (from 0.28 ± 0.07 to 0.44 ± 0.10, from basal to insulin-stimulated, 
respectively; ns) compared with the LoIMCL group (from 0.22 ± 0.08 to 0.55 ± 0.07, p < 
0.05) or 57 ± 7 % increase in HiIMCL vs 142 ± 8 % in LoIMCL, p < 0.001 (Fig. 14, panel 
A). The insulin-stimulated increase in the IRS-1-associated PI 3-kinase activity above basal 
activity was markedly decreased in the HiIMCL group (42 ± 13 % above basal) compared 
with the LoIMCL group (88 ± 13 % above basal, p < 0.05, Fig. 14, panel B).  
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Fig. 14. The stimulatory effect of insulin on IR tyrosine phosphorylation (panel A) normalized 
by protein expression and IRS-1-associated PI 3-kinase activity (panel B) in the HiIMCL and 
LoIMCL groups. Data are expressed as the percent increase from basal. P values refer to the 
statistical significance of the difference between the groups.  
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6.4. Gene expression in adipose tissue in HAL (study III) 
Characteristics of HIV subjects 
Clinical and biochemical characteristics of the patients are given in Table 2 in original 
publication III and Table 5. BMI and the total amount of abdominal fat measured by MRI 
were similar between the groups. HIV lipodystrophic patients on HAART (HAART+LD+ 
group) had approximately 2-fold less subcutaneous and 2-fold more intra-abdominal fat than 
those without lipodystrophy (HAART+LD- group). The HAART+LD+ group also had 
features of insulin resistance. HIV- and HAART-related characteristics did not differ between 
the groups (Table 5).  
 
Adipose tissue gene expression of PPARγ, SREBP-1c, PPARδ and PGC-1 
The mRNA concentrations of PPARγ, SREBP-1c, PPARδ, and PGC-1 are shown in Fig. 15. 
Expression of all these genes was significantly lower in the HAART+LD+ than the 
HAART+LD- group. PPARγ and SREBP-1c expressions were significantly interrelated in the 
HAART+LD+ group (r = 0.53, p < 0.01). 
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Fig. 15. The mRNA concentrations of PPARγ, SREBP-1c, PPARδ and PGC-1 relative to β-
actin and β2-microglobulin expression in subcutaneous adipose tissue in HAART+LD+ and 
HAART+LD- groups. *p < 0.05, **p < 0.01 for comparisons as indicated. 
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Genes of lipogenesis and fatty acid metabolism: LPL, ACS, ALBP, FATP-1, FATP-4, and 
KLBP 
Expression of LPL and ACS were significantly decreased in the HAART+LD+ group 
compared to the HAART+LD- group (Fig. 16). The mRNA concentrations of FATP-1 and 
ALBP did not differ between the groups (Fig. 16). The mRNA concentrations of FATP-4 (1.2 
± 0.2 vs 1.1 ± 0.1, HAART+LD+ vs HAART+LD-, ns) and KLBP (1.3 ± 0.1 vs 1.1 ± 0.2, 
respectively, ns) also did not differ between the groups.  
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Fig. 16. The mRNA concentration of LPL, ACS, ALBP and FATP-1 relative to β-actin and β2-
microglobulin expression in subcutaneous adipose tissue in HAART+LD+ and HAART+LD- 
groups. *p < 0.05, ***p < 0.001 for comparisons as indicated. 
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Glucose transport proteins: GLUT1 and GLUT2 
The mRNA concentrations of GLUT1 were not different between the groups while GLUT4 
mRNA concentrations were significantly decreased in patients with lipodystrophy (Fig. 17). 
Expression of PGC-1 correlated closely with that of GLUT4 within the HAART+LD+ group 
(Fig. 17).  
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Fig. 17. The mRNA concentration of GLUT4 relative to β2-microglobulin expression in 
subcutaneous adipose tissue in HAART+LD+ and HAART+LD- groups (upper panel) and 
the correlation between the mRNA concentrations of GLUT4 and PGC-1 in the HAART+LD+ 
group (lower panel). *p < 0.05 for HAART+LD+ vs. HAART+LD-. 
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Markers of inflammation: IL-6 and CD45 
The mRNA concentrations of CD45 and IL-6 were significantly higher in the HAART+LD+ 
than the HAART+LD- group (Fig. 18).  
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Fig. 18. The mRNA concentrations of IL-6 and CD45 relative to β2-microglobulin expression 
in subcutaneous adipose tissue in HAART+LD+ and HAART+LD- groups. *p < 0.05 for 
comparisons as indicated. 
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6.5. Adiponectin mRNA in adipose tissue and circulating adiponectin concentration in 
HAL (study IV) 
The same patients participated in study IV as in study III. Liver fat content was significantly 
higher in HAART+LD+ than in HAART+LD- group (Table 5). Liver fat content correlated 
closely with serum fasting insulin concentration (r = 0.60, p < 0.001). The mRNA 
concentration of adiponectin in subcutaneous adipose tissue and adiponectin concentration in 
serum were significantly decreased in the HAART+LD+ group when compared with the 
HAART+LD- group and correlated inversely with liver fat content (Fig. 19). 
S-Adiponectin
0.0
2.5
5.0
7.5
10.0
HAART+LD+ HAART+LD-
***
µg
/m
L
   Adiponectin mRNA
0.000
0.001
0.002
0.003
0.004
HAART+LD+ HAART+LD-
***
0 5 10 15
0.5
1
2
5
10
20
50 r= -0.50,
p<0.001
S-Adiponectin (µg/mL)
Li
ve
r 
fa
t (%
)
0.0001 0.001 0.01
0.5
1
2
5
10
20
50 r=-0.55,
p<0.001
Adiponectin mRNA
Li
ve
r 
fa
t (%
)
 
 
Fig. 19. Serum adiponectin and adipose tissue adiponectin mRNA concentrations relative to 
β-actin expression in subcutaneous adipose tissue (upper panels), and liver fat content (lower 
panels). Data are means ± SEM. ***p < 0.001 for HAARTLD+ vs. HAART+LD-.  
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7. DISCUSSION 
 
7.1. Methods 
7.1.1. Insulin signalling assays 
Currently, the in vivo effect of insulin on insulin signal transduction pathway in humans can 
only be studied in tissue biopsies. During intravenously maintained hyperinsulinaemia 
skeletal muscle accounts for 60-70 % whole-body glucose uptake (65), and is therefore an 
important target tissue for insulin action. In clinical studies, where the Bergström needle is 
used to obtain the muscle biopsy like in studies I and II, the sample contains non-muscle 
components, such as blood, fat, connective tissue and blood vessels. Based on earlier 
experience on metabolite assays, non-muscle contaminants decrease analytical precision by 
several mechanisms. First, the protein concentration used generally for normalization of the 
results may be over- or underestimated, depending on the nature of the contaminant. Second, 
non-muscle components may express the same intracellular proteins than muscle, but may be 
differentially regulated. This is especially important in signal transduction assays, where 
stimulation by insulin is known to trigger a rapid phosphorylation cascade of specific 
signalling proteins like IRS-1 in myocytes, but not in contaminating blood cells. In studies 
involving invasive procedures, like muscle biopsies, the ultimate reason to aim for better 
precision is to reduce the number of subjects needed to study. As stated above, conventionally 
the muscle biopsy is taken, snap-frozen in liquid nitrogen and then homogenized as such 
(‘wet’ sample). Study I describes an alternative and improved way to handle the muscle 
biopsy – freeze-drying and purification of the muscle biopsy specimen (‘dry’ sample). The 
purification after freeze-drying was done at room temperature and for 10 to 15 minutes per 
sample. The absolute signal intensities in all measured parameters, including IRS-1-associated 
PI 3-kinase activity and stimulation, were comparable between the ‘wet’ and ‘dry’ samples, 
which shows that the freeze-drying process does not significantly degrade signalling 
molecules, or influence the enzymatic activity of PI 3-kinase. To assess the coefficient of 
variation of measurement of a specific protein, we used immunoblotting with anti-p85 
antibodies to determine expression of the regulatory subunit of PI 3-kinase in rat 
gastrocnemius muscle. The reason for choosing this particular protein to determine the effect 
of contamination was due to the superb band integrity, quantifiability, and minimal inter-
assay variation in immunoblotting (data not shown) compared to other protein blots. The 
variation was found to be significantly higher in non-purified ‘wet’ samples. Regarding other 
insulin signalling molecules, we found protein expression of IR and IRS-1 to be slightly 
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lower, p85 similar, tyrosine phosphorylation of the IR significantly higher and PI 3-kinase 
activity similar in freeze-dried as compared to wet samples. We calculated by using the p85 
signal variation data, how many subjects would be needed to detect a 30 % difference in 
expression between the groups with 95 % confidence. The ‘dry’ technique (n = 10) would 
reach this theoretical goal by approximately 50 % fewer samples than the ‘wet’ technique (n = 
21). For this reason, muscle samples were freeze-dried and purified prior to insulin signalling 
assays done in study II.  
 
7.1.2. Insulin signalling during in vivo insulin stimulation 
Study I is one of the first to study effects of in vivo hyperinsulinaemia on insulin signalling in 
human skeletal muscle. In vitro studies used 150-250-fold higher insulin concentrations for 
stimulation insulin signalling molecules (95,151,260). As study I was begun in 1998, there 
were not enough data regarding the ideal time point of taking the biopsy for insulin signalling 
measurements. The 30-min time-point was chosen based on studies performed in vitro with 
surgically obtained human muscle strips, where 2-fold activation of PI 3-kinase and IR 
tyrosine phosphorylation has been observed between 20 and 60 min (260) and after 30 min 
(95), respectively. The designs of in vitro and in vivo studies included stimulation of different 
muscle groups by insulin, which may further complicate interpretation of data. Even though 
human muscle is a tissue, that is more mixed regarding muscle fibers, than animal tissue, 
some muscles have a predominant amount of either of the fiber types, e.g. soleus muscle 
contains more type I than type II fibers. In more recent studies examining the time-course for 
insulin signalling by performing a muscle biopsy, 6 times during a 120-min insulin infusion 
(315), a 2-fold increase in IRS-1-associated PI 3-kinase was observed at 30 min and a 5-fold 
increase at 120 min. Another study found 1.3-fold increase in PI 3-kinase activity after 40 min 
of hyperinsulinaemia (122), 1.8-fold after 120 min (142), and 2.0-fold increase - after 60 min 
(27). These data are consistent with our finding of a 1.7-fold increase in IRS-1-associated PI 
3-kinase activity in 30 min in normal subjects. The fold stimulation of IR tyrosine 
phosphorylation in response to physiological insulin infusion in study I was 1.4-fold, while 
Cusi et al. found 1.5-fold (61), and Koval et al. 1.7-fold stimulation (149).  
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7.1.3. 1H-MRS spectroscopy for IMCL 
In study II intramyocellular lipid was measured by a novel non-invasive method - 1H-MRS. 
Lipid quantitated intracellularly by electron microscopic morphometry and 1H-MRS has been 
shown to be closely correlated in tibialis muscle (123). Tibialis anterior muscle fibers run 
parallel, while in vastus lateralis muscle, which was used in the present study, muscle fibers 
are more randomly orientated (123). This implies that many fibers are located at an angle to 
each other. Whenever fiber orientation is 45 to 90 degrees relative to the magnet axis, some 
fibers cross over the “magic angle”, and the bulk magnetic susceptibility-shift between EMCL 
and IMCL is lost, with the EMCL signal being detected at the IMCL frequency. In our study, 
the volume of interest, the voxel was placed inside the lateral part of the vastus lateralis 
muscle to optimise parallel fiber orientation. The position of the voxel was chosen on the T1-
weighted magnetic resonance images so that it did not contain any visible fat or fasciae that 
would contain adipocytes.  
 
7.1.4. Total RNA isolation from adipose tissue and real-time PCR  
Adipocytes contain a relatively low amount of total RNA. In studies III and IV we measured 
the mRNA concentration of several genes that might be important for development of insulin 
resistance in HAL. This was particularly challenging given the paucity of subcutaneous fat in 
lipodystrophic patients. We isolated 3.1 ± 0.3 µg of RNA from 99 ± 2 mg, or 3.3 ± 0.4 µg 
RNA per 100 mg tissue (n = 81). A reverse-transcriptase reaction was done as the SYBER 
Green assay for the real-time PCR  LightCycler can be only done using cDNA. Other 
methods for measuring mRNA concentrations include competitive PCR, the ribonuclease 
protection assay, Northern blotting, and in situ hybridization, but they are all much less 
sensitive than real-time PCR, when one can see the amplification process in real time and 
define the specificity of the product by analyzing the melting curve. Like with other methods, 
one has to run a gel to verify the integrity of the product. In the LightCycler this analysis is 
performed automatically at the end of each run. Regarding sample volume, the method is very 
economical. For cDNA synthesis we used 0.1 µg of RNA (of a total of 3 µg), and then used 
only 0.1-1 ng of cDNA for each sample in the LightCycler. Since air has virtually no mass, 
the amplification process is significantly faster than cycling with the conventional thermal 
block. To measure the relative expression of the gene of interest, we first made a standard 
curve of the gene of interest and then included one standard point from this curve in each run. 
Expression of each gene of interest was calculated relative to a house-keeping gene.  
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7.2. Association of in vivo insulin resistance with impaired insulin signalling (study I) 
Increased fasting insulin concentration is the most physiological surrogate marker of insulin 
resistance. Therefore, we investigated a cohort of healthy men matched for age, body weight 
and physical fitness, and divided them by their median fasting insulin into two groups with 
low or high fasting insulin concentrations, respectively. The majority of previous studies have 
been performed in vitro with surgically obtained human muscle strips and pharmacological 
insulin concentrations (95,151,260). Thus, study I is among the first studies showing that 
physiological insulin concentrations stimulate key insulin signalling molecules in vivo in 
needle biopsies. After 30 minutes of physiological hyperinsulinaemia subjects with lower 
fasting insulin had 118 % higher insulin stimulated IR tyrosine phosphorylation and 50 % 
higher IRS-1-associated PI 3-kinase activity than those subjects with higher fasting insulin. 
These signalling defects were part of a cluster of abnormalities in insulin action, which 
included not only glucose but also lipid metabolism (Table 3). Moreover, there was a 
significant negative correlation between IRS-1-associated PI 3-kinase activity and fasting 
insulin concentrations. Thus, these data are among the first to document defects in insulin 
signalling in human skeletal muscle independent of body weight and physical fitness. It is 
possible that subjects with reduced insulin action had more intramyocellular fat than more 
insulin sensitive subjects. This possibility was investigated in study II. 
 
7.3. Insulin signalling and IMCL (study II) 
In the present study, both IR tyrosine phosphorylation and IRS-1-associated PI 3-kinase 
activation by insulin were significantly lower in the HiIMCL group than in the LoIMCL 
group. The defect in IRS-1-associated PI 3-kinase activity is similar to that recently found in 
fatless mice with a twofold increase in muscle TGs (141). In humans, an elevation of 
circulating FFA acutely, about 4-fold above basal, decreases whole-body glucose uptake by 
50 % and abolishes insulin stimulation of IRS-1-associated PI 3-kinase activity (72). IR 
tyrosine phosphorylation was not measured in these two studies. The present data imply that 
regardless of whether FFAs originate from intramyocellular TGs or from the circulation, they 
may similarly influence early insulin signalling events. In our study, the concentration of 
serum FFAs during hyperinsulinaemia, but not under fasting conditions, significantly 
correlated with IMCL. This finding is consistent with acute FFA infusion studies in which 
IMCL increased during hyperinsulinaemia but not under basal conditions, perhaps because 
the combined effects of increased FFA availability and increased inhibition of 
intramyocellular lipolysis by insulin favour IMCL accumulation (36). It is thus possible that 
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insulin resistance of lipolysis in adipose tissue or other sites, which contribute to circulating 
FFA, may be responsible for IMCL accumulation. On the other hand, because FFA fluxes 
were not quantitated in the present study, it is also possible that impaired insulin stimulation 
of FFA uptake in skeletal muscle or adipose tissue (87) was responsible for the higher FFA 
levels during hyperinsulinaemia in the HiIMCL group compared with the LoIMCL group. 
Whether it is IMCL or circulating FFA that causes the signalling defects, or whether the 
signalling defects precede lipid accumulation, cannot be determined in a cross-sectional 
study.  
 
Several possible mechanisms could link IMCL or circulating FFA to impaired insulin 
signalling. These include activation of signalling cascades known to downregulate either IR 
tyrosine phosphorylation or IRS-1 association with PI 3-kinase, such as activation of the 
hexosamine pathway (215), various PTPs (92), or PKC (136). The hexosamine pathway can 
be activated by infusion of either lipid or glucosamine (113). Both agents also decrease IRS-
1-associated PI 3-kinase activity (72,215). Activation of the hexosamine pathway also 
increases O-glycosylation of IRS-1 (215), which may reduce IRS-1 tyrosine phosphorylation 
and association with PI 3-kinase, but whether the effect of FFAs on the hexosamine pathway 
is important in mediating FFA-induced alterations in early insulin signalling and glucose 
uptake is not known and requires more definite experiments. Finally, it is also possible that 
increases in metabolites, such as malonyl-CoA (241) and LCACoA may mediate effects of 
increased lipid availability on glucose metabolism and early insulin signalling. Infusion of 
FFA in rats increases muscle LCACoA(240). This increase has been suggested to increase 
PKC, a serine/threonine kinase, which is associated with decreased tyrosine and increased 
serine phosphorylation of IRS-1 (99). However, in humans, PKC is lower in obese subjects 
than in lean subjects (127). LCACoA may also interact directly with glucose metabolism 
through the inhibition of enzymes such as GS (314) and hexokinase (281). 
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7.4. Adipose tissue in HAL 
7.4.1. Adipogenic transcription factors and PGC-1  
Expression of all transcription factors (PPARγ, SREBP-1c and PPARδ) and the transcription 
factor co-activator PGC-1 were decreased in lipoatrophic adipose tissue as were the lipogenic 
enzymes ACS and LPL, and GLUT4. In contrast, IL-6 expression and CD45 (a common 
leukocyte surface marker) expression were significantly higher in the lipodystrophic than the 
non-lipodystrophic patients.  
 
The HAART+LD+ group had almost 2-fold less subcutaneous and 2-fold more intra-
abdominal fat than the HAART+LD- group. Features of insulin resistance were found only in 
the HAART+LD+ group. In the face of comparable body mass indexes, these significant 
differences in fat distribution confirmed the self-reported and investigator-confirmed 
diagnosis of LD in the HAART+LD+ group.  
 
PPARγ is a transcription factor that is necessary for the development of mature adipocytes 
both in vitro and in vivo (236). PPARγ expression can be induced by C/EBPβ and δ (173). 
PPARγ and C/EBPα have positive cross-regulation, i.e. C/EBPα induces PPARγ expression 
and vice versa. PPARγ expression can also be induced by SREBP-1 (77). Expression of both 
PPARγ and SREBP-1c were decreased in subcutaneous adipose tissue in patients with HAL 
compared with non-lipodystrophic patients. Low PPARγ mRNA expression may be partly 
due to low SREBP-1c expression, as was suggested by the positive correlation between 
PPARγ and SREBP-1c mRNAs, but possibly also due to decreases in C/EBPβ and C/EBPα 
expression as was found in the study comparing lipodystrophic patients with normal subjects 
(20). In the present study, PPARδ mRNA concentrations were decreased in HAART+LD+ 
patients. A role of PPARδ in adipose tissue development is supported by diminished adipose 
tissue volume in PPARδ-null mice compared with wild-type mice (220). Since PPARδ 
activation promotes mitotic clonal expansion of 3T3-L1 preadipocytes, it has been suggested 
that PPARδ may affect the proliferation of adipocyte precursor cells and have less impact on 
terminal adipocyte differentiation (107). These data would suggest that low PPARδ 
expression may play a role in the loss of subcutaneous fat in HAART+LD+ patients. 
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PGC-1 expression has not been previously studied in patients with HAL. In mice, PGC-1 is 
exclusively expressed in brown adipose tissue (237), whereas PGC-1 expression has been 
found in white adipose tissue in humans (161). In the present study, PGC-1 expression in 
subcutaneous white adipose tissue was decreased in the HAART+LD+ group compared with 
the HAART+LD- group. PGC-1 was first identified as a co-activator of the nuclear receptor 
PPARγ (222). The decrease in PGC-1 expression may therefore have contributed to low 
transcriptional activity of PPARγ in these patients. In mice, ectopic expression of PGC-1 in 
white adipose cells increases expression of uncoupling protein-1, key enzymes of the 
respiratory chain, and the cellular content of mtDNA (222). The mtDNA content is decreased 
in subcutaneous adipose tissue of patients with HAL (299). Nucleoside analogue reverse 
transcriptase inhibitors appear to inhibit human mtDNA polymerase γ which could decrease 
mtDNA content (10,37). The present data suggest that low PGC-1 expression may contribute 
to decreased mitochondrial biogenesis in these patients. Since mitochondrial dysfunction may 
lead to apoptosis (98), mitochondrial damage may be responsible for the loss of subcutaneous 
adipose tissue in these patients (68,299). PGC-1 also induces GLUT4 expression in cultured 
muscle cells (188), and animals overexpressing PGC-1 in muscle are characterized by 
conversion of type II to type I muscle fibers, which are known to be insulin sensitive and 
express high amounts of GLUT4 (168). Our finding of a close correlation between adipose 
tissue PGC-1 and GLUT4 expression (r = 0.79, p < 0.0001) is in keeping with such data. 
Decreased expression of PGC-1 could thus also contribute to insulin resistance in these 
patients. 
 
7.4.2. Genes of lipogenesis and fatty acid metabolism 
The mRNA concentrations of proteins associated with fatty acid transport (FATP-1, FATP-4) 
and fatty acid intracellular binding (ALBP, KLBP) were similar in HAART+LD+ and 
HAART+LD- groups. Uptake of circulating FFAs into cells is likely to occur both by passive 
diffusion and by active transport (1). Three groups of membrane proteins have been 
implicated in the transport process: FATP, plasma membrane FA-binding protein (FABP) and 
FAT, also known as CD36 (1). FATP and FAT expressions are induced by PPARγ in mice 
(200). Despite lower expression of PPARγ in the HAART+LD+ than the HAART+LD- 
group, expression of FATP-1, FATP-4, ALBP or KLBP were unchanged. Whether this is 
because regulation of these genes differs in mice as compared to man is unclear. Both ALBP 
and KLBP are expressed in human macrophages (179). Thus it is possible that the similar 
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expression of FABPs in adipose tissue biopsies in the two patient groups could reflect a 
decrease in expression in adipocytes and an increase in macrophages in the HAL subjects. A 
recent mouse model, in which macrophages were deficient in aP2 (mouse analogue of human 
ALBP), revealed that the absence of aP2 was associated with decreased expression of 
proinflammatory cytokines (TNFα, IL-1β, IL-6) (179). Consequently, the unchanged 
expression of ALBP in the HAART+LD+ patients may have contributed to the increased 
expression of IL-6. An alternative explanation for the unchanged pattern of fatty acid binding 
protein expression in the HAART+LD+ and HAART+LD- groups is that a normally inactive 
pathway was activated in adipocytes undergoing apoptosis, which resulted in upregulation of 
genes, the expression of which is aimed at maintaining fatty acids in adipose tissue. 
 
Expression of ACS and LPL genes was reduced in the HAART+LD+ group compared with 
HAART+LD- group. ACS catalyzes conversion of long-chain fatty acids to their acyl-CoA 
esters that can then be used either for synthesis of cellular lipids such as TGs, or for β-
oxidation (248). Formation of acyl-CoA esters also prevents efflux of FFAs (248). PPARγ 
increases ACS expression both in preadipocytes in vitro and in adipose tissue in the rat in vivo 
(182). Proinflammatory cytokines (TNFα, IL-1) decrease the expression of ACS in the liver 
and adipose tissue in hamsters (186). The low ACS expression observed in patients with HAL 
may be a consequence of a low expression of PPARγ and an increased expression of TNFα as 
described in a previous study (20). Regulation of LPL expression resembles that of ACS in 
adipose tissue. Both SREBP-1 and PPARγ induce LPL expression in vitro and in rat adipose 
tissue (140,252), whereas proinflammatory cytokines (TNFα, IL-6) decrease the expression 
of LPL (85). Thus, both the decreases in PPARγ and SREBP-1 expression and the increase in 
IL-6 expression could have contributed to the low LPL expression. 
 
7.4.3. IL-6 and CD 45 expression 
Expression of IL-6 in subcutaneous adipose tissue was increased in the HAART+LD+ group. 
IL-6 is a multifunctional cytokine produced by many different cell types including immune 
cells, adipocytes, fibroblasts, stromal-vascular cells, endothelial cells, myocytes, and a variety 
of endocrine cells (85). As much as a third of the total circulating concentration of IL-6 has 
been estimated to originate from adipose tissue (85). However, of the IL-6 secreted from 
adipose tissue, only 10 % is secreted by adipocytes (85). The HAART+LD+ group had a 
higher number of white blood cells capable of IL-6 production in their adipose tissue as 
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judged from the significantly higher concentration of the mRNA encoding for CD45. CD45 is 
a tyrosine phosphatase, which is expressed exclusively in the white blood cell lineage (7). 
However, CD45 is expressed on these cells regardless of whether they are activated or resting. 
The increase in CD45 expression therefore may or may not reflect an increase in 
inflammation in lipodystrophic adipose tissue. The data do raise the possibility that the 
increased mRNA concentration of TNFα found in adipose tissue biopsies of these patients by 
Bastard et al may have originated from macrophages in addition to adipocytes (20). TNFα has 
pronounced catabolic effects in adipose tissue, including inhibition of C/EBPα, PPARγ, and 
LPL expression and induction of apoptosis (85). Interestingly, high levels of TNFα mRNA in 
adipose tissue and a high circulating concentration of TNFα were described in an adiponectin 
knockout mouse model (176). Adiponectin is a protein secreted by adipocytes, the plasma 
concentration of which is reduced in insulin resistant conditions and in type 2 diabetes (176), 
and according to very recent data also in non-HIV and HIV-LDs (2,203). It is therefore also 
possible that the increased TNFα expression in the study of Bastard et al. was due to low 
adiponectin in HAL (20). Since TNFα is known to induce expression of IL-6 (290), it is also 
possible that the low levels of adiponectin may contribute to increased expression of IL-6.  
 
Study III does not clarify the chain of events leading to the described alterations in adipose 
tissue gene expression. We confirm and extend the findings by Bastard et al., who compared 
adipose tissue gene expression between patients with HAL and HIV-negative controls (20). In 
the current comparison of two HIV-positive, HAART-treated groups with and without LD, it 
is possible that gene expression was affected by the HIV-infection or HAART in both groups 
since an HIV-negative group or an HIV-positive, but treatment-naive group was not studied. 
However, since the groups did not differ with respect to HIV-related characteristics, the 
observed differences most likely were attributable to LD. This implies that individual 
susceptibility may contribute to the development of HAL. Consistent with this, a functionally 
active polymorphism in the promoter region of the TNFα gene and a single nucleotide 
polymorphism in SREBP-1c gene have been shown to be associated with development of LD 
and hyperlipidaemia in these patients (178,193).  
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In vitro, both protease and nucleoside reverse transcriptase inhibitors inhibit adipocyte 
differentiation (41,71,166,234,303,334). The suggested mechanisms include both SREBP-
1/PPARγ dependent (41,71) and independent mechanisms (303,334). In addition, protease 
inhibitors have been shown to cause adipocyte death (71). Since antiretroviral combinations 
in clinical practice always include several agents, these in vitro data evaluating the effects of a 
single drug may not be applicable to in vivo situation. This is exemplified by a study which 
showed that the effects on adipocytes, produced by combinations of nucleoside reverse 
transcriptase and protease inhibitors are different from those elicited by each drug separately 
(234). 
 
7.4.4. Adiponectin expression and circulating concentration 
Adiponectin expression in adipose tissue and its circulating concentrations are significantly 
decreased in HIV-positive, HAART-treated patients with LD when compared with HAART-
treated patients without LD. Both serum and mRNA concentrations of adiponectin correlated 
closely with features of insulin resistance including liver fat content, suggesting that 
adiponectin deficiency may contribute to hepatic insulin resistance in these patients. 
 
Our findings of low serum concentration of adiponectin in HAL confirm those of Mynarcik et 
al. (203). Although we did not measure adiponectin protein concentrations in subcutaneous 
fat, the present study extends the data of Mynarcik et al. by demonstrating low expression of 
adiponectin in subcutaneous fat.  
 
Regarding the possible causes of adiponectin deficiency in the HAART+LD+ group, both 
groups were HIV-positive, had similar viral loads, CD4 cell counts and used comparable 
HAART regimens. The decrease in adiponectin therefore was a consequence of LD rather 
than the HIV-infection or antiretroviral therapy per se. The decrease in serum adiponectin in 
the HAART+LD+ group was not due to overall obesity, as both groups had similar absolute 
and relative weights. Healthy lean subjects with low subcutaneous fat volume have higher 
serum adiponectin concentrations than obese subjects (22). Therefore, the observed low 
serum adiponectin concentration in the HAART+LD+ group is more likely to reflect 
dysfunction of the remaining subcutaneous adipose tissue rather than reduced subcutaneous 
fat volume. 
  
Current data are limited regarding expression of adiponectin in subcutaneous vs. intra-
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abdominal fat. Adiponectin mRNA and protein levels were reduced in omental fat compared 
with those of subcutaneous fat in the study performed by Fisher et al. (81). In another study, 
human omental adipocytes secreted more adiponectin than subcutaneous adipocytes after 
insulin or rosiglitazone stimulation (201). Visceral fat has also been hypothesized to release 
an as yet unidentified factor that destabilizes adiponectin mRNA (105). In the present study, 
the significantly decreased serum adiponectin concentration together with the significantly 
increased intra-abdominal fat mass in the HAART+LD+ group compared to the 
HAART+LD- group and the strong inverse correlation between serum adiponectin 
concentration and intra-abdominal fat mass imply an inhibitory rather than a stimulatory 
effect of intra-abdominal fat on adiponectin production.  
 
We found a close correlation between serum adiponectin and liver fat content, and liver fat 
content correlated closely with fasting serum insulin concentrations. In mice, infusion of 
adiponectin enhances insulin sensitivity, β-oxidation in muscle, and decreases liver and 
muscle fat content (321). In another mouse model, adiponectin infusion has been shown to 
inhibit the expression of hepatic gluconeogenic enzymes and the rate of endogenous glucose 
production (57). In isolated primary rat hepatocytes, physiological doses of adiponectin have 
been shown to enhance insulin-induced suppression of glucose production (22). These data 
would support the idea that low adiponectin contributed to hepatic insulin resistance and 
fasting hyperinsulinaemia in the HAL patients.  
 
Adiponectin is a structural homologue of the TNFα family of trimeric cytokines and has anti-
inflammatory properties, which antagonize those of TNFα (288). TNFα decreases expression 
of adiponectin in 3T3-adipocytes (79). In an adiponectin knockout mouse model, lack of 
adiponectin was associated with high levels of TNFα mRNA in adipose tissue and high 
plasma TNFα concentrations (176). TNFα expression is increased in subcutaneous adipose 
tissue in patients with HAL (20). Increased TNFα could therefore contribute to low 
adiponectin expression in HAL, or vice versa.  
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7.5. Concluding remarks 
Insulin resistance is the main feature of type 2 diabetes mellitus. Skeletal muscle is the 
primary site of glucose disposal accounting for up to 70-80 % postprandial glucose disposal 
during hyperinsulinaemia (65). Consequently, skeletal muscle is a relevant target tissue to 
study the mechanisms of insulin resistance. In studies I and II we analyzed insulin signalling 
in healthy men without family history of type 2 diabetes, matched for body weight and 
physical fitness. In study I, we found a relationship between fasting plasma insulin 
concentrations and defects in early insulin signalling events. Thus, defects in proximal insulin 
signalling events are coupled to impaired insulin action in apparently healthy men. In study II, 
early insulin signalling events were impaired in healthy men with high intramyocellular lipid 
content, which was independent of body weight, aerobic capacity or genetic background. 
Thus, these data provide evidence that environmental factors, such as fat accumulation in the 
muscle, contribute to the development of insulin resistance. 
 
During recent years, it has become evident that not only obesity but also the opposite state – 
lipodystrophy - is associated with insulin resistance. Currently, the most common form of 
lipodystrophy is the one associated to highly-active antiretroviral therapy (HAART) for HIV 
infection. HAART therapy has dramatically improved the prognosis of HIV infection in 
industrial countries during the last decade. However, HAART-associated insulin resistance 
and potentially increased risk for cardiovascular mortality have become of great clinical 
concern. In the current cross-sectional study (studies III and IV), expression of adipogenic 
transcription factors, co-activator of PPARγ and adiponectin in subcutaneous adipose tissue
was decreased in HAART-treated patients with lipodystrophy (HAL) compared to those 
without lipodystrophy. Thus, these data suggest that observed alterations in gene expression 
may contribute to lipodystrophy in these subjects. In study IV, adiponectin expression was 
inversely correlated with liver fat content. Liver fat content was correlated with fasting serum 
insulin concentrations. Thus, these associations suggest that decreased adiponectin 
concentration may contribute to the development of insulin resistance in HAL patients via 
increased fat content in the liver.  
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8. SUMMARY AND CONCLUSIONS 
 
The results of studies I-IV can be summarized as follows:  
 
I. In rat skeletal muscle, phosphorylation, expression and enzymatic activity of insulin 
signalling molecules were similar or higher in freeze-dried purified muscle compared to 
conventionally proceded biopsies.  In human skeletal muscle, elevated fasting insulin 
concentrations associate with impaired insulin signalling independent of body weight. Thus, 
defects in early insulin signalling contribute to insulin resistance in healthy men. 
 
II. Healthy subjects with increased IMCL are less sensitive to insulin in vivo than those with 
IMCL below median, and have impaired insulin signalling independent of body weight and 
physical fitness. Thus, enhanced accumulation of intramyocellular lipid may contribute to the 
development of insulin resistance via impaired insulin signalling.  
 
III. Expression of adipogenic transcription factors, GLUT4, LPL, ACS and co-activator of 
PPARγ are decreased in HAART-patients with lipodystrophy compared to those without 
lipodystrophy while expression of IL-6 is increased. These multiple alterations in gene 
expression in subcutaneous adipose tissue of HAART-lipodystrophic patients may contribute 
to development of lipodystrophy and insulin resistance in these patients. 
 
IV. The concentration of adiponectin in serum and its expression in adipose tissue are lower 
in subcutaneous adipose tissue of HAART-lipodystrophic subjects than in HIV patients 
without lipodystrophy. Both serum adiponectin and adipose tissue adiponectin mRNA 
concentrations correlated with features of insulin resistance, including liver fat content. 
Adiponectin deficiency may therefore contribute to hepatic insulin resistance. 
 83 
9. ACKNOWLEDGMENTS 
The work for this thesis was carried out at the Department of Medicine, Division of Diabetes 
and at the Minerva Foundation Institute for Medical Research in Biomedicum, Helsinki, 
during the years 1999-2003. I want to thank Professor Marja-Riitta Taskinen for giving me 
the possibility to use and Professor Frej Fyhrquist for providing excellent laboratory facilities 
at my disposal at the Minerva Foundation. Part of the gene expression assays was performed 
at the King Gustaf V Research Institute, Karolinska Institute, Stockholm, Sweden. 
 
I want to express my deepest gratitude to Doctor Antti Virkamäki and Professor Hannele Yki-
Järvinen for their expert guidance throughout these years. I thank Dr. Virkamäki for sharing 
his rich laboratory experience and analytical thinking with me. I was honoured to be involved 
in very exciting projects designed by Professor Yki-Järvinen whose thinking has opened new 
perspectives in studying insulin resistance.  
 
Professor J. Antonie Maassen and docent Heikki Koistinen are gratefully acknowledged for 
the constructive review of this thesis.  
 
I would like to thank all our collaborators from Sweden, France and Japan for significant 
contribution to our experimental and writing process. 
 
I want to thank the volunteers who gave their muscle and fat biopsies for the sake of science. I 
tried to use these valuable samples as efficiently as possible.  
 
I was lucky to work with two wonderful ‘ladies of the lab’: Sari Haapanen and Mia 
Urjansson. Mia’s strong personality and endless energy have been very important for me. 
 
I highly appreciate expertise at any ‘time-point’, which I needed from any of the staff at 
Minerva Foundation. My Russian bow – to Tuulikki Nyman, the legendary manager Tupu, 
who always had all the answers to all my questions; to Riikka Kosonen, Maarit Piisilä and Pia 
Stewen, inexhaustible sources of good temper, who cheered me up in the exhausting battle 
with RNA and the LightCycler. I also thank Professor Frej Fyhrquist, Professor Ralph 
Gräsbeck, Anders Eriksson, Per-Henrik Groop, Tom Bäcklund, Mika Laine, Tina Grönholm, 
Sari Mäkimattila, Maarit Huopalainen, Terhi Suvanto, Riina Hatakka, Kid Törnquist, Benoit 
Dugue, Outi Saijonmaa, Ritva Leino and Annariitta Huopaniemi, and all the members of 
 84 
Lipid Lab for their wonderful company. Kiitos also to Anniina Oksanen and Kaisu Jormakka 
for making my summer 2002 so delightful. I want to thank the entire staff of Minerva 
Foundation for patience and tolerance towards me working with HIV positive samples in their 
sterile perfect RNA laboratory.  
 
I express my sincere gratitude to Professor Marja-Riitta Taskinen, my first Finnish supervisor 
during my student-exchange programme, who initiated my arrival to Finland from Russia and 
always showed maximum sympathy to me under any circumstances. 
 
I want to thank the colleagues I worked with, whose company has been very inspiring and 
whose friendship will always stay in my heart: Satu Vehkavaara, Robert Bergholm, Jukka 
Westerbacka, Marjo Tamminen, Mirja Tiikkainen, Takashi Goto, Jussi Sutinen, Katja 
Tuominen, Anneli Seppälä-Lindroos, Juha Vakkilainen, Kati Ylitalo, Helinä Perttunen-Nio, 
Hannele Hilden, and Ming-Lin Liu. My special thanks go to Satu Vehkavaara and Anneli 
Seppälä-Lindroos for providing me excellent muscle biopsy material and Jussi Sutinen and 
Katja Tuominen for amazing courage and efficiency in the HIV project. I also thank Maaria 
Puupponen and Carita Estlander-Kortman for their excellent secretarial and other help.  
 
I am sincerely grateful to a wonderful team at the Department of Molecular Cell Biology at 
Leiden University Medical Center for their help in setting up RNA and gene expression 
assays and in preparing this thesis. Dank u wel, Margriet Ouwens, Leen ‘t Hart, Els 
Willemstein-van Hove, Frans van Bussel and Professor J. Antonie Maassen.  
 
I want to thank my father-clinician Victor Vladimirovich, my Russian mentor Elena Smirnova 
from the Department of Internal Diseases at the Perm State Medical Academy, my alma 
mater, and Professor Robert J. Heine from Vrij University Amsterdam for fascinating me with 
the passion to science. I thank my old friends Yana Storozheva and Olja Holmanskih for their 
support and care despite the thousands kilometres distance between us. And I also thank my 
new friends, who brought much colour into my life in Helsinki: Kirsi Peltola, Oleg Trushin, 
Vladimir Rjabchenko, Ada Alagona (mille gracies, doctoressa Ritrovata!); Elena Grishankova 
and Violetta Ignatizheva (my HOAS bodies), Iva Guillaumet, Eric Nguen and Riina, Dmitry 
Novikov, Maria Kolehmainen, Olga Vanker.  
 
 85 
I want to say ‘spasibo, moi dorogie!’ to my wonderful parents Margarita and Victor from 
Perm for their endless care and love. This work wouldn’t be done without their support. I 
thank my brother Dmitry, Olga and small princess Polina for their love and warm hospitality 
during my visits to Moscow.  
 
I address my warmest thanks and liefs to the Pino family for understanding and love. I want to 
thank Henk and Gerda Noor for introducing me Europe 10 years ago and keeping up our 
unique friendship, and visiting me in Helsinki.  
 
I can hardly find right words to thank my dear friend Taco Pino for his love and care of me. I 
felt it every minute we were apart. I thank you, my dear man, for courage and patience you 
showed within these 3.5 years, and the fantastic time we always have together.  
 
I gratefully acknowledge financial support for these studies from Finnish Academy of 
Science, Centre of International Mobility (CIMO, Finland) and Minerva Foundation Institute 
for Medical Research as well as Roche Diagnostic (Russia) and EASD for giving me the 
possibility to attend medical congresses.  
 
Helsinki, May 2003 
 
 
 
Elena V Korsheninnikova 
 86 
10. REFERENCE LIST 
 
1. Abumrad, N.C., and A. Ibrahimi. 1999. Membrane proteins implicated in long-chain fatty acid uptake by 
mammalian cells: CD36, FATP and FABPm. Biochim Biophys Acta 1441:4-13. 
2. Addy, C.L., A. Gavrila, S. Tsiodras, K. Brodovicz, A.W. Karchmer, and C.S. Mantzoros. 2003. 
Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human 
immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol 
Metab  88:627-636. 
3. Ahima, R.S. and J.S. Flier. 2000. Leptin. Annu Rev Physiol 62:413-437. 
4. Ahmad, F., J.L. Azevedo, R. Cortright, G.L. Dohm, and B.J. Goldstein. 1997. Alterations in skeletal muscle 
protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes. J Clin 
Invest  100:449-458. 
5. Ahmad, F. and B.J. Goldstein. 1995. Purification, identification and subcellular distribution of three 
predominant protein-tyrosine phosphatase enzymes in skeletal muscle tissue. Biochim Biophys Acta 1248:57-69. 
6. Alessi, D.R., M. Deak, A. Casamayor, F.B. Caudwell, N. Morrice, D.G. Norman, P. Gaffney, C.B. Reese, 
C.N. MacDougall, D. Harbison, A. Ashworth, and M. Bownes. 1997. 3-Phosphoinositide-dependent protein 
kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase. Curr Biol 7:776-
789. 
7. Alexander, D.R. 2000. The CD45 tyrosine phosphatase: a positive and negative regulator of immune cell 
function. Semin Immunol 12:349-359. 
8. Almind, K., S.K. Frederiksen, M.G. Ahlgren, S. Urhammer, T. Hansen, J.O. Clausen, and O. Pedersen. 1998. 
Common amino acid substitutions in insulin receptor substrate-4 are not associated with Type II diabetes 
mellitus or insulin resistance. Diabetologia 41:969-974. 
9. Amatruda, J.M., J.N. Livingston, and D.H. Lockwood. 1985. Cellular mechanisms in selected states of insulin 
resistance: human obesity, glucocorticoid excess, and chronic renal failure. Diabetes Metab Rev 1:293-317. 
10. Anderson, K.S. 2002. Perspectives on the molecular mechanism of inhibition and toxicity of nucleoside 
analogs that target HIV-1 reverse transcriptase. Biochim Biophys Acta 1587:296-299. 
11. Anderwald, C., E. Bernroider, M. Krssak, H. Stingl, A. Brehm, M.G. Bischof, P. Nowotny, M. Roden, and 
W. Waldhausl. 2002. Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver 
and skeletal muscle. Diabetes 51:3025-3032. 
12. Araki, E., M.A. Lipes, M.E. Patti, J.C. Bruning, B. Haag, R.S. Johnson, and C.R. Kahn. 1994.  Alternative 
pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372:186-190. 
13. Arita, Y., S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, J. Miyagawa, K. Hotta, I. Shimomura, T. 
Nakamura, K. Miyaoka, H. Kuriyama, M. Nishida, S. Yamashita, K. Okubo, K. Matsubara, M. Muraguchi, Y. 
Ohmoto, T. Funahashi, and Y. Matsuzawa. 1999. Paradoxical decrease of an adipose-specific protein, 
adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83. 
14. Arner, P., T. Pollare, H. Lithell, and J.N. Livingston. 1987. Defective insulin receptor tyrosine kinase in 
human skeletal muscle in obesity and type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 30:437-
440. 
15. Aronson, D., M.D. Boppart, S.D. Dufresne, R.A. Fielding, and L.J. Goodyear. 1998. Exercise stimulates c-
Jun NH2 kinase activity and c-Jun transcriptional activity in human skeletal muscle. Biochem Biophys Res 
Commun 251:106-110. 
 87 
16. Aronson, D., S.D. Dufresne, and L.J. Goodyear. 1997. Contractile activity stimulates the c-Jun NH2-terminal 
kinase pathway in rat skeletal muscle.  J Biol Chem  272:25636-25640. 
17. Aronson, D., M.A. Violan, S.D. Dufresne, D. Zangen, R.A. Fielding, and L.J. Goodyear. 1997. Exercise 
stimulates the mitogen-activated protein kinase pathway in human skeletal muscle. J Clin Invest 99:1251-1257. 
18. Authier, F., R.A. Rachubinski, B.I. Posner, and J.J. Bergeron. 1994. Endosomal proteolysis of insulin by an 
acidic thiolmetalloprotease unrelated to insulin degrading enzyme. J Biol Chem 269:3010-3016. 
19. Barroso, I., M. Gurnell, V.E. Crowley, M. Agostini, J.W. Schwabe, M.A. Soos, G.L. Maslen, T.D. Williams, 
H. Lewis, A.J. Schafer, V.K. Chatterjee, and S. O'Rahilly. 1999. Dominant negative mutations in human 
PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883. 
20. Bastard, J.P., M. Caron, H. Vidal, V. Jan, M. Auclair, C. Vigouroux, J. Luboinski, M. Laville, M. Maachi, 
P.M. Girard, W. Rozenbaum, P. Levan, and J. Capeau. 2002. Association between altered expression of 
adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte 
differentiation and insulin resistance. Lancet 359:1026-1031. 
21. Baumann, C.A., V. Ribon, M. Kanzaki, D.C. Thurmond, S. Mora, S. Shigematsu, P.E. Bickel, J.E. Pessin, 
and A.R. Saltiel. 2000. CAP defines a second signalling pathway required for insulin-stimulated glucose 
transport. Nature 407:202-207. 
22. Berg, A.H., T.P. Combs, and P.E. Scherer. 2002. ACRP30/adiponectin: an adipokine regulating glucose and 
lipid metabolism. Trends Endocrinol Metab 13:84-89. 
23. Bergeron, R., S.F. Previs, G.W. Cline, P. Perret, R.R. Russell, III, L.H. Young, and G.I. Shulman. 2001. 
Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid 
metabolism in lean and obese Zucker rats.  Diabetes  50:1076-1082. 
24. Bergeron, R., R.R. Russell, III, L.H. Young, J.M. Ren, M. Marcucci, A. Lee, and G.I. Shulman. 1999. Effect 
of AMPK activation on muscle glucose metabolism in conscious rats. Am J Physiol 276:E938-E944. 
25. Bergman, R.N. and M. Ader. 2000. Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends 
Endocrinol Metab 11:351-356. 
26. Bjornholm, M., A.R. He, A. Attersand, S. Lake, S.C. Liu, G.E. Lienhard, S. Taylor, P. Arner, and J.R. 
Zierath. 2002. Absence of functional insulin receptor substrate-3 (IRS-3) gene in humans. Diabetologia 45:1697-
1702. 
27. Bjornholm, M., Y. Kawano, M. Lehtihet, and J.R. Zierath. 1997. Insulin receptor substrate-1 phosphorylation 
and phosphatidylinositol 3-kinase activity in skeletal muscle from NIDDM subjects after in vivo insulin 
stimulation. Diabetes 46:524-527. 
28. Bluher, M., M.D. Michael, O.D. Peroni, K. Ueki, N. Carter, B.B. Kahn, and C.R. Kahn. 2002. Adipose tissue 
selective insulin receptor knockout protects against obesity and obesity-related glucose intolerance. Dev Cell 
3:25-38. 
29. Boden, G., B. Lebed, M. Schatz, C. Homko, and S. Lemieux. 2001. Effects of acute changes of plasma free 
fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. Diabetes 50:1612-1617. 
30. Bonadonna, R.C., L.C. Groop, K. Zych, M. Shank, and R.A. DeFronzo. 1990. Dose-dependent effect of 
insulin on plasma free fatty acid turnover and oxidation in humans. Am J Physiol 259:E736-E750. 
31. Boppart, M.D., S. Asp, J.F. Wojtaszewski, R.A. Fielding, T. Mohr, and L.J. Goodyear. 2000. Marathon 
running transiently increases c-Jun NH2-terminal kinase and p38 activities in human skeletal muscle. J Physiol 
526 Pt 3:663-669. 
32. Bossenmaier, B., L. Mosthaf, H. Mischak, A. Ullrich, and H.U. Haring. 1997. Protein kinase C isoforms beta 
1 and beta 2 inhibit the tyrosine kinase activity of the insulin receptor. Diabetologia 40:863-866. 
 88 
33. Boulton, T.G., S.H. Nye, D.J. Robbins, N.Y. Ip, E. Radziejewska, S.D. Morgenbesser, R.A. DePinho, N. 
Panayotatos, M.H. Cobb, and G.D. Yancopoulos. 1991. ERKs: a family of protein-serine/threonine kinases that 
are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 65:663-675. 
34. Brady, M.J., A.C. Nairn, and A.R. Saltiel. 1997. The regulation of glycogen synthase by protein phosphatase 
1 in 3T3-L1 adipocytes. Evidence for a potential role for DARPP-32 in insulin action. J Biol Chem 272:29698-
29703. 
35. Bray, G.A. 1998. Obesity: a time bomb to be defused. Lancet 352:160-161. 
36. Brechtel, K., D.B. Dahl, J. Machann, O.P. Bachmann, I. Wenzel, T. Maier, C.D. Claussen, H.U. Haring, S. 
Jacob, and F. Schick. 2001. Fast elevation of the intramyocellular lipid content in the presence of circulating free 
fatty acids and hyperinsulinemia: a dynamic 1H-MRS study. Magn Reson Med 45:179-183. 
37. Brinkman, K., J.A. Smeitink, J.A. Romijn, and P. Reiss. 1999. Mitochondrial toxicity induced by nucleoside-
analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related 
lipodystrophy. Lancet 354:1112-1115. 
38. Burgess, J.W., I. Wada, N. Ling, M.N. Khan, J.J. Bergeron, and B.I. Posner. 1992. Decrease in beta-subunit 
phosphotyrosine correlates with internalization and activation of the endosomal insulin receptor kinase. J Biol 
Chem 267:10077-10086. 
39. Burks, D.J. and M.F. White. 2001. IRS proteins and beta-cell function. Diabetes 50 Suppl 1:S140-S145. 
40. Campbell, P.J., G.B. Bolli, P.E. Cryer, and J.E. Gerich. 1985. Pathogenesis of the dawn phenomenon in 
patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose 
utilization due to nocturnal surges in growth hormone secretion. N Engl J Med  312:1473-1479. 
41. Caron, M., M. Auclair, C. Vigouroux, M. Glorian, C. Forest, and J. Capeau. 2001. The HIV protease 
inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits 
preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378-1388. 
42. Carr, A. and D.A. Cooper. 2000. Adverse effects of antiretroviral therapy. Lancet 356:1423-1430. 
43. Carr, A., K. Samaras, A. Thorisdottir, G.R. Kaufmann, D.J. Chisholm, and D.A. Cooper. 1999. Diagnosis, 
prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and 
diabetes mellitus: a cohort study. Lancet 353:2093-2099. 
44. Carvalho, E., P.A. Jansson, M. Axelsen, J.W. Eriksson, X. Huang, L. Groop, C. Rondinone, L. Sjostrom, and 
U. Smith. 1999. Low cellular IRS 1 gene and protein expression predict insulin resistance and NIDDM. FASEB 
J 13:2173-2178. 
45. Carvalho, E., P.A. Jansson, I. Nagaev, A.M. Wenthzel, and U. Smith. 2001. Insulin resistance with low 
cellular IRS-1 expression is also associated with low GLUT4 expression and impaired insulin-stimulated glucose 
transport. FASEB J 15:1101-1103. 
46. Cederberg, A. and S. Enerback. 2003. Insulin resistance and type 2 diabetes-an adipocentric view. Curr Mol 
Med 3:107-125. 
47. Chalkley, S.M., M. Hettiarachchi, D.J. Chisholm, and E.W. Kraegen. 1998. Five-hour fatty acid elevation 
increases muscle lipids and impairs glycogen synthesis in the rat. Metabolism 47:1121-1126. 
48. Chen, H.C., S.J. Stone, P. Zhou, K.K. Buhman, and R.V.J. Farese. 2002. Dissociation of obesity and 
impaired glucose disposal in mice overexpressing acyl coenzyme A:diacylglycerol acyltransferase 1 in white 
adipose tissue. Diabetes 51:3189-3195. 
49. Chen, R., O. Kim, J. Yang, K. Sato, K.M. Eisenmann, J. McCarthy, H. Chen, and Y. Qiu. 2001. Regulation 
of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem  276:31858-31862. 
 89 
50. Chen, Y.R., X. Wang, D. Templeton, R.J. Davis, and T.H. Tan. 1996. The role of c-Jun N-terminal kinase 
(JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine 
cell death and proliferation. J Biol Chem 271:31929-31936. 
51. Chen, Z.P., G.K. McConell, B.J. Michell, R.J. Snow, B.J. Canny, and B.E. Kemp. 2000. AMPK si gnaling in 
contracting human skeletal muscle: acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol 
Endocrinol Metab 279:E1202-E1206. 
52. Chin, J.E., M. Dickens, J.M. Tavare, and R.A. Roth. 1993. Overexpression of protein kinase C isoenzymes 
alpha, beta I, gamma, and epsilon in cells overexpressing the insulin receptor. Effects on receptor 
phosphorylation and signaling. J Biol Chem 268:6338-6347. 
53. Chin, J.E., F. Liu, and R.A. Roth. 1994. Activation of protein kinase C alpha inhibits insulin-stimulated 
tyrosine phosphorylation of insulin receptor substrate-1. Mol Endocrinol 8:51-58. 
54. Clausen, J.O., T. Hansen, C. Bjorbaek, S.M. Echwald, S.A. Urhammer, S. Rasmussen, C.B. Andersen, L. 
Hansen, K. Almind, and K. Winther. 1995. Insulin resistance: interactions between obesity and a common 
variant of insulin receptor substrate-1. Lancet 346:397-402. 
55. Clement, K., C. Vaisse, B.S. Manning, A. Basdevant, B. Guy-Grand, J. Ruiz, K.D. Silver, A.R. Shuldiner, P. 
Froguel, and A.D. Strosberg. 1995. Genetic variation in the beta 3-adrenergic receptor and an increased capacity 
to gain weight in patients with morbid obesity. N Engl J Med 333:352-354. 
56. Cline, G.W., K.F. Petersen, M. Krssak, J. Shen, R.S. Hundal, Z. Trajanoski, S. Inzucchi, A. Dresner, D.L. 
Rothman, and G.I. Shulman. 1999. Impaired glucose transport as a cause of decreased insulin-stimulated muscle 
glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246. 
57. Combs, T.P., A.H. Berg, S. Obici, P.E. Scherer, and L. Rossetti. 2001. Endogenous glucose production is 
inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881. 
58. Combs, T.P., J.A. Wagner, J. Berger, T. Doebber, W.J. Wang, B.B. Zhang, M. Tanen, A.H. Berg, S. 
O'Rahilly, D.B. Savage, K. Chatterjee, S. Weiss, P.J. Larson, K.M. Gottesdiener, B.J. Gertz, M.J. Charron, P.E. 
Scherer, and D.E. Moller. 2002. Induction of adipocyte complement-related protein of 30 kilodaltons by 
PPARgamma agonists: a potential mechanism of insulin sensitization.  Endocrinology 143:998-1007. 
59. Cooksey, R.C. and D.A. McClain. 2002. Transgenic mice overexpressing the rate-limiting enzyme for 
hexosamine synthesis in skeletal muscle or adipose tissue exhibit total body insulin resistance. Ann N Y Acad Sci 
967:102-111. 
60. Couillard, C., P. Mauriege, P. Imbeault, D. Prud'homme, A. Nadeau, A. Tremblay, C. Bouchard, and J.P. 
Despres. 2000. Hyperleptinemia is more closely associated with adipose cell hypertrophy than with adipose 
tissue hyperplasia. Int J Obes Relat Metab Disord 24:782-788. 
61. Cusi, K., K. Maezono, A. Osman, M. Pendergrass, M.E. Patti, T. Pratipanawatr, R.A. DeFronzo, C.R. Kahn, 
and L.J. Mandarino. 2000. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated 
signaling in human muscle. J Clin Invest  105:311-320. 
62. De Beer, R., B.A. van den, D. van Ormondt, W.W. Pijnappel, J.A. den Hollander, A.J. Marien, and P.R. 
Luyten. 1992. Application of time-domain fitting in the quantification of in vivo 1H spectroscopic imaging data 
sets. NMR Biomed 5:171-178. 
63. De Pirro, R., A. Green, M.Y. Kao, and J.M. Olefsky. 1981. Effects of prednisolone and dexamethasone in 
vivo and in vitro: studies of insulin binding, deoxyglucose uptake and glucose oxidation in rat adipocytes. 
Diabetologia 21:149-153. 
64. De Vos, P., A.M. Lefebvre, S.G. Miller, M. Guerre-Millo, K. Wong, R. Saladin, L.G. Hamann, B. Staels, 
M.R. Briggs, and J. Auwerx. 1996. Thiazolidinediones repress ob gene expression in rodents via activation of 
peroxisome proliferator-activated receptor gamma. J Clin Invest 98:1004-1009. 
 90 
65. DeFronzo, R.A., E. Jacot, E. Jequier, E. Maeder, J. Wahren, and J.P. Felber. 1981. The effect of insulin on 
the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous 
catheterization. Diabetes 30:1000-1007. 
66. DeFronzo, R.A., J.D. Tobin, and R. Andres. 1979. Glucose clamp technique: a method for quantifying 
insulin secretion and resistance. Am J Physiol 237:E214-E223. 
67. Dohm, G.L., C.W. Elton, J.E. Friedman, P.F. Pilch, W.J. Pories, S.M.J. Atkinson, and J.F. Caro. 1991. 
Decreased expression of glucose transporter in muscle from insulin-resistant patients. Am J Physiol 260:E459-
E463. 
68. Domingo, P., X. Matias-Guiu, R.M. Pujol, E. Francia, E. Lagarda, M.A. Sambeat, and G. Vazquez. 1999. 
Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 13:2261-2267. 
69. Dominici, F.P. and D. Turyn. 2002. Growth hormone-induced alterations in the insulin-signaling system. Exp 
Biol Med 227:149-157. 
70. Douen, A.G., T. Ramlal, A. Klip, D.A. Young, G.D. Cartee, and J.O. Holloszy. 1989. Exercise-induced 
increase in glucose transporters in plasma membranes of rat skeletal muscle. Endocrinology 124:449-454. 
71. Dowell, P., C. Flexner, P.O. Kwiterovich, and M.D. Lane. 2000. Suppression of preadipocyte differentiation 
and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 275:41325-41332. 
72. Dresner, A., D. Laurent, M. Marcucci, M.E. Griffin, S. Dufour, G.W. Cline, L.A. Slezak, D.K. Andersen, 
R.S. Hundal, D.L. Rothman, K.F. Petersen, and G.I. Shulman. 1999. Effects of free fatty acids on glucose 
transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259. 
73. Ebihara, K., Y. Ogawa, H. Masuzaki, M. Shintani, F. Miyanaga, M. Aizawa-Abe, T. Hayashi, K. Hosoda, G. 
Inoue, Y. Yoshimasa, O. Gavrilova, M.L. Reitman, and K. Nakao. 2001. Transgenic overexpression of leptin 
rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448. 
74. Echwald, S.M., H. Bach, H. Vestergaard, B. Richelsen, K. Kristensen, T. Drivsholm, K. Borch-Johnsen, T. 
Hansen, and O. Pedersen. 2002. A P387L variant in protein tyrosine phosphatase-1B (PTP-1B) is associated 
with type 2 diabetes and impaired serine phosphorylation of PTP-1B in vitro. Diabetes 51:1-6. 
75. Eck, M.J., S. Dhe-Paganon, T. Trub, R.T. Nolte, and S.E. Shoelson. 1996. Structure of the IRS-1 PTB 
domain bound to the juxtamembrane region of the insulin receptor. Cell 85:695-705. 
76. Elchebly, M., P. Payette, E. Michaliszyn, W. Cromlish, S. Collins, A.L. Loy, D. Normandin, A. Cheng, J. 
Himms-Hagen, C.C. Chan, C. Ramachandran, M.J. Gresser, M.L. Tremblay, and B.P. Kennedy. 1999. Increased 
insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 
283:1544-1548. 
77. Fajas, L., K. Schoonjans, L. Gelman, J.B. Kim, J. Najib, G. Martin, J.C. Fruchart, M. Briggs, B.M. 
Spiegelman, and J. Auwerx. 1999. Regulation of peroxisome proliferator-activated receptor gamma expression 
by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications 
for adipocyte differentiation and metabolism. Mol Cell Biol 19:5495-5503. 
78. Fantin, V.R., Q. Wang, G.E. Lienhard, and S.R. Keller. 2000. Mice lacking insulin receptor substrate 4 
exhibit mild defects in growth, reproduction, and glucose homeostasis. Am J Physiol Endocrinol Metab 
278:E127-E133. 
79. Fasshauer, M., J. Klein, S. Neumann, M. Eszlinger, and R. Paschke. 2002. Hormonal regulation of 
adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 290:1084-1089. 
80. Ferrannini, E., E.J. Barrett, S. Bevilacqua, and R.A. DeFronzo. 1983. Effect of fatty acids on glucose 
production and utilization in man. J Clin Invest 72:1737-1747. 
 91 
81. Fisher, F.M., P.G. McTernan, G. Valsamakis, R. Chetty, A.L. Harte, A.J. Anwar, J. Starcynski, J. Crocker, 
A.H. Barnett, C.L. McTernan, and S. Kumar. 2002. Differences in adiponectin protein expression: effect of fat 
depots and type 2 diabetic status. Horm Metab Res 34:650-654. 
82. Flier, J.S. 1992. Lilly Lecture: syndromes of insulin resistance. From patient to gene and back again. 
Diabetes 41:1207-1219. 
83. Forouhi, N.G., G. Jenkinson, E.L. Thomas, S. Mullick, S. Mierisova, U. Bhonsle, P.M. McKeigue, and J.D. 
Bell. 1999. Relation of triglyceride stores in skeletal muscle cells to central obesity and insulin sensitivity in 
European and South Asian men. Diabetologia 42:932-935. 
84. Friedman, J.E., T. Ishizuka, J. Shao, L. Huston, T. Highman, and P. Catalano. 1999. Impaired glucose 
transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational 
diabetes. Diabetes 48:1807-1814. 
85. Fruhbeck, G., J. Gomez-Ambrosi, F.J. Muruzabal, and M.A. Burrell. 2001. The adipocyte: a model for 
integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol 
Metab 280:E827-E847. 
86. Fujii, N., T. Hayashi, M.F. Hirshman, J.T. Smith, S.A. Habinowski, L. Kaijser, J. Mu, O. Ljungqvist, M.J. 
Birnbaum, L.A. Witters, A. Thorell, and L.J. Goodyear. 2000. Exercise induces isoform-specific increase in 
5'AMP-activated protein kinase activity in human skeletal muscle. Biochem Biophys Res Commun  273:1150-
1155. 
87. Furler, S.M., G.J. Cooney, B.D. Hegarty, M.Y. Lim-Fraser, E.W. Kraegen, and N.D. Oakes. 2000. Local 
factors modulate tissue-specific NEFA utilization: assessment in rats using 3H-(R)-2-bromopalmitate. Diabetes 
49:1427-1433. 
88. Garg, A. 2002. The lipodystrophies and other primary disorders of adipose tissue. In  Harrison's Principles of 
Internal Medicine. E. Brauwald, A.S. Fauci, D.L. Kasper, A.S. Houser, D.L. Longo, and J.L. Jameson, editors.  
New York. Pages 2316-2319. 
89. Gavrilova, O., B. Marcus-Samuels, D. Graham, J.K. Kim, G.I. Shulman, A.L. Castle, C. Vinson, M. 
Eckhaus, and M.L. Reitman. 2000. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic 
mice. J Clin Invest 105:271-278. 
90. Gavrilova, O., B. Marcus-Samuels, L.R. Leon, C. Vinson, and M.L. Reitman. 2000. Leptin and diabetes in 
lipoatrophic mice. Nature 403:850-851. 
91. George, S., D. Savage, and S. O'Rahilly. 2003. Hereditary and acquired syndromes of severe insulin 
resistance. In Textbook of Diabetes. G. Williams and J.C. Pickup. Blackwell Science, chapter 29. 
92. Goldstein, B.J., F. Ahmad, W. Ding, P.M. Li, and W.R. Zhang. 1998. Regulation of the insulin signalling 
pathway by cellular protein-tyrosine phosphatases. Mol Cell Biochem 182:91-99. 
93. Goldstein, B.J. and C.R. Kahn. 1989. Analysis of mRNA heterogeneity by ribonuclease H mapping: 
application to the insulin receptor. Biochem Biophys Res Commun 159:664-669. 
94. Goodpaster, B.H., F.L. Thaete, and D.E. Kelley. 2000. Thigh adipose tissue distribution is associated with 
insulin resistance in obesity and in type 2 diabetes mellitus. Am J Clin Nutr 71:885-892. 
95. Goodyear, L.J., F. Giorgino, L.A. Sherman, J. Carey, R.J. Smith, and G.L. Dohm. 1995. Insulin receptor 
phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are 
decreased in intact skeletal muscle strips from obese subjects. J Clin Invest 95:2195-2204. 
96. Gray, R.E., C.J. Tanner, W.J. Pories, K.G. MacDonald, and J.A. Houmard. 2003. Effect of weight loss on 
muscle lipid content in morbidly obese subjects. Am J Physiol Endocrinol Metab 284:E726-E732. 
 92 
97. Greco, A.V., G. Mingrone, A. Giancaterini, M. Manco, M. Morroni, S. Cinti, M. Granzotto, R. Vettor, S. 
Camastra, and E. Ferrannini. 2002. Insulin resistance in morbid obesity: reversal with intramyocellular fat 
depletion. Diabetes 51:144-151. 
98. Green, D.R. and J.C. Reed. 1998. Mitochondria and apoptosis. Science 281:1309-1312. 
99. Griffin, M.E., M.J. Marcucci, G.W. Cline, K. Bell, N. Barucci, D. Lee, L.J. Goodyear, E.W. Kraegen, M.F. 
White, and G.I. Shulman. 1999. Free fatty acid-induced insulin resistance is associated with activation of protein 
kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274. 
100. Grinspoon, S. Insulin resistance in the HIV-lipodystrophy syndrome. 2001. Trends Endocrinol Metab 
12:413-419. 
101. Groop, L.C., M. Kankuri, C. Schalin-Jantti, A. Ekstrand, P. Nikula-Ijas, E. Widen, E. Kuismanen, J. 
Eriksson, A. Franssila-Kallunki, C. Saloranta, et al. 1993. Association between polymorphism of the glycogen 
synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328:10-14. 
102. Grunfeld, C. and K.R. Feingold. 1991. The metabolic effects of tumor necrosis factor and other cytokines. 
Biotherapy 3:143-158. 
103. Gumbiner, B., J.F. Mucha, J.E. Lindstrom, I. Rekhi, and J.N. Livingston. 1996.  Differential effects of acute 
hypertriglyceridemia on insulin action and insulin receptor autophosphorylation. Am J Physiol 270: E424-E429. 
104. Hadigan, C., J.B. Meigs, C. Corcoran, P. Rietschel, S. Piecuch, N. Basgoz, B. Davis, P. Sax, T. Stanley, 
P.W. Wilson, R.B. D'Agostino, and S. Grinspoon. 2001. Metabolic abnormalities and cardiovascular disease risk 
factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32:130-139. 
105. Halleux, C.M., M. Takahashi, M.L. Delporte, R. Detry, T. Funahashi, Y. Matsuzawa, and S.M. Brichard. 
2001. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. 
Biochem Biophys Res Commun 288:1102-1107. 
106. Handberg, A., A. Vaag, P. Damsbo, H. Beck-Nielsen, and J. Vinten. 1990. Expression of insulin regulatable 
glucose transporters in skeletal muscle from type 2 (non-insulin-dependent) diabetic patients. Diabetologia 
33:625-627. 
107. Hansen, J.B., H. Zhang, T.H. Rasmussen, R.K. Petersen, E.N. Flindt, and K. Kristiansen. 2001. Peroxisome 
proliferator-activated receptor delta (PPARdelta)-mediated regulation of preadipocyte proliferation and gene 
expression is dependent on cAMP signaling. J Biol Chem 276:3175-3182. 
108. Hansen, L., T. Hansen, H. Vestergaard, C. Bjorbaek, S.M. Echwald, J.O. Clausen, Y.H. Chen, M.X. Chen, 
P.T. Cohen, and O. Pedersen. 1995. A widespread amino acid polymorphism at codon 905 of the glycogen-
associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of 
insulin. Hum Mol Genet 4:1313-1320. 
109. Haque, W.A., I. Shimomura, Y. Matsuzawa, and A. Garg. 2002. Serum adiponectin and leptin levels in 
patients with lipodystrophies. J Clin Endocrinol Metab 87:2395. 
110. Hart, G.W. 1997. Dynamic O-linked glycosylation of nuclear and cytoskeletal proteins. Annu Rev Biochem 
66:315-335. 
111. Hartman, H.B., X. Hu, K.X. Tyler, C.K. Dalal, and M.A. Lazar. 2002. Mechanisms regulating adipocyte 
expression of resistin. J Biol Chem 277:19754-19761. 
112. Haugen, F., A. Jorgensen, C.A. Drevon, and P. Trayhurn. 2001. Inhibition by insulin of resistin gene 
expression in 3T3-L1 adipocytes. FEBS Lett 507:105-108. 
113. Hawkins, M., N. Barzilai, R. Liu, M. Hu, W. Chen, and L. Rossetti. 1997. Role of the glucosamine pathway 
in fat-induced insulin resistance. J Clin Invest 99:2173-2182. 
 93 
114. Hayashi, T., M.F. Hirshman, N. Fujii, S.A. Habinowski, L.A. Witters, and L.J. Goodyear. 2000. Metabolic 
stress and altered glucose transport: activation of AMP-activated protein kinase as a unifying coupling 
mechanism. Diabetes  49:527-531. 
115. Hayashi, T., M.F. Hirshman, E.J. Kurth, W.W. Winder, and L.J. Goodyear. 1998. Evidence for 5' AMP-
activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes 47:1369-
1373. 
116. Hirosumi, J., G. Tuncman, L. Chang, C.Z. Gorgun, K.T. Uysal, K. Maeda, M. Karin, and G.S. Hotamisligil. 
2002. A central role for JNK in obesity and insulin resistance. Nature 420:333-336. 
117. Hirshman, M.F., H. Wallberg-Henriksson, L.J. Wardzala, E.D. Horton, and E.S. Horton. 1988. Acute 
exercise increases the number of plasma membrane glucose transporters in rat skeletal muscle. FEBS Lett 
238:235-239. 
118. Holgado-Madruga, M., D.R. Emlet, D.K. Moscatello, A.K. Godwin, and A.J. Wong. 1996. A Grb2-
associated docking protein in EGF- and insulin-receptor signalling. Nature 379:560-564. 
119. Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-
mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin 
resistance. Science 271:665-668. 
120. Hotamisligil, G.S. and B.M. Spiegelman. 1994. Tumor necrosis factor alpha: a key component of the 
obesity-diabetes link. Diabetes 43:1271-1278. 
121. Hotta, K., T. Funahashi, Y. Arita, M. Takahashi, M. Matsuda, Y. Okamoto, H. Iwahashi, H. Kuriyama, N. 
Ouchi, K. Maeda, M. Nishida, S. Kihara, N. Sakai, T. Nakajima, K. Hasegawa, M. Muraguchi, Y. Ohmoto, T. 
Nakamura, S. Yamashita, T. Hanafusa, and Y. Matsuzawa. 2000. Plasma concentrations of a novel, adipose-
specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599. 
122. Houmard, J.A., C.D. Shaw, M.S. Hickey, and C.J. Tanner. 1999.  Effect of short-term exercise training on 
insulin-stimulated PI 3-kinase activity in human skeletal muscle. Am J Physiol 277:E1055-E1060. 
123. Howald, H., C. Boesch, R. Kreis, S. Matter, R. Billeter, B. Essen-Gustavsson, and H. Hoppeler. 2002. 
Content of intramyocellular lipids derived by electron microscopy, biochemical assays, and (1)H-MR 
spectroscopy. J Appl Physiol 92:2264-2272. 
124. Hribal, M.L., M. Federici, O. Porzio, D. Lauro, P. Borboni, D. Accili, R. Lauro, and G. Sesti. 2000. The 
Gly-->Arg972 amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal 
muscle cells. J Clin Endocrinol Metab 85:2004-2013. 
125. Ihlemann, J., T. Ploug, Y. Hellsten, and H. Galbo. 1999. Effect of tension on contraction-induced glucose 
transport in rat skeletal muscle. Am J Physiol 277:E208-E214. 
126. Itani, S.I., N.B. Ruderman, F. Schmieder, and G. Boden. 2002. Lipid-induced insulin resistance in human 
muscle is associated with changes in diacylglycerol, protein kinase C, and IkappaB-alpha. Diabetes 51:2005-
2011. 
127. Itani, S.I., Q. Zhou, W.J. Pories, K.G. MacDonald, and G.L. Dohm. 2000. Involvement of protein kinase C 
in human skeletal muscle insulin resistance and obesity. Diabetes 49:1353-1358. 
128. Jacob, S., J. Machann, K. Rett, K. Brechtel, A. Volk, W. Renn, E. Maerker, S. Matthaei, F. Schick, C.D. 
Claussen, and H.U. Haring. 1999. Association of increased intramyocellular lipid content with insulin resistance 
in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes 48:1113-1119. 
129. Juhan-Vague, I. and M.C. Alessi. 1997. PAI-1, obesity, insulin resistance and risk of cardiovascular events. 
Thromb Haemost 78:656-660. 
130. Kadish, A.H., R.L. Litle, and J.C. Sternberg. 1968. A new and rapid method for the determination of 
glucose by measurement of rate of oxygen consumption. Clin Chem 14:116-131. 
 94 
131. Kadowaki, T., K. Hara, N. Kubota, K. Tobe, Y. Terauchi, T. Yam auchi, K. Eto, H. Kadowaki, M. Noda, R. 
Hagura, and Y. Akanuma. 2002. The role of PPARgamma in high-fat diet-induced obesity and insulin resistance. 
J Diabetes Complications 16:41-45. 
132. Kahn, B.B. and J.S. Flier. 2000. Obesity and insulin resistance. J Clin Invest 106:473-481. 
133. Kahn, C.R., J.S. Flier, R.S. Bar, J.A. Archer, P. Gorden, M.M. Martin, and J. Roth. 1976. The syndromes of 
insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 294:739-745. 
134. Kanety, H., R. Feinstein, M.Z. Papa, R. Hemi, and A. Karasik. 1995. Tumor necrosis factor alpha-induced 
phosphorylation of insulin receptor substrate-1 (IRS-1). Possible mechanism for suppression of insulin-
stimulated tyrosine phosphorylation of IRS-1. J Biol Chem 270:23780-23784. 
135. Kanety, H., R. Hemi, M.Z. Papa, and A. Karasik. 1996. Sphingomyelinase and ceramide suppress insulin-
induced tyrosine phosphorylation of the insulin receptor substrate-1. J Biol Chem 271:9895-9897. 
136. Kellerer, M., R. Lammers, and H.U. Haring. 1999. Insulin signal transduction: possible mechanisms for 
insulin resistance. Exp Clin Endocrinol Diabetes 107:97-106. 
137. Kellerer, M., J. Mushack, E. Seffer, H. Mischak, A. Ullrich, and H.U. Haring. 1998.  Protein kinase C 
isoforms alpha, delta and theta require insulin receptor substrate-1 to inhibit the tyrosine kinase activity of the 
insulin receptor in human kidney embryonic cells (HEK 293 cells). Diabetologia 41:833-838. 
138. Kido, Y., D.J. Burks, D. Withers, J.C. Bruning, C.R. Kahn, M.F. White, and D. Accili. 2000. Tissue-
specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 
105:199-205. 
139. Kido, Y., J. Nakae, and D. Accili. 2001. Clinical review 125: The insulin receptor and its cellular targets.  J 
Clin Endocrinol Metab 86:972-979. 
140. Kim, J.B. and B.M. Spiegelman. 1996. ADD1/SREBP1 promotes adipocyte differentiation and gene 
expression linked to fatty acid metabolism. Genes Dev 10:1096-1107. 
141. Kim, J.K., O. Gavrilova, Y. Chen, M.L. Reitman, and G.I. Shulman. 2000. Mechanism of insulin resistance 
in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460. 
142. Kim, Y.B., S.E. Nikoulina, T.P. Ciaraldi, R.R. Henry, and B.B. Kahn. 1999. Normal insulin-dependent 
activation of Akt/protein kinase B, with diminished activation of phosphoinositide 3-kinase, in muscle in type 2 
diabetes. J Clin Invest 104:733-741. 
143. Kirwan, J.P., L.F. del Aguila, J.M. Hernandez, D.L. Williamson, D.J. O'Gorman, R. Lewis, and R.K. 
Krishnan. 2000. Regular exercise enhances insulin activation of IRS-1-associated PI3-kinase in human skeletal 
muscle. J Appl Physiol 88:797-803. 
144. Klein, H.H., H. Vestergaard, G. Kotzke, and O. Pedersen. 1995. Elevation of serum insulin concentration 
during euglycemic hyperinsulinemic clamp studies leads to similar activation of insulin receptor kinase in 
skeletal muscle of subjects with and without NIDDM. Diabetes 44:1310-1317. 
145. Kops, G.J. and B.M. Burgering. 1999. Forkhead transcription factors: new insights into protein kinase B (c-
Akt) signaling. J Mol Med 77:656-665. 
146. Kosaki, A., T.S. Pillay, L. Xu, and N.J. Webster. 1995. The B isoform of the insulin receptor signals more 
efficiently than the A isoform in HepG2 cells. J Biol Chem  270:20816-20823. 
147. Kosztolanyi, G. 1997. Leprechaunism/Donohue syndrome/insulin receptor gene mutations: a syndrome 
delineation story from clinicopathological description to molecular understanding. Eur J Pediatr 156:253-255. 
148. Kotani, K., W. Ogawa, M. Matsumoto, T. Kitamura, H. Sakaue, Y. Hino, K. Miyake, W. Sano, K. 
Akimoto, S. Ohno, and M. Kasuga. 1998. Requirement of atypical protein kinase C lambda for insulin 
stimulation of glucose uptake but not for Akt activation in 3T3-L1 adipocytes. Mol Cell Biol 18:6971-6982. 
 95 
149. Koval, J.A., K. Maezono, M.E. Patti, M. Pendergrass, R.A. DeFronzo, and L.J. Mandarino. 1999. Effects of 
exercise and insulin on insulin signaling proteins in human skeletal muscle. Med Sci Sports Exerc 31:998-1004. 
150. Krebs, M., M. Krssak, P. Nowotny, D. Weghuber, S. Gruber, V. Mlynarik, M. Bischof, H. Stingl, C. 
Furnsinn, W. Waldhausl, and M. Roden. 2001. Free fatty acids inhibit the glucose-stimulated increase of 
intramuscular glucose-6-phosphate concentration in humans. J Clin Endocrinol Metab 86:2153-2160. 
151. Krook, A., M. Bjornholm, D. Galuska, X.J. Jiang, R. Fahlman, M.G.J. Myers, H. Wallberg-Henriksson, and 
J.R. Zierath. 2000. Characterization of signal transduction and glucose transport in skeletal muscle from type 2 
diabetic patients. Diabetes 49:284-292. 
152. Krook, A., U. Widegren, X.J. Jiang, J. Henriksson, H. Wallberg-Henriksson, D. Alessi, and J.R. Zierath. 
2000. Effects of exercise on mitogen- and stress-activated kinase signal transduction in human skeletal muscle. 
Am J Physiol Regul Integr Comp Physiol  279:R1716-R1721. 
153. Krssak, M., P.K. Falk, A. Dresner, L. DiPietro, S.M. Vogel, D.L. Rothman, M. Roden, and G.I. Shulman. 
1999. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR 
spectroscopy study. Diabetologia 42:113-116. 
154. Kruszynska, Y.T. 2003. Normal metabolism: the physiology of fuel homeostasis. In Textbook of Diabetes. 
J.C. Pickup and G. Williams, editors. Blackwell Science. Chapter 9. 
155. Kruszynska, Y.T., D.S. Worrall, J. Ofrecio, J.P. Frias, G. Macaraeg, and J.M. Olefsky. 2002. Fatty acid-
induced insulin resistance: decreased muscle PI3K activation but unchanged Akt phosphorylation. J Clin 
Endocrinol Metab 87:226-234. 
156. Kulkarni, R.N., J.C. Bruning, J.N. Winnay, C. Postic, M.A. Magnuson, and C.R. Kahn. 1999. Tissue-
specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that 
in type 2 diabetes. Cell 96:329-339. 
157. Kulkarni, R.N., J.N. Winnay, M. Daniels, J.C. Bruning, S.N. Flier, D. Hanahan, and C.R. Kahn. 1999. 
Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest 
104:R69-R75. 
158. Kumada, M., S. Kihara, S. Sumitsuji, T. Kawamoto, S. Matsumoto, N. Ouchi, Y. Arita, Y. Okamoto, I. 
Shimomura, H. Hiraoka, T. Nakamura, T. Funahashi, and Y. Matsuzawa. 2003. Association of 
hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23:85-89. 
159. Kuroyama, H., T. Sanke, S. Ohagi, M. Furuta, H. Furuta, and K. Nanjo. 1994. Simple tandem repeat DNA 
polymorphism in the human glycogen synthase gene is associated with NIDDM in Japanese subjects. 
Diabetologia 37:536-539. 
160. Kurth-Kraczek, E.J., M.F. Hirshman, L.J. Goodyear, and W.W. Winder. 1999. 5' AMP-activated protein 
kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48:1667-1671. 
161. Larrouy, D., H. Vidal, F. Andreelli, M. Laville, and D. Langin. 1999. Cloning and mRNA tissue 
distribution of human PPARgamma coactivator-1. Int J Obes Relat Metab Disord 23:1327-1332. 
162. Le Good, J.A., W.H. Ziegler, D.B. Parekh, D.R. Alessi, P. Cohen, and P.J. Parker. 1998. Protein kinase C 
isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1. Science 281:2042-2045. 
163. Lee, A.D., P.A. Hansen, and J.O. Holloszy. 1995. Wortmannin inhibits insulin-stimulated but not 
contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett 361:51-54. 
164. Lee, A.D., P.A. Hansen, J. Schluter, E.A. Gulve, J. Gao, and J.O. Holloszy. 1997.  Effects of epinephrine on 
insulin-stimulated glucose uptake and GLUT-4 phosphorylation in muscle. Am J Physiol 273:C1082-C1087. 
165. Lembo, G., B. Capaldo, V. Rendina, G. Iaccarino, R. Napoli, R. Guida, B. Trimarco, and L. Sacca. 1994. 
Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol 266:E242-
E247. 
 96 
166. Lenhard, J.M., D.K. Croom, J.E. Weiel, and D.A. Winegar. 2000. HIV protease inhibitors stimulate hepat ic 
triglyceride synthesis. Arterioscler Thromb Vasc Biol 20:2625-2629. 
167. Lillioja, S., D.M. Mott, B.V. Howard, P.H. Bennett, H. Yki-Jarvinen, D. Freymond, B.L. Nyomba, F. Zurlo, 
B. Swinburn, and C. Bogardus. 1988. Impaired glucose tolerance as a disorder of insulin action. Longitudinal 
and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225. 
168. Lin, J., H. Wu, P.T. Tarr, C.Y. Zhang, Z. Wu, O. Boss, L.F. Michael, P. Puigserver, E. Isotani, E.N. Olson, 
B.B. Lowell, R. Bassel-Duby, and B.M. Spiegelman. 2002. Transcriptional co-activator PGC-1 alpha drives the 
formation of slow-twitch muscle fibres. Nature 418:797-801. 
169. Lin, Y., S.I. Itani, T.G. Kurowski, D.J. Dean, Z. Luo, G.C. Yaney, and N.B. Ruderman. 2001. Inhibition of 
insulin signaling and glycogen synthesis by phorbol dibutyrate in rat skeletal muscle. Am J Physiol Endocrinol 
Metab 281:E8-E15. 
170. Liu, L.S., M. Spelleken, K. Rohrig, H. Hauner, and J. Eckel. 1998. Tumor necrosis factor-alpha acutely 
inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor. Diabetes 
47:515-522. 
171. Longo, R., P. Pollesello, C. Ricci, F. Masutti, B.J. Kvam, L. Bercich, L.S. Croce, P. Grigolato, S. Paoletti, 
B. de Bernard, et al. 1995. Proton MR spectroscopy in quantitative in vivo determination of fat content in human 
liver steatosis. J Magn Reson Imaging 5:281-285. 
172. Louis, S.N., G.P. Jackman, T.L. Nero, D. Iakovidis, and W.J. Louis. 2000. Role of beta -adrenergic receptor 
subtypes in lipolysis. Cardiovasc Drugs Ther 14:565-577. 
173. Lowell, B.B. 1999. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. 
Cell 99:239-242. 
174. Lukaski, H.C., P.E. Johnson, W.W. Bolonchuk, and G.I. Lykken. 1985. Assessment of fat-free mass using 
bioelectrical impedance measurements of the human body. Am J Clin Nutr  41:810-817. 
175. Lund, S., G.D. Holman, O. Schmitz, and O. Pedersen. 1995. Contraction stimulates translocation of glucose 
transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin. Proc Natl Acad Sci 
USA 92:5817-5821. 
176. Maeda, N., I. Shimomura, K. Kishida, H. Nishizawa, M. Matsuda, H. Nagaretani, N. Furuyama, H. Kondo, 
M. Takahashi, Y. Arita, R. Komuro, N. Ouchi, S. Kihara, Y. Tochino, K. Okutomi, M. Horie, S. Takeda, T. 
Aoyama, T. Funahashi, and Y. Matsuzawa. 2002. Diet-induced insulin resistance in mice lacking 
adiponectin/ACRP30. Nat Med 8:731-737. 
177. Maegawa, H., Y. Shigeta, K. Egawa, and M. Kobayashi. 1991. Impaired autophosphorylation of insulin 
receptors from abdominal skeletal muscles in nonobese subjects with NIDDM. Diabetes 40:815-819. 
178. Maher, B., A. Alfirevic, F.J. Vilar, E.G. Wilkins, B.K. Park, and M. Pirmohamed. 2002. TNF-alpha 
promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16:2013-2018. 
179. Makowski, L., J.B. Boord, K. Maeda, V.R. Babaev, K.T. Uysal, M.A. Morgan, R.A. Parker, J. Suttles, S. 
Fazio, G.S. Hotamisligil, and M.F. Linton. 2001. Lack of macrophage fatty-acid-binding protein aP2 protects 
mice deficient in apolipoprotein E against atherosclerosis. Nat Med 7:699-705. 
180. Malmstrom, R., M.R. Taskinen, S.L. Karonen, and H. Yki-Jarvinen. 1996. Insulin increases plasma leptin 
concentrations in normal subjects and patients with NIDDM. Diabetologia 39:993-996. 
181. Manco, M., G. Mingrone, A.V. Greco, E. Capristo, D. Gniuli, A. De Gaetano, and G. Gasbarrini. 2000. 
Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. 
Metabolism 49:220-224. 
 97 
182. Martin, G., K. Schoonjans, A.M. Lefebvre, B. Staels, and J. Auwerx. 1997. Coordinate regulation of the 
expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma 
activators. J Biol Chem 272:28210-28217. 
183. Masuzaki, H., J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier. 2001. A 
transgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170. 
184. McGuire, E.A., J.H. Helderman, J.D. Tobin, R. Andres, and M. Berman. 1976. Effects of arterial versus 
venous sampling on analysis of glucose kinetics in man. J Appl Physiol 41:565-573. 
185. McGuire, M.C., R.M. Fields, B.L. Nyomba, I. Raz, C. Bogardus, N.K. Tonks, and J. Sommercorn. 1991. 
Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. 
Diabetes 40:939-942. 
186. Memon, R.A., J. Fuller, A.H. Moser, P.J. Smith, K.R. Feingold, and C. Grunfeld. 1998. In vivo regulation 
of acyl-CoA synthetase mRNA and activity by endotoxin and cytokines. Am J Physiol 275:E64-E72. 
187. Mendez, R., G. Kollmorgen, M.F. White, and R.E. Rhoads. 1997. Requirement of protein kinase C zeta for 
stimulation of protein synthesis by insulin. Mol Cell Biol 17:5184-5192. 
188. Michael, L.F., Z. Wu, R.B. Cheatham, P. Puigserver, G. Adelmant, J.J. Lehman, D.P. Kelly, and B.M. 
Spiegelman. 2001. Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells 
by the transcriptional coactivator PGC-1. Proc Natl Acad Sci USA 98:3820-3825. 
189. Michie, H.R., T.J. Eberlein, D.R. Spriggs, K.R. Manogue, A. Cerami, and D.W. Wilmore. 1988. 
Interleukin-2 initiates metabolic responses associated with critical illness in humans. Ann Surg 208:493-503. 
190. Michie, H.R., P.J. Guillou, and D.W. Wilmore. 1989. Tumour necrosis factor and bacterial sepsis. Br J Surg 
76:670-671. 
191. Michie, H.R., D.R. Spriggs, K.R. Manogue, M.L. Sherman, A. Revhaug, S.T. O'Dwyer, K. Arthur, C.A. 
Dinarello, A. Cerami, and S.M. Wolff. 1988. Tumor necrosis factor and endotoxin induce similar metabolic 
responses in human beings. Surgery 104:280-286. 
192. Miles, J., R. Glasscock, J. Aikens, J. Gerich, and M. Haymond. 1983. A microfluorometric method for the 
determination of free fatty acids in plasma. J Lipid Res 24:96-99. 
193. Miserez, A.R., P.Y. Muller, L. Barella, M. Schwietert, P. Erb, P.L. Vernazza, and M. Battegay. 2001. A 
single-nucleotide polymorphism in the sterol-regulatory element-binding protein 1c gene is predictive of HIV-
related hyperlipoproteinaemia. AIDS 15:2045-2049. 
194. Moitra, J., M.M. Mason, M. Olive, D. Krylov, O. Gavrilova, B. Marcus-Samuels, L. Feigenbaum, E. Lee, 
T. Aoyama, M. Eckhaus, M.L. Reitman, and C. Vinson. 1998. Life without white fat: a transgenic mouse. Genes 
Dev 12:3168-3181. 
195. Moller, D.E., A. Yokota, J.F. Caro, and J.S. Flier. 1989. Tissue-specific expression of two alternatively 
spliced insulin receptor mRNAs in man. Mol Endocrinol 3:1263-1269. 
196. Montague, C.T., J.B. Prins, L. Sanders, J. Zhang, C.P. Sewter, J. Digby, C.D. Byrne, and S. O'Rahilly. 
1998. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384-1391. 
197. Moore, G.B., H. Chapman, J.C. Holder, C.A. Lister, V. Piercy, S.A. Smith, and J.C. Clapham. 2001. 
Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice. Biochem Biophys Res Commun 
286:735-741. 
198. Mosthaf, L., K. Grako, T.J. Dull, L. Coussens, A. Ullrich, and D.A. McClain. 1990. Functionally distinct 
insulin receptors generated by tissue-specific alternative splicing. EMBO J 9:2409-2413. 
 98 
199. Motley, E.D., S.M. Kabir, K. Eguchi, A.L. Hicks, C.D. Gardner, C.M. Reynolds, G.D. Frank, and S. 
Eguchi. 2001. Protein kinase C inhibits insulin-induced Akt activation in vascular smooth muscle cells. Cell Mol 
47:1059-1062. 
200. Motojima, K., P. Passilly, J.M. Peters, F.J. Gonzalez, and N. Latruffe. 1998. Expression of putative fatty 
acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in 
a tissue- and inducer-specific manner. J Biol Chem 273:16710-16714. 
201. Motoshima, H., X. Wu, M.K. Sinha, V.E. Hardy, E.L. Rosato, D.J. Barbot, F.E. Rosato, and B.J. Goldstein. 
2002. Differential regulation of adiponectin secretion from cultured human omental and subcutaneous 
adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662-5667. 
202. Mu, J., J.T. Brozinick, Jr., O. Valladares, M. Bucan, and M.J. Birnbaum. 2001. A role for AMP-activated 
protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol Cell 7:1085-1094. 
203. Mynarcik, D.C., T. Combs, M.A. McNurlan, P.E. Scherer, E. Komaroff, and M.C. Gelato. 2002. 
Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J 
Acquir Immune Defic Syndr 31:514-520. 
204. Nagaev, I. and U. Smith. 2001. Insulin resistance and type 2 diabetes are not related to resistin expression in 
human fat cells or skeletal muscle. Biochem Biophys Res Commun 285:561-564. 
205. National Food and Nutritional Institute. 1987. Measuring Obesity - Classification and Description of 
Antropometric Data. Report on a WHO Consultation on the Epidemiology of Obesity. WHO 1-22. 
206. Nicholson, K.M. and N.G. Anderson. 2002. The protein kinase B/Akt signalling pathway in human 
malignancy. Cell Signal 14:381-395. 
207. Nolan, J.J., G. Freidenberg, R. Henry, D. Reichart, and J.M. Olefsky. 1994. Role of human skeletal muscle 
insulin receptor kinase in the in vivo insulin resistance of noninsulin-dependent diabetes mellitus and obesity. J 
Clin Endocrinol Metab 78:471-477. 
208. Nuutila, P., V.A. Koivisto, J. Knuuti, U. Ruotsalainen, M. Teras, M. Haaparanta, J. Bergman, O. Solin, 
L.M. Voipio-Pulkki, and U. Wegelius. 1992. Glucose-free fatty acid cycle operates in human heart and skeletal 
muscle in vivo. J Clin Invest 89:1767-1774. 
209. Olefsky, J.M., J. Johnson, F. Liu, P. Jen, and G.M. Reaven. 1975. The effects of acute and chronic 
dexamethasone administration on insulin binding to isolated rat hepatocytes and adipocytes. Metabolism 24:517-
527. 
210. Oral, E.A., V. Simha, E. Ruiz, A. Andewelt, A. Premkumar, P. Snell, A.J. Wagner, A.M. DePaoli, M.L. 
Reitman, S.I. Taylor, P. Gorden, and A. Garg. 2002. Leptin-replacement therapy for lipodystrophy. N Engl J 
Med 346:570-578. 
211. Ouchi, N., S. Kihara, Y. Arita, K. Maeda, H. Kuriyama, Y. Okamoto, K. Hotta, M. Nishida, M. Takahashi, 
T. Nakamura, S. Yamashita, T. Funahashi, and Y. Matsuzawa. 1999. Novel modulator for endothelial adhesion 
molecules: adipocyte-derived plasma protein adiponectin. Circulation  100:2473-2476. 
212. Ouchi, N., S. Kihara, Y. Arita, M. Nishida, A. Matsuyama, Y. Okamoto, M. Ishigami, H. Kuriyama, K. 
Kishida, H. Nishizawa, K. Hotta, M. Muraguchi, Y. Ohmoto, S. Yamashita, T. Funahashi, and Y. Matsuzawa. 
2001. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger 
receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063. 
213. Owuor, E.D. and A.N. Kong. 2002. Antioxidants and oxidants regulated signal transduction pathways. 
Biochem Pharmacol 64:765-770. 
214. Pan, D.A., S. Lillioja, A.D. Kriketos, M.R. Milner, L.A. Baur, C. Bogardus, A.B. Jenkins, and L.H. 
Storlien. 1997. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 46:983-988. 
 99 
215. Patti, M.E., A. Virkamaki, E.J. Landaker, C.R. Kahn, and H. Yki-Jarvinen. 1999. Activation of the 
hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling 
events in skeletal muscle. Diabetes 48:1562-1571. 
216. Pedersen, O., J.F. Bak, P.H. Andersen, S. Lund, D.E. Moller, J.S. Flier, and B.B. Kahn. 1990. Evidence 
against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 
39:865-870. 
217. Pederson, T. and C.M. Rondinone. 2000. Regulation of proteins involved in insulin signaling pathways in 
differentiating human adipocytes. Biochem Biophys Res Commun  276:162-168. 
218. Perseghin, G., P. Scifo, F. De Cobelli, E. Pagliato, A. Battezzati, C. Arcelloni, A. Vanzulli, G. Testolin, G. 
Pozza, A. Del Maschio, and L. Luzi. 1999.  Intramyocellular triglyceride content is a determinant of in vivo 
insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 
2 diabetic parents. Diabetes 48:1600-1606. 
219. Pessin, J.E., W. Gitomer, Y. Oka, C.L. Oppenheimer, and M.P. Czech. 1983. Beta-adrenergic regulation of 
insulin and epidermal growth factor receptors in rat adipocytes. J Biol Chem 258:7386-7394. 
220. Peters, J.M., S.S. Lee, W. Li, J.M. Ward, O. Gavrilova, C. Everett, M.L. Reitman, L.D. Hudson, and F.J. 
Gonzalez. 2000. Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse 
peroxisome proliferator-activated receptor beta (delta). Mol Cell Biol 20:5119-5128. 
221. Phillips, D.I., S. Caddy, V. Ilic, B.A. Fielding, K.N. Frayn, A.C. Borthwick, and R. Taylor. 1996. 
Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. 
Metabolism 45:947-950. 
222. Puigserver, P., Z. Wu, C.W. Park, R. Graves, M. Wright, and B.M. Spiegelman. 1998. A cold-inducible 
coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839. 
223. Randle P.J., Garland P.B., Hales C.N., and Newsholme E.A. 1963. The glucose fatty-acid cycle; its role in 
insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet i 785-789. 
224. Rannels, S.R. and L.S. Jefferson. 1980. Effects of glucocorticoids on muscle protein turnover in perfused 
rat hemicorpus. Am J Physiol 238:E564-E572. 
225. Rask, E., B.R. Walker, S. Soderberg, D.E. Livingstone, M. Eliasson, O. Johnson, R. Andrew, and T. 
Olsson. 2002. Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11 
beta-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 87:3330-3336. 
226. Rasmussen, B.B. and W.W. Winder. 1997. Effect of exercise intensity on skeletal muscle malonyl-CoA and 
acetyl-CoA carboxylase. J Appl Physiol 83:1104-1109. 
227. Ravussin, E. and S.R. Smith. 2002. Increased fat intake, impaired fat oxidation, and failure of fat cell 
proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 
967:363-378. 
228. Rayfield, E.J., M.J. Ault, G.T. Keusch, M.J. Brothers, C. Nechemias, and H. Smith. 1982. Infection and 
diabetes: the case for glucose control. Am J Med 72:439-450. 
229. Razeghi, P., M.E. Young, J.L. Alcorn, C.S. Moravec, O.H. Frazier, and H. Taegtmeyer. 2001. Metabolic 
gene expression in fetal and failing human heart. Circulation 104:2923-2931. 
230. Reitman, M.L., M.M. Mason, J. Moitra, O. Gavrilova, B. Marcus-Samuels, M. Eckhaus, and C. Vinson. 
1999. Transgenic mice lacking white fat: models for understanding human lipoatrophic diabetes. Ann N Y Acad 
Sci 892:289-96. 
231. Rhodes, C.J. and M.F. White. 2002. Molecular insights into insulin action and secretion. Eur J Clin Invest 
32:3-13. 
 100 
232. Rizza, R.A., L.J. Mandarino, and J.E. Gerich. 1982. Cortisol-induced insulin resistance in man: impaired 
suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin 
action. J Clin Endocrinol Metab 54:131-138. 
233. Rizza, R.A., L.J. Mandarino, and J.E. Gerich. 1982. Effects of growth hormone on insulin action in man. 
Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of 
glucose utilization. Diabetes 31:663-669. 
234. Roche, R., I. Poizot-Martin, C.M. Yazidi, E. Compe, J.A. Gastaut, J. Torresani, and R. Planells. 2002. 
Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16:13-20. 
235. Rondinone, C.M., L.M. Wang, P. Lonnroth, C. Wesslau, J.H. Pierce, and U. Smith. 1997. Insulin receptor 
substrate (IRS) 1 is reduced and IRS-2 is the main docking protein for phosphatidylinositol 3-kinase in 
adipocytes from subjects with non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 94:4171-4175. 
236. Rosen, E.D., P. Sarraf, A.E. Troy, G. Bradwin, K. Moore, D.S. Milstone, B.M. Spiegelman, and R.M. 
Mortensen. 1999. PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 
4:611-617. 
237. Rosen, E.D. and B.M. Spiegelman. 2000. Molecular regulation of adipogenesis. Annu Rev Cell Dev Biol 
16:145-171. 
238. Ross, S.R., R.A. Graves, and B.M. Spiegelman. 1993.  Targeted expression of a toxin gene to adipose 
tissue: transgenic mice resistant to obesity. Genes Dev 7:1318-1324. 
239. Rossetti, L. 2000. Perspective: Hexosamines and nutrient sensing. Endocrinology 141:1922-1925. 
240. Ruderman, N.B., A.K. Saha, D. Vavvas, T. Kurowski, D.R. Laybutt, C. Schmitz-Peiffer, T. Biden, and 
E.W. Kraegen. 1998. Malonyl CoA as a metabolic switch and a regulator of insulin sensitivity. Adv Exp Med 
Biol 441:263-270. 
241. Ruderman, N.B., A.K. Saha, D. Vavvas, and L.A. Witters. 1999. Malonyl-CoA, fuel sensing, and insulin 
resistance. Am J Physiol 276:E1-E18. 
242. Ryysy, L., A.M. Hakkinen, T. Goto, S. Vehkavaara, J. Westerbacka, J. Halavaara, and H. Yki-Jarvinen. 
2000. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin 
absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes  
49:749-758. 
243. Salinas, M., R. Lopez-Valdaliso, D. Martin, A. Alvarez, and A. Cuadrado. 2000. Inhibition of PKB/Akt1 by 
C2-ceramide involves activation of ceramide-activated protein phosphatase in PC12 cells. Mol Cell Neurosci 
15:156-169. 
244. Saltiel, A.R. 2001. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 
104:517-529. 
245. Saltiel, A.R. and C.R. Kahn. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. 
Nature 414:799-806. 
246. Sammalkorpi, K. 1989. Glucose intolerance in acute infections. J Intern Med 225:15-19. 
247. Sasaoka, T. and M. Kobayashi. 2000. The functional significance of Shc in insulin signaling as a substrate 
of the insulin receptor. Endocr J 47:373-381. 
248. Schaffer, J.E. and H.F. Lodish. 1994. Expression cloning and characterization of a novel adipocyte long 
chain fatty acid transport protein. Cell 79:427-436. 
249. Schick, F., B. Eismann, W.I. Jung, H. Bongers, M. Bunse, and O. Lutz. 1993. Comparison of localized 
proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Magn 
Reson Med 29:158-167. 
 101 
250. Schmitz-Peiffer, C. 2002. Protein kinase C and lipid-induced insulin resistance in skeletal muscle. Ann N Y 
Acad Sci 967:146-157. 
251. Schmitz-Peiffer, C., D.L. Craig, and T.J. Biden. 1999. Ceramide generation is sufficient to account for the 
inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. J 
Biol Chem 274:24202-24210. 
252. Schoonjans, K., J. Peinado-Onsurbe, A.M. Lefebvre, R.A. Heyman, M. Briggs, S. Deeb, B. Staels, and J. 
Auwerx. 1996. PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response 
via a PPRE in the lipoprotein lipase gene. EMBO J 15:5336-5348. 
253. Schubert, K.M., M.P. Scheid, and V. Duronio. 2000. Ceramide inhibits protein kinase B/Akt by promoting 
dephosphorylation of serine 473. J Biol Chem 275:13330-13335. 
254. Schunkert, H. 2002. Obesity and target organ damage: the heart. Int J Obes Relat Metab Disord 26 Suppl 
4:S15-S20. 
255. Seckl, J.R. and B.R. Walker. 2001. Minireview: 11beta-hydroxysteroid dehydrogenase type 1- a tissue-
specific amplifier of glucocorticoid action. Endocrinology 142:1371-1376. 
256. Seino, S. and G.I. Bell. 1989. Alternative splicing of human insulin receptor messenger RNA. Biochem 
Biophys Res Commun 159:312-316. 
257. Senn, J.J., P.J. Klover, I.A. Nowak, and R.A. Mooney. 2002. Interleukin-6 induces cellular insulin 
resistance in hepatocytes. Diabetes 51:3391-3399. 
258. Senn, J.J., P.J. Klover, I.A. Nowak, T.A. Zimmer, L.G. Koniaris, R.W. Furlanetto, and R.A. Mooney. 2003. 
Suppressor of cytokine signaling-3 (SOCS-3): A potential mediator of interleukin-6 dependent insulin resistance 
in hepatocytes. J Biol Chem 30. 
259. Sesti, G., M. Federici, M.L. Hribal, D. Lauro, P. Sbraccia, and R. Lauro. 2001. Defects of the insulin 
receptor substrate (IRS) system in human metabolic disorders. FASEB J 15:2099-2111. 
260. Shepherd, P.R., B.T. Nave, J. Rincon, L.A. Nolte, A.P. Bevan, K. Siddle, J.R. Zierath, and H. Wallberg-
Henriksson. 1997. Differential regulation of phosphoinositide 3-kinase adapter subunit variants by insulin in 
human skeletal muscle. J Biol Chem 272:19000-19007. 
261. Sherwood, D.J., S.D. Dufresne, J.F. Markuns, B. Cheatham, D.E. Moller, D. Aronson, and L.J. Goodyear. 
1999. Differential regulation of MAP kinase, p70(S6K), and Akt by contraction and insulin in rat skeletal 
muscle. Am J Physiol 276:E870-E878. 
262. Shimomura, I., T. Funahashi, M. Takahashi, K. Maeda, K. Kotani, T. Nakamura, S. Yamashita, M. Miura, 
Y. Fukuda, K. Takemura, K. Tokunaga, and Y. Matsuzawa. 1996. Enhanced expression of PAI-1 in visceral fat: 
possible contributor to vascular disease in obesity. Nat Med 2:800-803. 
263. Shimomura, I., R.E. Hammer, S. Ikemoto, M.S. Brown, and J.L. Goldstein. 1999. Leptin reverses insulin 
resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76. 
264. Shimomura, I., R.E. Hammer, J.A. Richardson, S. Ikemoto, Y. Bashmakov, J.L. Goldstein, and M.S. 
Brown. 1998. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in 
adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12:3182-3194. 
265. Shimomura, I., M. Matsuda, R.E. Hammer, Y. Bashmakov, M.S. Brown, and J.L. Goldstein. 2000. 
Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of 
lipodystrophic and ob/ob mice. Mol Cell 6:77-86. 
266. Standaert, M.L., L. Galloway, P. Karnam, G. Bandyopadhyay, J. Moscat, and R.V. Farese. 1997. Protein 
kinase C-zeta as a downstream effector of phosphatidylinositol 3-kinase during insulin stimulation in rat 
adipocytes. Potential role in glucose transport. J Biol Chem 272:30075-30082. 
 102 
267. Stannard, S.R., M.W. Thompson, K. Fairbairn, B. Huard, T. Sachinwalla, and C.H. Thompson. 2002. 
Fasting for 72 h increases intramyocellular lipid content in nondiabetic, physically fit men. Am J Physiol 
Endocrinol Metab 283:E1185-E1191. 
268. Stefan, N. and M. Stumvoll. 2002. Adiponectin-its role in metabolism and beyond. Horm Metab Res 
34:469-474. 
269. Steppan, C.M., S.T. Bailey, S. Bhat, E.J. Brown, R.R. Banerjee, C.M. Wright, H.R. Patel, R.S. Ahima, and 
M.A. Lazar. 2001. The hormone resistin links obesity to diabetes. Nature 409:307-312. 
270. Stewart, J.M. and J.A. Blakely. 2000. Long chain fatty acids inhibit and medium chain fatty acids activate 
mammalian cardiac hexokinase. Biochim Biophys Acta 1484:278-286. 
271. Stork, P.J. and J.M. Schmitt. 2002. Crosstalk between cAMP and MAP kinase signaling in the regulation of 
cell proliferation. Trends Cell Biol 12:258-266. 
272. Stumvoll, M. and H. Haring. 2002. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala 
polymorphism. Diabetes 51:2341-2347. 
273. Stumvoll, M., O. Tschritter, A. Fritsche, H. Staiger, W. Renn, M. Weisser, F. Machicao, and H. Haring. 
2002. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: 
interaction with family history of type 2 diabetes. Diabetes 51:37-41. 
274. Summers, S.A., L.A. Garza, H. Zhou, and M.J. Birnbaum. 1998. Regulation of insulin-stimulated glucose 
transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol Cell Biol 18:5457-5464. 
275. Sutinen, J., A.M. Hakkinen, J. Westerbacka, A. Seppala-Lindroos, S. Vehkavaara, J. Halavaara, A. 
Jarvinen, M. Ristola, and H. Yki-Jarvinen. 2002. Increased fat accumulation in the liver in HIV-infected patients 
with antiretroviral therapy-associated lipodystrophy. AIDS 16:2183-2193. 
276. Sykiotis, G.P. and A.G. Papavassiliou. 2001. Serine phosphorylation of insulin receptor substrate-1: a novel 
target for the reversal of insulin resistance. Mol Endocrinol 15:1864-1869. 
277. Szczepaniak, L.S., E.E. Babcock, F. Schick, R.L. Dobbins, A. Garg, D.K. Burns, J.D. McGarry, and D.T. 
Stein. 1999. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am J Physiol 
276:E977-E989. 
278. Tamemoto, H., T. Kadowaki, K. Tobe, T. Yagi, H. Sakura, T. Hayakawa, Y. Terauchi, K. Ueki, Y. 
Kaburagi, S. Satoh, et al. 1994. Insulin resistance and growth retardation in mice lacking insulin receptor 
substrate-1. Nature 372:182-186. 
279. Taylor, S.I. 1992. Lilly Lecture: molecular mechanisms of insulin resistance. Lessons from patients with 
mutations in the insulin-receptor gene. Diabetes  41:1473-1490. 
280. Teruel, T., R. Hernandez, and M. Lorenzo. 2001. Ceramide mediates insulin resistance by tumor necrosis 
factor-alpha in brown adipocytes by maintaining Akt in an inactive dephosphorylated state. Diabetes 50:2563-
2571. 
281. Thompson, A.L. and G.J. Cooney. 2000. Acyl-CoA inhibition of hexokinase in rat and human skeletal 
muscle is a potential mechanism of lipid-induced insulin resistance. Diabetes 49:1761-1765. 
282. Thomsen, C., U. Becker, K. Winkler, P. Christoffersen, M. Jensen, and O. Henriksen. 1994. Quantification 
of liver fat using magnetic resonance spectroscopy. Magn Reson Imaging 12:487-495. 
283. Tiikkainen, M., R. Bergholm, S. Vehkavaara, A. Rissanen, A.M. Hakkinen, M. Tamminen, K. Teramo, and 
H. Yki-Jarvinen. 2003. Effects of identical weight loss on body composition and features of insulin resistance in 
obese women with high and low liver fat content. Diabetes 52:701-707. 
 103 
284. Tiikkainen, M., M. Tamminen, A.M. Hakkinen, R. Bergholm, S. Vehkavaara, J. Halavaara, K. Teramo, A. 
Rissanen, and H. Yki-Jarvinen. 2002. Liver-fat accumulation and insulin resistance in obese women with 
previous gestational diabetes. Obes Res 10:859-867. 
285. Traxinger, R.R. and S. Marshall. 1991. Coordinated regulation of glutamine:fructose-6-phosphate 
amidotransferase activity by insulin, glucose, and glutamine. Role of hexosamine biosynthesis in enzyme 
regulation. J Biol Chem 266:10148-10154. 
286. Trayhurn, P. 1996. New insights into the development of obesity: obese genes and the leptin system. Proc 
Nutr Soc 55:783-791. 
287. Treadway, J.L., D.E. James, E. Burcel, and N.B. Ruderman. 1989. Effect of exercise on insulin receptor 
binding and kinase activity in skeletal muscle. Am J Physiol 256:E138-E144. 
288. Tsao, T.S., H.F. Lodish, and J. Fruebis. 2002. ACRP30, a new hormone controlling fat and glucose 
metabolism. Eur J Pharmacol 440:213-221. 
289. Utriainen, T., R. Malmstrom, S. Makimattila, and H. Yki-Jarvinen. 1996. Supraphysiological 
hyperinsulinemia increases plasma leptin concentrations after 4 h in normal subjects. Diabetes 45:1364-1366. 
290. Vanden Berghe, W., L. Vermeulen, G. De Wilde, K. De Bosscher, E. Boone, and G. Haegeman. 2000. 
Signal transduction by tumor necrosis factor and gene regulation of the inflammatory cytokine interleukin-6. 
Biochem Pharmacol 60:1185-1195. 
291. Vgontzas, A.N., D.A. Papanicolaou, E.O. Bixler, A. Kales, K. Tyson, and G.P. Chrousos. 1997. Elevation 
of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin 
Endocrinol Metab 82:1313-1316. 
292. Vinson, C.R., T. Hai, and S.M. Boyd. 1993. Dimerization specificity of the leucine zipper-containing bZIP 
motif on DNA binding: prediction and rational design.  Genes Dev 7:1047-1058. 
293. Virkamaki, A., I. Puhakainen, V.A. Koivisto, H. Vuorinen-Markkola, and H. Yki-Jarvinen. 1992. 
Mechanisms of hepatic and peripheral insulin resistance during acute infections in humans. J Clin Endocrinol 
Metab 74:673-679. 
294. Virkamaki, A., K. Ueki, and C.R. Kahn. 1999. Protein-protein interaction in insulin signaling and the 
molecular mechanisms of insulin resistance. J Clin Invest 103:931-943. 
295. Vollenweider, P., B. Menard, and P. Nicod. 2002.  Insulin resistance, defective insulin receptor substrate 2 -
associated phosphatidylinositol-3' kinase activation, and impaired atypical protein kinase C (zeta/lambda) 
activation in myotubes from obese patients with impaired glucose tolerance. Diabetes 51:1052-1059. 
296. Vuorinen-Markkola, H., V.A. Koivisto, and H. Yki-Jarvinen. 1992. Mechanisms of hyperglycemia-induced 
insulin resistance in whole body and skeletal muscle of type I diabetic patients. Diabetes 41:571-580. 
297. Wadley, G.D., R.J. Tunstall, A. Sanigorski, G.R. Collier, M. Hargreaves, and D. Cameron-Smith. 2001. 
Differential effects of exercise on insulin-signaling gene expression in human skeletal muscle. J Appl Physiol 
90:436-440. 
298. Wakelam, M.J. 1998. Diacylglycerol-when is it an intracellular messenger? Biochim Biophys Acta 
1436:117-126. 
299. Walker, U.A., M. Bickel, V.S. Lutke, U.P. Ketelsen, H. Schofer, B. Setzer, N. Venhoff, V. Rickerts, and S. 
Staszewski. 2002. Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and 
structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 
29:117-121. 
300. Walston, J., K. Silver, C. Bogardus, W.C. Knowler,  F.S. Celi, S. Austin, B. Manning, A.D. Strosberg, M.P. 
Stern, N. Raben, et al. 1995. Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in 
the beta 3-adrenergic-receptor gene. N Engl J Med 333:343-347. 
 104 
301. Way, J.M., C.Z. Gorgun, Q. Tong, K.T. Uysal, K.K. Brown, W.W. Harrington, W.R.J. Oliver, T.M. 
Willson, S.A. Kliewer, and G.S. Hotamisligil. 2001. Adipose tissue resistin expression is severely suppressed in 
obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651-
25653. 
302. Way, J.M., W.W. Harrington, K.K. Brown, W.K. Gottschalk, S.S. Sundseth, T.A. Mansfield, R.K. 
Ramachandran, T.M. Willson, and S.A. Kliewer. 2001. Comprehensive messenger ribonucleic acid profiling 
reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene 
expression in multiple insulin-sensitive tissues. Endocrinology 142:1269-1277. 
303. Wentworth, J.M., T.P. Burris, and V.K. Chatterjee. 2000.  HIV protease inhibitors block human 
preadipocyte differentiation, but not via the PPARgamma/RXR heterodimer. J Endocrinol 164:R7-R10. 
304. Weyer, C., J.E. Foley, C. Bogardus, P.A. Tataranni, and R.E. Pratley. 2000. Enlarged subcutaneous 
abdominal adipocyte size, but not obesity itself, predicts type II diabetes independent of insulin resistance. 
Diabetologia. 43:1498-1506. 
305. Weyer, C., J.K. Wolford, R.L. Hanson, J.E. Foley, P.A. Tataranni, C. Bogardus, and R.E. Pratley. 2001. 
Subcutaneous abdominal adipocyte size, a predictor of type 2 diabetes, is linked to chromosome 1q21-q23 and is 
associated with a common polymorphism in LMNA in Pima Indians. Mol Genet Metab  72:231-238. 
306. White, M.F. and C.R. Kahn. 1994. The insulin signaling system. J Biol Chem 269:1-4. 
307. Widegren, U., X.J. Jiang, A. Krook, A.V. Chibalin, M. Bjornholm, M. Tally, R.A. Roth, J. Henriksson, H. 
Wallberg-Henriksson, and J.R. Zierath. 1998. Divergent effects of exercise on metabolic and mitogenic signaling 
pathways in human skeletal muscle. FASEB J 12:1379-1389. 
308. Widegren, U., J.W. Ryder, and J.R. Zierath. 2001. Mitogen-activated protein kinase signal transduction in 
skeletal muscle: effects of exercise and muscle contraction. Acta Physiol Scand 172:227-238. 
309. Widen, E., M. Lehto, T. Kanninen, J. Walston, A.R. Shuldiner, and L.C. Groop. 1995. Association of a 
polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N 
Engl J Med 333:348-351. 
310. Wiman, B., J. Chmielewska, and M. Ranby. 1984. Inactivation of tissue plasminogen activator in plasma. 
Demonstration of a complex with a new rapid inhibitor. J Biol Chem 259:3644-3647. 
311. Winder, W.W. 2001. Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J 
Appl Physiol 91:1017-1028. 
312. Winder, W.W., B.F. Holmes, D.S. Rubink, E.B. Jensen, M. Chen, and J.O. Holloszy. 2000. Activation of 
AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol 88:2219-
2226. 
313. Withers, D.J., J.S. Gutierrez, H. Towery, D.J. Burks, J.M. Ren, S. Previs, Y. Zhang, D. Bernal, S. Pons, G.I. 
Shulman, S. Bonner-Weir, and M.F. White. 1998. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 
391:900-904. 
314. Wititsuwannakul, D. and K.H. Kim. 1977.  Mechanism of palmityl coenzyme A inhibition of liver glycogen 
synthase.  J Biol Chem 252:7812-7817. 
315. Wojtaszewski, J.F., B.F. Hansen, Gade, B. Kiens, J.F. Markuns, L.J. Goodyear, and E.A. Richter. 2000. 
Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes 49:325-331. 
316. Wojtaszewski, J.F., B.F. Hansen, B. Kiens, and E.A. Richter. 1997. Insulin signaling in human skeletal 
muscle: time course and effect of exercise. Diabetes 46:1775-1781. 
317. Wojtaszewski, J.F., P. Nielsen, B.F. Hansen, E.A. Richter, and B. Kiens. 2000. Isoform-specific and 
exercise intensity-dependent activation of 5'-AMP-activated protein kinase in human skeletal muscle. J Physiol 
528 Pt 1:221-226. 
 105 
318. Wolf, G., T. Trub, E. Ottinger, L. Groninga, A. Lynch, M.F. White, M. Miyazaki, J. Lee, and S.E. 
Shoelson. 1995. PTB domains of IRS-1 and Shc have distinct but overlapping binding specificities. J Biol Chem 
270:27407-27410. 
319. Wu, X., J. Hoffstedt, W. Deeb, R. Singh, N. Sedkova, A. Zilbering, L. Zhu, P.K. Park, P. Arner, and B.J. 
Goldstein. 2001. Depot-specific variation in protein-tyrosine phosphatase activities in human omental and 
subcutaneous adipose tissue: a potential contribution to differential insulin sensitivity. J Clin Endocrinol Metab  
86:5973-5980. 
320. Yamauchi, T., J. Kamon, Y. Minokoshi, Y. Ito, H. Waki, S. Uchida, S. Yamashita, M. Noda, S. Kita, K. 
Ueki, K. Eto, Y. Akanuma, P. Froguel, F. Foufelle, P. Ferre, D. Carling, S. Kimura, R. Nagai, B.B. Kahn, and T. 
Kadowaki. 2002. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-
activated protein kinase. Nat Med 8:1288-1295. 
321. Yamauchi, T., J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. 
Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M.L. Reitman, H. Kagechika, K. Shudo, 
M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel, and T. Kadowaki. 2001. The fat-
derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 
7:941-946. 
322. Yang, W.S., W.J. Lee, T. Funahashi, S. Tanaka, Y. Matsuzawa, C.L. Chao, C.L. Chen, T.Y. Tai, and L.M. 
Chuang. 2001. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, 
adiponectin. J Clin Endocrinol Metab 86:3815-3819. 
323. Yeh, J.I., E.A. Gulve, L. Rameh, and M.J. Birnbaum. 1995. The effects of wortmannin on rat skeletal 
muscle. Dissociation of signaling pathways for insulin- and contraction-activated hexose transport. J Biol Chem 
270:2107-2111. 
324. Yenush, L., K.J. Makati, J. Smith-Hall, O. Ishibashi, M.G.J. Myers, and M.F. White. 1996. The pleckstrin 
homology domain is the principal link between the insulin receptor and IRS-1. J Biol Chem  271:24300-24306. 
325. Yki-Jarvinen, H. 1984. Sex and insulin sensitivity. Metabolism 33:1011-1015. 
326. Yki-Jarvinen, H. 1992. Glucose toxicity. Endocr Rev 13:415-431. 
327. Yki-Jarvinen, H., M.C. Daniels, A. Virkamaki, S. Makimattila, R.A. DeFronzo, and D. McClain. 1996. 
Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. 
Diabetes 45:302-307. 
328. Yki-Jarvinen, H., E. Helve, and V.A. Koivisto. 1987. Hyperglycemia decreases glucose uptake in type I 
diabetes. Diabetes 36:892-896. 
329. Yki-Jarvinen, H. and V.A. Koivisto. 1984. Continuous subcutaneous insulin infusion therapy decreases 
insulin resistance in type 1 diabetes. J Clin Endocrinol Metab 58:659-666. 
330. Yki-Jarvinen, H. and V.A. Koivisto. 1986. Natural course of insulin resistance in type I diabetes. N Engl J 
Med 315:224-230. 
331. Yki-Jarvinen, H., E.A. Nikkila, K. Kubo, and J.E. Foley. 1986. Assay of glucose transport in human fat 
cells obtained by needle biopsy. Diabetologia 29:287-290. 
332. Yki-Jarvinen, H., J. Sutinen, A. Silveira, E. Korsheninnikova, R.M. Fisher, K. Kannisto, E. Ehrenborg, P. 
Eriksson, and A. Hamsten. 2003. Regulation of plasma PAI-1 concentrations in HAART-Associated 
lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 23:688-694. 
333. Yu, M., E. Blomstrand, A.V. Chibalin, A. Krook, and J.R. Zierath. 2001. Marathon running increases 
ERK1/2 and p38 MAP kinase signalling to downstream targets in human skeletal muscle. J Physiol 536:273-
282. 
 106 
334. Zhang, B., K. MacNaul, D. Szalkowski, Z. Li, J. Berger, and D.E. Moller. 1999. Inhibition of adipocyte 
differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 84:4274-4277. 
335. Zhou, G., R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk -Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. 
Musi, M.F. Hirshman, L.J. Goodyear, and D.E. Moller. 2001. Role of AMP-activated protein kinase in 
mechanism of metformin action. J Clin Invest 108:1167-1174. 
336. Zierath, J.R. 2002. Invited review: Exercise training-induced changes in insulin signaling in skeletal 
muscle. J Appl Physiol 93:773-781. 
337. Zouali, H., G. Velho, and P. Froguel. 1993. Polymorphism of the glycogen synthase gene and non-insulin-
dependent diabetes mellitus. N Engl J Med 328:1568. 
 
